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1 Introduction 
1.1 Class I cytokine receptors  
Cytokines are secreted mediators (15-25 kDa) for intercellular communication. 
Cytokines elicit their broad spectrum of activities in development, differentiation, 
proliferation, immune responses, and apoptosis through binding to specific cell 
surface receptors. They can act in an autocrine as well as a paracrine fashion [1, 2].  
Structural analysis was the basis to group cytokines into different structural classes, 
including the helical cytokines [3], the trimeric tumor necrosis factor (TNF) family [4], 
the cysteine knot growth factors [5], and the β-trefoil growth factors [6]. Another 
classificiation is based on receptor engagement by cytokines. On the basis of 
common structural features, the cytokine receptors are grouped into different 
superfamilies: class I cytokine receptors [7], class II cytokine receptors [8], tumor 
necrosis factor receptors [9], interleukin-1 (IL-1) receptors [10], tyrosine kinase 
receptors [11], serine/threonie kinase receptors [12], chemokine receptors [13], and 
IL-17 receptors [14]. 
Class I cytokine receptors bind helical cytokines. These polypeptides are synthesized 
and secreted by cells in response to many stimuli, and mediate their effects by 
binding to specific receptors on the surface of target cells [15].  
Class I cytokine receptors share little primary sequence homology [16] but they share 
a modular architecture, which is characterized by a ~200 residue-long cytokine-
binding homology domain (CHD) possessing the classical binding motif for cytokines 
[16]. The CHD consists of two tandem fibronectin type-III (FNIII) domains and it 
represents the signature recognition module for helical cytokines that is present on 
every type I cytokine receptor. The upper, N-terminal domain contains two pairs of 
conserved cysteins that form interstrand disulfide bonds [17]. The lower, C-terminal 
domain contains a conserved Trp-Ser-X-Trp-Ser (WSXWS) motif [16, 18, 19]. The 
basic CHD motif is present in every member of the class I cytokine receptors, and for 
some, such as the receptor for the growth hormone, a single CHD is sufficient to 
mediate ligand binding and receptor homodimerization [19]. Other receptors require 
additional domains like immunglobulin-like (Ig-like) domain and additional membrane- 
proximal fibronectin type-III domains to function and respond to cytokines [20, 21]. 
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cytokine receptor chain(s) 
erythropoietin erythropoietin receptor 
thrompoietin thrombopoietin receptor 
growth hormone growth hormone receptor 
prolactin prolactin receptor 
leptin leptin receptor 
granulocyte-colony 
stimulating factor granulocyte-colony stimulating factor receptor 
viral interleukin-6  
glycoprotein 130 
interleukin-6 interleukin 6 receptor α  
interleukin-11 interleukin-11 receptor α  
interleukin-27 (p28) Epstein-Barr induced gene 3 interleukin-27 receptor α (WSX-1) 
cardiotrophin-like cytokine cytokine-like factor-1 
leukemia inhibitory factor 
receptor 
ciliary 
neurotrophic 
factor 
receptor α 
ciliary neurotrophic factor 
neuropoetin 
leukemia inhibitory factor 
 
oncostatin M 
oncostatin M receptor 
interleukin-31 glycoprotein 130-like receptor  
interleukin-12 (p35) 
interleukin-12 (p40) interleukin-12 receptor β2 interleukin-12 
receptor β1 interleukin-23 (p19) interleukin-23 receptor 
interleukin-4 
interleukin-4 receptor α interleukin-13 
receptor α1 
Interleukin-13 
interleukin-13 receptor α2 
thymic stromal 
lymphopoietin interleukin-7 receptor α 
thymic stromal lymphopoietin 
receptor 
interleukin 7 
interleukin-2 
receptor γc 
interleukin-2 interleukin-2 receptor α interleukin-2 
receptor β interleukin-15 Interleukin-15 
receptor α 
interleukin-4 interleukin-4 receptor α 
interleukin-9 interleukin-9 receptor α 
interleukin-21 interleukin-21 receptor α 
interleukin-3 
interleukin-3 receptor βc 
interleukin-3 receptor α 
interleukin-5 interleukin-5 receptor α 
granulocyte-macrophage 
colony-stimulating factor 
granulocyte-macrophage colony-
stimulating factor receptor α 
 
Table 1.1 Overview of all class I cytokine receptor chain complexes and their utilization by 
cytokines. Group 1 receptor chains (purple) have an extracellular domain that consists solely of a 
CHD [7]. Group 2 receptors (blue) are structurally related to the archetypal glycoprotein 130 (gp130). 
Specifc for this group are the N-terminally Ig-like domains and/or the three FNIII domains between 
their CHD and transmembrane domains [7, 22]. Group 3 receptor chains (yellow) also generally 
possess an N-terminal Ig-like domain in addition to the CHD, and are either soluble or have short 
intracellular regions [7]. These receptors belong to the α-receptors which do not participate in signaling 
but are important for initial ligand binding. Group 4 receptor chains (brown) are characterized by an 
extracellular CHD motif and a long intracellular domain [7]. Group 5 receptors (orange) often have 
extracellular, N-terminal Ig-like domains in addition to the CHD domain, and have short intracellular 
domains [7]. Additionally constituents of receptor complexes of the IL-2R functional family, the IL-2Rα 
and IL-15Rα receptor chains (both highlighted in green) are not members of the class I family 
receptors, but instead contain distinctive ‘sushi domain’ structures. This table has been adapted in 
modified form from Liongue and Ward [23]. 
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The superfamily of class I cytokine receptors can be subdivided into five families 
based on sequence and structural homology of the receptor and their ligands which 
are listed in Table 1.1. Class I cytokine receptors lack intrinsic kinase activity. 
However, they are non-covalently associated with Janus kinases (JAKs – JAK1, 
JAK2, JAK3 and TYK2). These tyrosine kinases are autophosphorylated upon 
receptor engagement by cytokines, and subsequently activate downstream signaling 
events, e.g. the phosphorylation of signaling transducing and activators of 
transcription (STATs – STAT1-6) transcription factors [24, 25]. 
In the following chapters the IL-6 family of receptor complexes, which are of special 
interest for this work, should be introduced with focus on receptor utilization, receptor 
complex formation, signal transduction, and biological effects. 
1.2 The family of IL-6 cytokine receptors 
1.2.1 Receptor utilization 
The IL-6 family of cytokines signaling through the common receptor subunit gp130 
comprises IL-6, viral IL-6, IL-11, IL-27, CNTF, CT-1, LIF, cardiotrophin-like cytokine 
(CLC/NNT-1), neuropoetin (NP), and OSM [26-29]. NP is expressed in mice but not 
in humans due to a frameshift in its coding sequence caused by an 8-bp deletion 
[29]. Additionally, also IL-31 can be grouped to this family because of binding to the 
gp130-like protein (GPL or IL-31R) [30]. All these cytokines belong to the long chain 
four helix bundle class of cytokines, consisting of four long α-helixes termed A, B, C , 
and D, which are arranged in an up-up-down-down topology (Figure 1.2A) [3] . 
Gp130 can form homodimers (based on the usage of the signal transducing receptor 
chains) in the presence of IL-6, viral IL-6 or IL-11 [28, 31, 32], or heterodimerize with 
the LIFR, when recruited by LIF, OSM, CNTF, CT-1, CLC, and NP [29, 33-36]. 
Additionally OSM can bind the OSMR, which again, heterodimerizes with gp130 [37]. 
IL-27, which a composite cytokine consisting of the four helix bundle cytokine p28 
and soluble cytokine receptor EBI3, binds to another related type I cytokine receptor, 
WSX-1, which heterodimerizes with gp130 [27]. IL-31 instead does not bind to gp130 
but to the related GPL, which heterodimerizes with OSMR to trigger IL-31 mediated 
events [30] (Figure 1.1). 
Some cytokines of the IL-6-like family depend on the initial binding to a specific α-
receptor before a signaling competent complex of the β-receptors can be formed 
(Figure 1.1). 
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Figure 1.1 Gp130-type receptors and utilization by IL-6-like cytokines. Depicted are receptor 
complexes with IL-6-like cytokines and the domain structure of each receptor (e.g. gp130: D1-D6). The 
α-receptors consist of IL-6Rα (grey), IL-11Rα (yellow-brownish), CNTFRα (light blue) or soluble 
CNTFRα (sCNTFRα), CLF-1 (light purple) and EBI-3 (light orange). The latter two are part of the 
composite cytokines CLC/CLF-1 and IL-27, respectively. The scheme of the complex of 
CLC/membrane bound CNTFRα/LIFR/gp130 does not include CLF-1 [38]. It is shown to point out the 
differences in the delivery of CLC. The β-receptors are gp130 (black), LIFR (red), OSMR (green), 
WSX-1 (purple), and GPL (blue). In contrast to the α-receptors they are characterized by longer 
cytoplasmic domains, reflecting their involvement in signal transduction. See text for details.  
 
IL-6 and IL-11 first bind to the IL-6 receptor α (IL-6Rα), and IL-11 receptor α (IL-
11Rα), respectively [31, 32]. The IL-6Rα can also be expressed as a soluble form. It 
is generated by shedding or alternative splicing and acts agonistically [39]. CNTF, 
CLC, and NP were shown to bind initially to the CNTF receptor (CNTFR), and they 
share a conserved binding site [41]. The CNTFR carries a glycosyl-
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phosphatidylinositol anchor to attach to the membrane. It has been shown that CLC 
forms a composite cytokine when it is associated with the soluble receptor cytokine-
like factor (CLF-1) [36]. CLF-1 mainly behaves as a chaperone protein, allowing 
secretion of CLC. Furthermore, it has also been observed that CLC can form a 
second secreted composite cytokine when associated with the soluble form of 
CNTFR [40]. CT-1 binds directly to the LIFR, and induces gp130/LIFR heterodimer 
formation, but the presence of an additional glycosylphosphatidylinositol-anchored 
receptor specific for CT-1 has been hypothesized [35].  
1.2.2 Receptor complex formation and transmission of the signal  
A major feature of the gp130-type receptors is the presence of more domains than 
needed for ligand binding. Thus, one part is responsible for ligand binding (e.g. 
gp130: D1-D3) and the other is involved in transmitting the signal into cells (e.g. 
gp130: D4-D6) [41]. According to this gp130-type receptors are often called ‘complex’ 
or tall receptors.  
A major feature of IL-6-like cytokines is the existence of three different sites for 
receptor subunit binding (Figure 1.2B) in contrast to other four helix bundle cytokines 
like the growth hormone which posses only two sites for receptor binding [19]. The 
crystal structure of the hexameric complex of IL-6/IL-6Rα/gp130-D1D2D3 revealed 
that IL-6 use the canonical sites I and II to engage the α-receptor and gp130 CHD, 
respectively. Site III of IL-6 engages the Ig-like domain of gp130 so that each gp130 
contacts two different IL-6 molecules in an antiparallel fashion [21]. Other reports 
strengthen the site III paradigm for this family of cytokines. The 4.0 Å structure of the 
D1-D5 domains of the LIFR in complex with LIF used a high-affinity site III interaction 
to engage the D3 Ig-like domain of LIFR [42]. Also modeling of the quartenary 
CNTF/CNTFRα/LIFR/gp130 using single-particle reconstruction of the entire complex 
[43], crystal structure of LIF/gp130 [44] and CNTF [45] revealed that site I of CNTF 
engages CNTFRα CHD, site II engages gp130 CHD and site III engages the Ig-like 
domain of the LIFR as presented in the work of Wang et al. [46]. It has also been 
hypothesized that WSX-1 which lacks the Ig-like domain engages site II of IL-27 (p28 
subunit) via its CHD, while site III is free to interact with the second signaling receptor 
gp130 [43]. 
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Figure 1.2 The four helix bundle cytokines. (A) Schematic representation of the four helix bundle 
cytokines with an up-up-down-down topology. The four helixes are designated as A, B, C, D. (B) 
Ribbon representation of the IL-6 structure solved by NMR spectroscopy [47]. The interaction sites 
with the different receptor subunits are encircled and marked (site I: IL-6Rα, site II: gp130 CHD, site 
III: gp130 Ig-like domain) [41].  
 
The membrane proximal domains of gp130 (D4-D6) are involved in transmitting the 
signal to the cytoplasmic domain. Deletion mutants lacking D4, D5, or D6 showed no 
or impaired signal transduction activities [48]. Furthermore, a study using single-
particle electron microscopy of the symmetric IL-6/IL-6Rα/gp130-D1-D6 revealed that 
gp130 is bent such that the membrane proximal domains of gp130 are close together 
at the cell surface before entering the cell membrane, enabling activation of 
intracellular signaling [49]. This has also been observed by analyzing the hexameric 
IL-11/IL-11Rα/gp130 complex by cyroelectron microscopic analysis [50]. A high-
resolution crystal structure of gp130-D1-D6 could confirm this and furthermore 
revealed that the domains D4 and D5 are orientated such that they lie across each 
other at an angle of approximately 80°, resulting in an acute bend in the structure. 
Thus the ectodomain of gp130 adopts a wide-open ‘C’-shape [51]. Moreover, the 
elucidation of the asymmetric full-length CNTF/CNTFRα/LIFR/gp130 complex 
displayed also a close apposition of gp130 D5 and LIFR D7 domains, which is a 
result of a bend between D4 and D5 of gp130 and D6 and D7 of the LIFR [43]. This 
is consistent with a functional study of the gp130/LIFR complex [52]. This study 
showed that the juxtamembrane and transmembrane regions of the full-length 
CNTF/CNTFRα/LIFR/gp130 complex join as a continuous, rigid unit, which indicates 
that they are closely associated at all times after ligand engagement and sensitively 
transduce ligand engagement to the membrane-proximal intracellular signaling 
regions [43]. This finding is consistent with a cellular study in which insertion of 1-4 
A B C D
A B
NH3 COOH
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alanine residues to the juxtamembrane intracellular region of gp130 lead to 
successive impairment but not abolishment of JAKs and receptor phosphorylation 
[53], so that the dimer needs to be positioned not only in close proximity to allow for 
full activation of the receptor, but also to be aligned in a specific manner [53]. 
However, the molecular mechanism how cytokine binding is coupled to JAK 
activation is not fully understood. 
1.2.3 Signal transduction 
As found for many cytokines, IL-6-like cytokines also induce activation of tyrosine 
kinases of the JAK family. The signal transducing chains gp130, LIFR and OSMR are 
associated with JAK1, JAK2 and TYK2 [54-56]. For WSX-1 only the association with 
JAK1 has been shown [57]. The same is true for GPL, but has not been tested for 
other JAK family members so far [58]. The association of JAKs to cytokine receptors 
is mediated by membrane-proximal box1/2 regions. Box1 is a proline-rich motif of 
eight amino acid residues essential for JAK association, whereas box2, a cluster of 
hydrophobic amino acid residues followed by positively charged amino acids, is 
necessary for JAK association only in some receptors. gp130, LIFR and OSMR 
contain box1/2 regions [33, 37, 59]. WSX-1 as well as GPL only exhibits a box1 motif 
[60, 61].  
After ligand binding and close apposition of the cytoplasmic regions the JAKs 
become autophosphorylated at distinct tyrosine residues. Subsequently, the receptor 
is phosphorylated at specific tyrosines. For human gp130 it has been shown that at 
least five of six tyrosines are phosphorylated after ligand binding. The LIFR contains 
five [26], the OSMR nine [26], the WSX-1 two [60], and the GPL three [61] potential 
tyrosine-phosphorylation sites. It has been demonstrated that phosphorylation of the 
four membrane distal tyrosine residues in gp130 contribute to STAT binding and 
phosphorylation [62, 63]. The consensus sequences YXPQ and YXXQ are proposed 
for STAT1 and STAT3 binding [62, 63]. Therefore, every IL-6-like cytokine has the 
ability to induce STAT3 and to a minor extent STAT1 phosphorylation. This is also 
true for IL-31, even though it does not engage gp130, because the OSMR as well as 
GPL can activate STAT1 and STAT3 on their own [58, 64]. Phosphorylated WSX-1 
can only bind STAT1 [57] even if the consensus sequence YXPQ is missing but IL-27 
also induces STAT3 phosphorylation since it engages gp130 [27].  
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Figure 1.3 Signaling cascades activated by IL-6 with focus on STAT and MAPK/ERK and PI3K 
activation. See text for details.  
 
The LIFR and the OSMR can also activate STAT5, with OSMR being the most potent 
activator [65, 66]. Interestingly, this activation may not require receptor 
phosphorylation due to direct interaction between STAT5 with JAKs [67], but as 
shown for human OSMR, STAT5 can also be activated by binding to a 
phosphorylated tyrosine motif (Tyr837/Tyr839) [68]. Upon STAT phosphorylation, the 
STAT members dimerize and translocate into the nucleus where they recognize DNA 
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binding sites in the promoter of their target genes [69]. STAT3 target genes are e.g. 
acute-phase proteins [70], the transcription factor c-myc [71] or the serine/threonine 
kinase Pim-1 [72].  
Signaling via STATs it tightly regulated. There are different pathways for the inhibition 
of STATs. So called suppressor of cytokine signaling (SOCS) proteins represent 
negative-feedback inhibitors and their expression is induced by e.g. IL-6, LIF, IL-11 
and OSM [73-75]. Those proteins exhibit their inhibitory potential by directly 
interacting with JAK proteins, thereby inhibiting the phosphorylation of gp130, STATs 
and JAKs themselves [73, 75]. Another mechanism has been proposed for SOCS3 
which binds directly to Tyr759 of gp130 [76, 77]. It has been proposed that receptor 
recruitment of SOCS3 is a prerequisite for subsequent JAK binding. Another pathway 
of inhibition is dephosphorylation of phosphorylated STAT proteins by tyrosine-
phosphatases, as shown for STAT1 [78, 79]. Cytokines signaling by STATs can also 
be inhibited by protein inhibitor of activated STATs (PIAS) [80, 81].  
Besides the JAK/STAT pathway, IL-6-like cytokines can also activate the mitogen 
activated protein kinase (MAPK) pathway. The Src homology protein 2 tyrosine 
phosphatase-2 (SHP2) binds to Tyr759 of gp130 [63] or Tyr974 of LIFR [82] and 
becomes phosphorylated. The adaptor protein growth factor receptor bound protein 2 
(Grb2) is recruited to further activate the Ras/Raf/MAPK pathway. The adaptor 
protein Grb2-associating binder 1 (Gab1) is also involved in the activation of the 
Ras/Raf/MAPK pathway [83]. It is know that upon cytokine treatment, Gab1 is 
recruited to the plasma membrane and bind to phosphatidylinositol-(3,4,5)-phosphate 
(PtdIns(3,4,5)P3) and becomes phosphorylated by unknown tyrosine-kinases [84]. 
Thereafter, SHP2 and PI3K as well as other proteins are recruited to Gab1 [83, 85]. 
The OSMR also can activate the MAPK-pathway but instead of SHP2 utilizes the 
SH2- and collagen-homology-domain containing protein (Shc), which is recruited to 
the receptor via Tyr861 [86]. Thus, all IL-6-like cytokines including IL-31 can activate 
the MAPK-pathway. Besides ERK1/2 acitvation, IL-6 or OSM can also activate 
stress-induced MAPK: p38 and c-Jun N-terminal kinase (JNK) [66, 87]. However, the 
molecular mechanism has not been elucidated so far.  
Furthermore, it has been demonstrated that IL-6 as well as OSM can activate the 
phosphoinositol-3-kinase (PI3K) cascade. The molecular mechanisms that lead  
to the activation of PI3K are also not completely clarified. After stimulation with IL-6, 
the adaptor protein Grb2-associating binder 1 (Gab1) binds SHP-2 and to PI3K as 
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described above [83, 85]. In addition, the adaptor protein insulin receptor substrate-1 
(IRS-1) is connected with PI3K following OSM stimulation [88]. One downstream 
target of PI3K is the serine/threonine kinase Akt, which can phosphorylate many 
other downstream targets [89]. A summary of the principle signaling pathways 
mediated by IL-6 is shown in Figure 1.3.  
1.2.4 Biological effects of IL-6-like cytokines 
All IL-6-like cytokines trigger a similar pattern of signal transduction pathways 
because they share gp130 as a signaling subunit. Hence, IL-6-like cytokines exhibit 
redundant functions. This has been shown by analyzing the potency of IL-6, IL-11, 
LIF, OSM, CNTF, and CT-1 to induce acute-phase proteins [90-92].  
Despite this redundancy, specific biological effects of cytokines in this family exist. 
This can be explained by a different cellular expression of the respective receptor 
subunits. In the following text some important redundant and non-redundant 
biological effects with respect to physiological functions of IL-6-like cytokines are 
presented. 
IL-6 is involved in haematopoiesis. IL-6 was initially described as a B-cell maturating 
factor that activates B-cells in a T-cell-independent manner to produce 
immunoglobulins [93, 94]. Furthermore, IL-6 controls the differentiation of monocytes 
into macrophages [95] and acts a promoter of maturation of megacaryocytes [96]. IL-
6 also acts on T-cells. It has a helper function in the induction of cytotoxic CD8 T-
cells [97] and is responsible for the differentiation of naïve CD4 T-cells into follicular 
T-cells [98] or B-cell helper T-cells (ThB cells), which do not show characteristics of 
Th1, Th2, Th17, or follicular T-cells [99]. Interestingly, IL-6 together with TGFβ leads 
to the differentiation of naïve CD4 T-cells into Th17 cells [100]. IL-6 in combination 
with the soluble IL-6Rα, which has been named trans-signaling, acts as a pyrogenic 
factor, thereby inducing leucocytosis which is beneficial for clearance of infection 
[101]. Another role of IL-6 trans-signaling in acute inflammation is the replacement of 
neutrophils by mononuclear cells/macrophages, which is an important step in the 
resolution of inflammation [102, 103]. Moreover, IL-6 trans-signaling has a beneficial 
impact on liver regeneration after liver injury [104].  
IL-11 also acts on haematopoietic cells. It has been shown that IL-11 acts as a 
potantiator of megacaryopoiesis and thrombocytopoiesis [105, 106]. The IL-11Rα is 
also expressed on a variety of epithelial cells including alveolar, bronchial and 
INTRODUCTION   
- 11 - 
gastrointerstinal epithelial cells, suggesting that IL-11 may play an important role in 
pulmonary inflammation [107] and normal growth control of gastrointestinal epithelial 
cells [108]. Moreover, IL-11 plays a role in embryogenesis because IL-11R-/- female 
mice a sterile due to a defect in the decidua formation and fetoplacental development 
[109]. 
LIF also is a factor which potentiates megacaryopoiesis [110]. Furthermore, LIF is 
important for embryogenesis because LIF-/- female mice are sterile due to defect 
during blastocyst implantation [111]. It has also been demonstrated that LIF 
preserves the totipotentiality of murine embryonic stem cells [112]. LIF also displays 
effects in the nervous system where it enhances the survival of sensory and motor 
neurons [113] as well as oligodendrocytes [114].  
OSM also exhibit thrombocytopoietic properties [115]. OSMR-/- mice have reduced 
frequencies of erythroid and megakaryocyte progenitors in bone marrow [116]. 
Besides, those mice exhibit impaired regeneration after liver injury [117]. OSM also is 
involvet in neuronal development since OSM-/- mutants have a defect in the 
development of a subtype of nociceptive neurons [118]. Unlike IL-6 trans-signaling, 
OSM signaling via OSMR limits monocytic cell recruitment in acute inflammation 
[119].  
CNTF exhibits its function by maintaining the survival of parasympathetic and 
motorneurons [120]. Thus CNTF-/- mice develop mild progressive motorneuron 
degeneration [121]. CNTF also exhibits leptin-like abilities. It reduces adiposity, 
hyperphagia, and hyperinsulinemia of leptin-/- or leptin-resistant (db/db) mice [122]. 
However, CNTF does not inhibit adipogenesis [123]. 
CLC regulates immunity by stimulating B cell function and antibody production, with 
preference for Th2 over Th1 immunoglobuline types [124]. Furthermore, CLC is a 
circadian regulator of locomotor activity [125].  
CT-1 seems to play an important role in neuronal development because CT-/- mice 
show a lethal phenotype due to an increased loss of motorneurons [126]. 
Furthermore, CT-1, which is released from the heart in vivo in response to hypoxia, 
acts in an autocrine or paracrine manner to serve potentially critical cardioprotective 
roles [127, 128].  
NP like CNTF also mediates motorneuron survival [29]. With respect to obesity, NP 
can inhibit adipogenesis but induces insulin-resistance [123].  
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IL-27 is a potent initiator of Th1-type immune responses [57, 129]. Moreover, IL-27 
can inhibit the differentiation of Th17 cells [130]. Besides the T-cell developmental 
functions of IL-27, it has also been demonstrated that IL-27 exerts interferon-like 
functions in liver cells and that this can contribute to the antiviral response in these 
cells [131]. 
IL-31 also has an impact on haematopoiesis. GPL-/- mice display decreased absolute 
numbers and cycling status of immature subsets of hematopoietic progenitor cells in 
bone marrow and spleen [132]. Moreover, GPL-/- mice show negative regulatory 
abilities of limiting type 2 (Th2-mediated) inflammation [133, 134].  
1.2.5 Ligand-dependent, constitutively active gp130 variants 
Interestingly, a marked activation of the Interleukin-6 signaling pathway in 
inflammatory hepatocellular adenomas was directly caused by gain-of-function 
mutations within the gp130 receptor chain, which led to ligand-independent, 
constitutively active gp130 proteins [135]. Almost all of these gp130 variants display a 
somatic in-frame deletion mutation that targets the binding site for IL-6 (site II). The 
gain-of-function gp130 mutations in these human hepatocellular adenomas are linked 
to the activation of the acute inflammatory phase observed in tumourous hepatocytes 
[135]. 
Previously, a ligand-independent, constitutively active gp130 variant has been 
established in this laboratory. Stuhlmann-Laeisz et al. replaced the entire 
extracellular portion of gp130 with the c-jun leucine zipper region to create the 
chimeric receptor protein L-gp130 [136]. Upon retroviral transduction into a factor-
dependent pre B-cell line, STAT3 as well as ERK1/2 phosphorylation was detected 
and the cells exhibited ligand-independent growth over several months [136]. 
Furthermore transfection of murine embryonal stem cells with L-gp130 led to up-
regulation of the stem cell factor OCT-4 and thus suppression of differentiation [136].  
The leucine zippers used to ligand independently activate gp130 are naturally found 
in transcription factors, such as Fos and Jun which form the AP-1 transcription factor 
complex. Naturally, Fos and Jun leucine zippers form heterodimers, but the Jun 
leucine zipper can also form stable homodimers albeit with significantly lower 
stability. The Fos leucine zipper forms an unstable homodimer, which provides a 
thermodynamic driving force for preferential heterodimer formation with Jun leucine 
zipper [137, 138]. Therefore, the leucine zipper based technology should be used to 
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generate ligand-independent, constitutively active receptor gp130-type complexes. 
During this work, it was shown that this approach was not suitable to generate ligand-
independent, constitutively active heterodimeric receptor complexes (Results 4.1-
4.3). Therefore a novel system comprising IL-15/IL-15Rα should be used to achieve 
ligand-independent, constitutive activation of heterodimeric gp130-type receptor 
complexes. 
1.3 IL-15 and the IL-15Rα 
IL-15 belong to the group of four helix bundle cytokines (Figure 1.4A) [3]. 
Interestingly, the α-receptor for IL-15 does not belong to the class I cytokine 
receptors like IL-6Rα. The IL-15Rα it is a type I transmembrane protein and is related 
to the IL-2Rα [139]. The cytokine binding domain of the IL-15Rα is called sushi 
domain (Figure 1.4A). Sushi domains are common motifs. They contain four 
cysteines forming two disulfide bonds in a 1–3 and 2–4 pattern and found in a 
number of proteins involved in the complement and coagulation cascades [140]. New 
insight in cytokine binding has been revealed by analyzing the complex of IL-15/IL-
15Rα. So far cytokine/cytokine receptor interaction was believed to occur in a ‘hot 
spot’ manner, meaning that the binding interfaces interact by hydrophobic forces 
(Figure 1.4 A)[141]. Another common mechanism was solved by analyzing the IL-
4/IL-4Rα complex which has been described to interact in an ‘avocado-like’ manner, 
with an outer mantle of hydrophobic side chain moieties and an inner core of polar 
groups (Figure 1.4 A) [142].  
For the IL-15/IL-15Rα complex instead, a novel mechanism of cytokine binding has 
been postulated. Most residues participating in the interaction are charged amino 
acids. The binding epitope of the IL-15Rα-sushi domain exhibits almost basic 
residues, whereas the IL-15 epitope comprises acidic residues (Figure 1.4A and C) 
[143]. Hence, the IL-15/IL-15Rα complex exhibits a very low dissociation rate (koff). 
This results in a low equilibrium binding constant (kD) in comparison to other 
cytokine/cytokine receptors as shown in Table 1.2.  
The IL-15/IL-15Rα complex binds to cognate β- and γ-receptors to initiate signaling. 
Interestingly, the IL-15/IL-15Rα complex utilizes the same signaling complex like the 
IL-2/IL-2Rα complex, the IL-2Rβ and IL-2Rγc [144]. The IL-2Rβ and IL-2Rγc belong 
to the group 4 and group 5 of class I cytokine receptors, respectively (Table 1.1). 
After receptor-ligand interaction associated JAKs are activated. The IL-2Rβ chain is 
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associated with JAK1, whereas IL-2Rγc is associated with JAK3, which in turn results 
in the phosphorylation of STAT3 and STAT5, respectively [145]. Additional signaling 
pathways triggered by IL-15 involve the phosphorylation of the Src family cytoplasmic 
tyrosine kinases Lck, Fyn, and Lyn, Syk kinase, PI3K and Akt as well as the 
Ras/Raf/MAPK pathway and NF-κB activation [146-150]. 
 
 
 
Figure 1.4 Biochemical mechanisms of ligand/receptor interaction, structure and electrostatic 
surface potential of IL-15 and IL-15Rα-sushi domain. A) Schematic representations of different 
biochemical mechanisms of ligand/receptor interaction. Only the ligands and their biochemical 
properties of the binding interfaces are shown for the ‘hot spot’ and the ‘avocado-like’ models. (B) 
Model of the complex of the IL-15Rα-sushi domain (blue) and IL-15 (yellow) as ribbon representation 
[143]. (C) Electrostatic surface potential of the IL-15Rα-sushi domain and IL-15. Negative charges are 
displayed in red, positive charges in blue. The complex of the α-receptor and its ligand were rotated by 
90° (the receptor left hand, the ligand right hand) [143].  
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complex kon (M-1 s-1) koff (s-1) kD (pM) reference 
IL-2/IL-2Rα 1.06 x 107 0.298 28100 [151] 
IL-4/IL-4Rα 1.9 x 107 2 x 10-3 105 [152] 
IL-6/IL-6Rα 1.9 x 107 6.4 x 10-3 34000 [153] 
IL-15/IL-15Rα 3.7 x 105 1.4 x 10-5 38 [154] 
IL-15/IL-15Rα-sushi 2.5 x 105 3.8 x 10-4 1500 [154] 
Table 1.2 Binding constants of cytokines and their cognate receptor. 
Several reports have suggested that the simultaneous expression of IL-15Rα in the 
same cell is necessary for the production and secretion of IL-15 under physiological 
conditions [155-159]. IL-15 complexes with the IL-15Rα in the endoplasmic reticulum 
(ER) in a chaperone-like manner and is passaged through the classical secretion 
pathway involving ER and the Golgi apparatus [160, 161]. Thereafter, IL-15 in 
complex with its α-receptor is expressed at the cell surface and can stimulate 
neighbouring cells expressing IL-2Rβ and IL-2Rγc in a trans-presentation manner. 
For example, this has been demonstrated for dendritic cells (DC), which presented 
the IL-15/IL-15Rα complex at the cell surface, supported natural killer cell (NK) 
activation [160].  
IL-15 can be detected in sera of mice and cell culture supernatants in a 
heterocomplex with soluble IL-15Rα [162]. Different sIL-15Rα molecules can be 
generated by alternative splicing or proteolytic cleavage  with different outcomes for 
signaling [162]. Whereas proteolysis might primarily be responsible for the generation 
of sIL-15Rα capable of inhibiting IL-15 action [162, 163], the secreted sIL-15Rα-sushi 
domain, which is generated by alternative splicing, exhibits agonistic qualities [162]. 
The latter has also been tested in a study using recombinant sIL-15Rα-sushi domain 
[154]. A study using different sIL-15Rα-sushi variants revealed that addition of 13 
amino acids encoded by exon 3 (the sushi domain is encoded by exon 2) leads to a 
stabilization of the IL-15/IL-15Rα complex by decreasing its dissociation rate but 
acted antagonistically in the presence of IL-15 [164]. 
Taken togehter, the complex of IL-15 and IL-15Rα displays an exceptional low koff 
and therefore a very low kD. This finding should be used in this work to generate 
ligand-independent and constitutively active heterodimeric complexes of all gp130-
type receptors.  
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2 Aim of the work  
The aim of this work was to generate ligand-independent, constitutively active, 
heterodimeric receptor complexes of all gp130-type receptors. Besides the 
homodimeric gp130-mediated signaling, other receptor complexes such as 
gp130/LIFR, gp130/OSMR, gp130/WSX-1, and GPL/OSMR could involved in 
inflammatory diseases and cancer. Furthermore, a new methodology to generate 
ligand-independent, constitutively active receptor complexes could be a useful tool to 
study the biochemical characteristics of several gp130-type heterodimeric receptor 
complexes with respect to signaling without any need of ligand treatment. 
Additionally, using this technology in vivo would be an advantage in comparison to 
ectopically expressed cytokines because expression of those ligand-independent, 
constitutively active, heterodimeric receptor complexes could be addressed at a cell 
autonomous level. 
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3 Material & methods 
3.1 Material 
3.1.1 Antibiotics 
Ampicillin (Carl Roth GmbH, Karlsruhe, Germany)   f.c. 100 µg/ml 
Kanamycin (Carl Roth GmbH, Karlsruhe, Germany)  f.c. 25 µg/ml 
Puromycin (PAA Laboratories GmbH, Cölbe, Germany) f.c. 1.5 µg/ml 
Hygromycin B (PAA Laboratories GmbH, Cölbe, Germany) f.c. 1 mg/ml 
 
3.1.2 Antibodies 
3.1.2.1 Primary antibodies 
α-c-myc mouse monoclonal antibody (9E10) recognizes human, mouse 
and rat c-myc protein as well as Myc-tag. Raised against a peptid 
corresponding to residues 408 – 439 of human c-myc (Santa 
Cruz Biotechnology, Inc., Heidelbeg, Germany). 
        WB: 1:1000 
 
α-FLAG   rabbit polyclonal antibodies recognize FLAG®-tag (DYKDDDDK) 
(Sigma-Aldrich Chemie, Taufkirchen, Germany). 
    WB: 1:1000 
 
α-FLAG   mouse monoclonal antibody (M2) recognizes FLAG®-tag 
(DYKDDDDK) (Sigma-Aldrich Chemie, Taufkirchen, Germany). 
    WB: 1:1000; FC 1:1000 (1 µg)  
   
α-GFP mouse monoclonal antibody (7.1 and 13.1) recognizes the green 
flourescent protein (GFP) (Aequorea victoria), GFP derivatives 
such as e.g. YFP, EYFP and CFP (Roche Applied Science, 
Mannheim, Germany). 
    WB: 1:1000; IP: 1:40 (2 µg) 
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α-IL-15 mouse monoclonal antibody recognizes human IL-15 
(PeproTech GmbH, Hamburg Germany). 
   FC: 1:100 (1 µg) 
 
α-IL-15 rabbit polyclonal antibody recognizes human IL-15 (AbD Serotec, 
Düsseldorf, Germany). 
    WB: 1:5000; IP: 1:100 (2 µg) 
 
α-gp130 rabbit polyclonal antibody (C-20) recognizes the intracellular 
domain of human, mouse and rat gp130 (Santa Cruz 
Biotechnology, Inc., Heidelbeg, Germany). 
    WB: 1:1000; IP: 1:40 (1 µg) 
 
α-Myc-tag rabbit monoclonal antibody (71D10) recognizes Myc-tag 
sequence (EQKLISEEDL) corresponding to residues 410 – 419 
of human c-myc (Cell Signaling Technology, Inc., Danvers, MA, 
USA, (New England Biolabs GmbH, Frankfurt, Germany)). 
   WB: 1:1000; FC: 1:1000 
 
α-Phospho-p44/42 rabbit polyclonal antibody recognizes broad species p44/42 
MAP kinase MAP kinase only if phosphorylated at residues Thr202 / Tyr204 
(Cell Signaling Technology, Inc., Danvers, MA, USA, (New 
England Biolabs GmbH, Frankfurt, Germany)). 
  WB: 1:1000 
 
α-p44/42  rabbit polyclonal antibody recognizes broad species  p44/42 
MAP Kinase MAP kinase (Cell Signaling Technology, Inc., Danvers, MA, USA, 
(New England Biolabs GmbH, Frankfurt, Germany)). 
    WB: 1:1000 
 
α-Phospho-STAT1 rabbit monoclonal antibody (58D6) recognizes  human, mouse 
and rat  STAT1 only if phosphorylated at residue Tyr701 (Cell 
Signaling Technology, Inc., Danvers, MA, USA, (New England 
Biolabs GmbH, Frankfurt, Germany)). 
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  WB: 1:1000 
  
α- STAT1 rabbit polyclonal antibodies recognize human, mouse, rat and 
monkey  STAT1 (Cell Signaling Technology, Inc., Danvers, MA, 
USA, (New England Biolabs GmbH, Frankfurt, Germany)). 
  WB: 1:1000 
 
α-Phospho-STAT3 rabbit monoclonal antibody (D3A7) recognizes  human, mouse 
and rat  STAT3 only if phosphorylated at residue Tyr705 (Cell 
Signaling Technology, Inc., Danvers, MA, USA, (New England 
Biolabs GmbH, Frankfurt, Germany)). 
  WB: 1:1000 
 
α- STAT3 mouse monoclonal antibody (124H6) recognizes  human, mouse, 
rat  and monkey STAT3 (Cell Signaling Technology, Inc., 
Danvers, MA, USA, (New England Biolabs GmbH, Frankfurt, 
Germany)). 
  WB: 1:1000 
 
α-Phospho- mouse monoclonal antibody (P-Tyr-100) recognizes tyrosine- 
Tyrosine  phosphorylated residues (Cell Signaling Technology, Inc., 
Danvers, MA, USA, (New England Biolabs GmbH, Frankfurt, 
Germany)). 
    WB: 1:2000 
3.1.2.2 Secondary antibodies 
ImmunoPure peroxidase conjugated goat anti-mouse IgG (H+L) (Thermo Fisher 
Scientific, p/a Perbio Science Deutschland, Bonn, Germany) 
 WB: 1:10,000  
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ImmunoPure peroxidase conjugated goat anti-rabbit IgG (H+L) (Thermo Fisher 
Scientific, p/a Perbio Science Deutschland, Bonn, Germany) 
 WB: 1:10,000 
 
Allophycocyanin conjugated AffiniPure F(ab’)2 fragment goat anti-mouse IgG (H+L) 
(Dianova GmbH, Hamburg, Germany) 
 FC: 1:100 
 
AlexaFluor® 488 conjugated F(ab’)2 fragment goat anti-rabbit IgG (H+L) (Invitrogen 
GmbH, Karlruhe, Germany) 
 FC: 1:100 
3.1.3 Bacterial media  
Luria Bertani (LB) medium    10 g NaCl 
       10 g  peptone 
       5 g yeast extract  
       ad 1 l  
       (pH 7.5) 
 
Luria Bertani (LB) plates    10 g NaCl 
       10 g  peptone 
       5 g yeast extract  
       20 g agar 
       ad 1 l  
       (pH 7.5) 
 
3.1.4 Buffers and Solutions 
Blocking buffer     1x TBS-T 
(Western blot)     5% nonfat dry milk 
DNA loading dye (6x)    0.1% bromophenol blue 
(agarose gel)     0.1% xylene cyanol  
       10 mM EDTA   
       40% glycerol 
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FACS buffer      1x PBS 
(flow cytometry)     1% BSA 
 
Mild lysis buffer      50 mM Tris-HCl (pH 7.5) 
(cell lysis)      150 mM NaCl  
1% Triton X-100  
1 x  protease inhibitor cocktail  
 
Laemmli buffer (5x)     185 mM Tris-HCl (pH 6.8)  
(SDS-PAGE)     50% glycerol 
10% sodium dodecyl sulfate 
5% β-mercaptoethanol  
0.05% bromphenol blue 
 
Lysis buffer      50 mM Tris-HCl (pH 7.5) 
(cell lysis)      150 mM NaCl 
2 mM EDTA 
1 mM NaF  
1 mM Na3VO4 
1% IGEPAL (NP-40)  
1% Trition-X-100 
 
Immunoprecipitation buffer    20 mM Tris-HCl (pH 7.5) 
(cell lysis)      150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1% Triton X-100  
2.5 mM Na4P2O7 
1 mM β-glycerophosphate 
1 mM Na3VO4 
1 x protease inhibitor cocktail  
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Phosphate buffered saline - PBS (1x)  137 mM NaCl  
(cell culture)      2.7 mM KCl 
       4.3 mM Na2HPO4 
       
1.47 mM KH2PO4 
       
(pH 7.6) 
 
Running gel (10%)    3.87 ml  ddH2O 
(SDS-PAGE)   2.55 ml   1.5 M Tris-HCl (pH 8.8) 
0.1 ml   10% sodium dodecyl sulfate 
3.33 ml   30% Acrylamide-Bis 29:1 
100 µl   10% Ammonium persulfate 
10 µl   TEMED 
 
S1 Buffer       50 mM Tris-HCl (pH 8.0) 
(Miniprep)       10 mM EDTA 
100 µg/ml RnaseA 
 
S2 Buffer       200 mM NaOH 
(Miniprep)       1% sodium dodecyl sulfate 
 
S3 Buffer       2.8 M KAc, pH 5.1 
(Miniprep) 
 
SDS Running buffer     25 mM Tris base   
(SDS-PAGE)      192 mM glycine 
0.1% sodium dodecyl sulfate
 
 
 
Stacking gel (4 %)     3.725 ml  ddH2O 
(SDS-PAGE)   0.625 ml   0.5 M Tris-HCl (pH 6.8) 
0.05 ml   10% sodium dodecyl sulfate 
0.67 ml   30% Acrylamide-Bis 29:1 
100 µl   10% Ammonium persulfate 
10 µl   TEMED 
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Stripping buffer     62.5 mM Tris-HCl (pH 6.8) 
(Western blot)     2% sodium dodecyl sulfate 
0.1% β-mercaptoethanol   
 
TBE (0.5x)       44.5 mM boric-acid 
(agarose-gels)     10 mM EDTA, pH 8.0 
44.5 mM Tris-HCl   
    
Transfer Buffer     25 mM Tris base  
(Western blot)     0.2 M glycine   
20% methanol  
(pH 8.5)   
 
 
Tris buffered saline with Tween 20  10 mM Tris base  
(1xTBS-T)      150 mM NaCl  
(Western blot)     0.1 % Tween 20 
(pH 7.6) 
 
3.1.5 Cell culture media, solutions and material 
DMEM or DMEM -/-    Dulbecco’s Modified Eagle Medium 
(high glucose 4.5 g/l and stable 
glutamin) (PAA Laboratories GmbH, 
Cölbe, Germany)  
 
DMEM +/+       Dulbecco’s Modified Eagle Medium 
(high glucose 4.5 g/l and stable 
glutamin) (PAA Laboratories GmbH, 
Cölbe, Germany) supplemented with 
10% fetal bovine serum (PAA 
Laboratories GmbH, Cölbe, Germany) 
and 1% penecillin / streptomycin (PAA 
Laboratories GmbH, Cölbe, Germany) 
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IMDM  Iscove’s modified DMEM (with L-
Glutamine) (PAA Laboratories GmbH, 
Cölbe, Germany) 
 
Trypsin EDTA (PAA Laboratories GmbH, Cölbe, Germany) 
 
Cell culture material was from Sarstedt AG & Co (Nürnbrecht, Germany). 
 
3.1.6 Cell lines  
Ba/F3-gp130  murine pre B-cell line stably 
transfected with a cDNA coding for 
human gp130. These cells grow in 
dependence of IL-6 and sIL-6R. 
Ba/F3-gp130 cells were from Immunex 
(Seattle, WA, USA). 
 
COS-7       African green monkey 
(Cercopithecus aethiops) kidney 
fibroblast-like cell line suitable for 
transient transfections (ATCC: CRL-
1651). 
 
Phoenix-Eco  packaging cell line (HEK293T) which 
is stably transfected with cDNAs 
expressing group-specific antigen, 
polymerase and envelope proteins for 
ecotrophic viruses. This cell line was a 
kind gift of Ursula Klingmüller (DKFZ, 
Heidelberg, Germany). 
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3.1.7 Chemicals 
All chemicals were from Carl Roth GmbH (Karlsuhe, Germany), Merck KGAa 
(Darmstadt, Germany) or Sigma-Aldrich Chemie, Taufkirchen, Germany). 
3.1.8 Enzymes 
All enzymes, including restriction enzymes, polymerases and DNA modifying 
enzymes are from Fermentas GmbH (St. Leon-Rot, Germany). 
3.1.9 Molecular weight markes 
For DNA analysis, GeneRulerTM 1 kb DNA ladder (250 – 10000 bp) was used. For 
protein analysis prestained molecular weight marker (25 – 120 kDa) was used. Both 
markes were obtained from Fermentas GmbH (St. Leon-Rot, Germany) 
3.1.10 Kits 
Cell viabilty assay: CellTiter-Blue® Cell Viability Assay (Promega GmbH, Mannheim, 
Germany) 
 
ECL detektion: ECL PlusTm (GE Healthcare, Munich, Germany) 
 
PCR clean up and gel extraction: Nucleospin® Extract II (Macherey-Nagel GmbH & 
Co. KG, Düren, Germany) 
 
Plasmid midi preparation: Nucleobond® Xtra Midi (Macherey-Nagel GmbH & Co. KG, 
Düren, Germany)  
 
Protein concentration determination: BCA protein assay (Thermo Fisher Scientific, 
p/a Perbio Science Deutschland, Bonn, Germany) 
 
RNA preparation: Nucleospin® RNA II (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany)  
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3.1.11 Oligonucleotides 
All oligonucleotides were purchased from Metabion GmbH (Munich, Germany). All 
oligonucleotides used are listed in Table 3.1. 
Name Sequence 5’-3’ 
5’Fos GAATTGTGCGGCGGCTTAACTGATACACTCCAA 
5’∆cysFos GAATTGGGCGGCGGCTTAACTGATACACTCCAA 
3’Fos AGTCGAATTCAGCTGCCAGGATGAACTC 
5’SPgp130FLAG GATCCTCGAGTCTAGACCCCGCAAG 
3’SPgp130FLAG for 
Fos-gp130 
GCCGCCGCACAATTCTTTATC 
3’SPgp130FLAG for  
∆cysFos-gp130 
GCCGCCGCCCAATTCTTTATC 
5’mWSX-1 GACTGAATTCTCACTTCACCTACCAGATAATAGG 
3’mWSX-1 GACTGGATCCTCAGACTAGAAGGCCCAGCTCCTC 
5’PPL-IL-15 GATCCTCGAGCCACCATGGACAGCAAAGGTTCG 
3’PPL-IL-15 GATCGAATTCAGAAGTGTTGATGAACATTTG 
5’mycsushi AGCGAGGAGGACCTGATCACATGCCCTCCCCCC 
3’sushi GATCGAATTCGTCTCTAATGCATTTGAG 
5’SPgp130myc GATCCTCGAGCCACCATGTTGACGTTGCAGACTTG 
3’SPgp130myc CAGGTCCTCCTCGCTGATCAGCTTCTGCTCACCTGTAGATTCAGTGG 
5’hygromycin B 
resistance 
GATCAAGCTTCCACCATGAAAAAGCCTGAACTCACC 
3’hygromycin B 
resistance 
GATCGTCGACTCAGTTAGCCTCCCCCATC 
5’hLIFR GAATTCCCGGAGAAGAGTATGTATGTG 
3’hLIFR GGATCCTTAATCGTTTGGTTTGTTCTG 
5’hOSMR GAATTCCCCAGTGCTACGTTCACG 
3’hOSMR GGATCCTTAGCAGTAGTGTT CACC 
5’hGPL GAATTCGGGACCAGCATAAATTTC 
3’hGPL GGATCCTTAGACTTCTCCCTTGG 
oligo-dT TTTTTTTTTTTTTTTTTT 
5’IL-15check CCACCATGGACAGCAAAG 
5’SPgp130check CCACCATGTTGACGTTGC 
3’gp130check TCACTGAGGCATGTAGCC 
3’WSX-1check TCAGACTAGAAGGCCCAG 
3’LIFRcheck ATCGTTTGGTTTGTTCTG 
3’OSMRcheck TTAGCAGTAGTGTTCACC 
3’GPLcheck TTAGACTTCTCCCTTGG 
5’mc-myc TTCTCAGCCGCTGCCAAGCTGGTC 
3’mc-myc GGTTTGCTGTGGCCTCGGGATGGA 
5’mPIM-1 GATCATCAAGGGCCAAGTGT 
3’mPim-1 CCATCTTGGTGACCCAGTCT 
5’beta-actin GTGGGGCGCCCCAGGCACCA 
3’beta-actin CTCCTTAATGTCACGCACGATTTC  
T7 promotor TAATACGACTCACTATAGGG 
M13 rev GGAAACAGCTATGACCATG 
5’pMOWS AGCCCTTTGTACACCCTAAGC 
3’pMOWS AGCAATAGCATGATACAAAGG 
Table 3.1 List of all primers used in this work. 
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3.1.12 Plasmids 
p409  mammalian expression vector for transient transfection; 
ampicillin-resistance 
 
p409-hLIFR mammalian expression vector for transient transfection; encodes 
human full-length human LIFR; ampicillin-resistance [165] 
 
p409-hOSMR mammalian expression vector for transient transfection; encodes 
human full-length human OSMR; ampicillin resistance [166] 
 
pBSK   cloning vector; ampicillin-resistance 
 
pBSK-L-gp130 cloning vector; it encodes constitutively active L-gp130; ampicillin 
resistance [136]   
 
pBSK-PPL-IL-15 cloning vector; it encodes human IL-15 which has an alternative  
signal peptide of bovine preprolactin; ampicillin-resistance; was a 
kind gift of Yannick Jacques (Nantes, France) [167] 
 
pcDNA3.1-hGPL mammalian expression vector for transfection; encodes human 
full-length GPL (IL-31R); ampicillin-resistance; was a kind gift of 
Hugues Gascan (Angers, France)  
 
pCEP4 an episomal mammalian expression vector; encodes hygromycin 
B resistance gene; ampicillin-resistance (Invitrogen GmbH, 
Karlsruhe, Germany).  
 
pEYFP-hgp130 Mammalian expression vector for transient transfection; it 
encodes EYFP-tagged full-length human gp130; kanamycin-
resistance [168] 
 
pMOWS Mammalian expression vector for retroviral transduction,   
ampicillin resistance and puromycin-resistance [169] 
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pPCR-script-HIL-6 cloning vector; encodes Hyper-IL-6; ampicillin-resistance  
 
pQE30-Fos bacterial expression vector; it encodes codon optimized Fos 
peptide (Geneart); ampicillin-resistance 
 
pQE30- bacterial expression vector, it encodes the sushi domain of 
IL-15Rα-sushi human IL-15Rα; ampicillin resistance [143] 
 
3.1.13 Recombinant proteins 
Hyper-IL-6 (HIL-6), a fusion protein of human IL-6 and human sIL-6R was produced 
in our working group as described [170]. Human IL-27 was a kind gift of Christoph 
Hölscher (Borstel, Germany). Human IL-15, human IL-15Rα-sushi domain was 
produced in our institute by Inken Lorenzen [143].  
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3.2 Methods 
3.2.1 Molecular biology 
3.2.1.1 Polymerase chain reaction (PCR) 
To amplify DNA sequences for cloning or detection, PCR was used. Pfu polymerase 
(Fermentas GmbH, St. Leon-Rot, Germany) was used for amplification of DNA for 
subsequent cloning, while Taq or DreamTaqTM DNA polymerases (Fermentas GmbH, 
St. Leon-Rot, Germany) were used for detection of specific DNA sequences.  
The following reaction mixture was used for the different applications: 
 
 Template  10 – 100 ng plasmid or 1 µl of cDNA or bacterial colonies 
 Forward primer 10 µM  
 Reverse primer  10 µM 
 dNTPs    10 mM each   
 PCR buffer (10x) 5 µl 
 Polymerase  1 U 
 ddH2O  ad 50 µl  
 
The PCR was performed with the following step gradient: 
 95°C   2 min 
 95°C   45 s 
 55°C   45 s   30 - 35 cycles  
 72°C   60-90 s 
 72°C   5 min  
 
A splicing by overlapping extension PCR (SOE-PCR) approach was used to ligate 
two PCR fragments. The mixture, as described above, was used and 1 µl of each 
PCR reaction was used as a template.   
3.2.1.2 Phosphorylation of PCR fragments 
For a subsequent blunt end ligation, PCR fragments obtained from PCR with Pfu 
polymerase were phosphorylatd with T4 polynucleotid kinase (Fermentas GmbH, St. 
Leon-Rot, Germany). In detail, 8 µl of PCR product were mixed with 1 µl ligase buffer 
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and 1 µl (10 U) of T4 polynucleotid kinase and incubated for 30 min at 37°C. 
Subsequently, the mixture was incubated for 20 min at 65°C to inactivate the 
enzyme. 5 µl thereof was used for ligation. 
3.2.1.3 Digestion of DNA 
The digestion of plasmids or PCR framgents was performed with restriction enzymes. 
The DNA was incubated with an appropriate amount of restriction enzymes in the 
recommended buffer for 1-3 h or overnight at 37°C. The digestion was terminated by 
addition of DNA sample buffer and the digested DNA was applied to an agarose gel.  
If a digestion with two enzymes was performed, the guide webpage of Fermentas 
GmbH was consulted (http://www.Fermentas GmbH.com/en/tools/doubledigest). If 
DNA blunting by fill-in 5’-overhangs was performed after digestion with the first 
enzyme, the DNA was purified using Nucleospin® Extract II (Macherey-Nagel GmbH 
& Co. KG, Düren, Germany) following the manufacturer’s instructions before the 
second digestion step was prepared. For a preparative digestion 10 µg of plasmid 
DNA and 10 U of each restriction enzyme were used in a total volume of 50 µl. For 
an analytical digestion 1 µg of plasmid DNA or 5 µl of a plasmid mini preparation and 
at least 3 U of each restriction enzyme were used in a total volume of 20 µl and 
incubated for 1 h at 37°C 
3.2.1.4 DNA blunting 
Klenow fragment (Fermentas GmbH, St. Leon-Rot, Germany) was used for DNA 
blunting by fill-in 5’-overhangs. After digestion with the appropriate restriction enzyme 
2 µl of dNTPs (10 mM) and 10 U of Klenow fragment were added (in all cases of 
DNA blunting the buffer used for digestion was 100% compatible with Klenow 
fragment). The mixture was incubated for 1 h at 37°C and the DNA was purified 
using Nucleospin® Extract II (Macherey-Nagel GmbH & Co. KG, Düren, Germany) 
following the manufacturer’s instructions. 
3.2.1.5 Dephosphorylation of Plasmid DNA 
After enzymatic restriction, the plasmid DNA was dephosphorylated by direct addition 
of 1 U Calf Intestinal Alkaline Phosphatase (CIAP) (Fermentas GmbH, St. Leon-Rot, 
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Germany) to the restriction reaction (the buffer used for digestion was 100% 
compatible with CIAP). The reaction was carried out at 37°C for 1-2 h. 
3.2.1.6 DNA Gel-electrophoresis 
DNA fragments were separated with horizontal electrophoresis chambers (Bio-Rad 
Laboratories GmbH, Munich, Germany) using agarose gels. Agarose gels were 
prepared by heating 1-2% (w/v) agarose (Biozym Scientific GmbH, Hess. Oldendorf, 
Germany) in 0.5x TBE buffer, depending on the size of the DNA fragments and the 
gels were supplemented with 0.002% ethidium bromide. The samples were mixed 
with an appropriate amount of 6x DNA sample buffer and loaded on the agarose gel. 
The gels were run at constant voltage (100 V) and finally documented using the Gel 
Doc 2000 UV-light documentation system (Bio-Rad Laboratories GmbH, Munich, 
Germany). 
3.2.1.7 Extraction of DNA fragments from agarose gel 
For isolation and purification of DNA fragments from agarose gels, ethidium bromide-
stained gels were illuminated with UV-light and the appropriate DNA band was 
excised from the gel with a clean scalpel and transferred into a reaction tube. The 
fragment was isolated by using Nucleospin® Extract II (Macherey-Nagel GmbH & Co. 
KG, Düren, Germany) following the manufacturer’s instructions. 
3.2.1.8 Determination of DNA or RNA concentration 
DNA concentration was determined spectroscopically using an Ultrospec 3000 
spectrophotometer (Pharmacia Biotech) or NanoDrop® ND-1000 (Peqlab 
Biotechnologie GmbH, Erlangen, Germany). For the Ultrospec 3000 
spectrophotometer the DNA or RNA were diluted 1:100 and the absorbance of 260 
nm, 280 nm and 320 nm were measured. The NanoDrop® ND-1000 can detect 
concentrations between 2 and 3700 ng/ul for dsDNA; 2 and 3000 ng/ul RNA and 2 
and 2400 ng/ul ssDNA, without dilution of samples. The ratio of A260/A280 of 1.8 or 
higher for DNA and 2.0 or higher for RNA indicated the purity of nucleic acid 
samples.  
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3.2.1.9 Ligation of DNA fragments 
For ligation cleaved and dephosphoylated vector and cleaved or phosphorylated 
insert were mixed in a ratio of 1:3 – 1:5 supplemented with 2 µl of ligation buffer and 
1 µl of T4 DNA ligase (Fermentas GmbH, St. Leon-Rot, Germany) in a total volume 
of 20 µl. The ligation approach was incubated for 2 h at room temperature and/or at 
4°C overnight.  
3.2.1.10 Transformation of chemocompetent E.coli  
One aliqout of chemocompetent XL-1-Blue E.coli were mixed with 10 – 100 ng of 
plasmid DNA or 20 µl of a ligation mixture and incubated for 10 min on ice. After a 
heat shock of 90 s at 42°C the cells were incubated for 10 min on ice. Subsequently, 
1 ml of LB-medium was added and the bacteria were incubated for 1 h at 37°C. 
Afterwards the bacteria were centrifuged (6000 x g, 1 min), the supernatant was 
removed, the pellet was resuspended in 100 µl LB-medium, and plated on LB-agar 
plates containing the appropriate antibiotics. Plates were incubated overnight at 
37°C. 
3.2.1.11 Plasmid isolation from 2 ml bacteria suspension – plasmid mini 
preparation 
2 ml LB-medium supplemented with the appropriate antibiotic was inoculated with a 
single colony and incubated overnight at 37°C and 600 rpm. Cultures were pelleted 
by centrifugation (6,000 x g, 1 min) and resuspended in 100 µl Buffer S1. For 
bacterial lysis the suspension was supplemented with 100 µl Buffer S2 and incubated 
for 2-3 min at room temperature. Subsequent 100 µl of Buffer S3 was added and the 
mixture was inverted until a homogenous suspension containing a white precipitate 
was formed. The bacterial lysate was cleared by centrifugation (16,000 x g, 10 min) 
and the resulting supernatant was transferred to a new reaction tube and 
supplemented with 600 µl ice cold 100% ethanol. The plasmid DNA was pelleted by 
centrifugation (16,000 x g, 10 min at 4°C) and washed once with ice cold 70% 
ethanol. The DNA pellet was dried in a speedvac and dissolved in 50 µl ddH2O. 
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3.2.1.12 Plasmid isolation from 100 ml bacteria suspension – plasmid midi 
preparation 
For preparation of large quantities of DNA, the Nucleobond® Xtra Midi kit (Macherey-
Nagel GmbH & Co. KG Düren, Germany) was used. A single colony was inoculated 
in 100 ml LB-medium supplemented with the appropriate antibiotic and incubated 
overnight at 37°C and 180 rpm. The culture was transferred into two 50 ml tubes and 
the cells were pelleted by centrifugation (4,000 x g, 25 min, 4°C). The plasmid was 
isolated from the bacteria according to the manufacture’s protocol. Finally the DNA 
pellet was resuspended in 120 µl ddH2O and the DNA concentration was determined. 
3.2.1.13 DNA sequencing 
DNA sequencing was performed by the company SeqLab GmbH, (Göttingen, 
Germany). For sequencing 0.7 µg of DNA and 20 µM sequencing primer were diluted 
in 7 µl ddH2O. 
3.2.1.14 RNA isolation 
Total RNA from Ba/F3-gp130 cells (~10 x 106 cells) was isolated with the 
Nucleospin® Extract II (Macherey-Nagel GmbH & Co. KG, Düren, Germany)  
following the manufacturer’s instructions and the RNA concentration was determined 
by UV-spectrophotometry.  
3.2.1.15 Reverse Transcription (RT) 
2 µg of total RNA was used for reverse transcrition reaction. In detail, 2 µg of total 
RNA were mixed with 100 µM oligo-dT primer in a total volume of 13 µl. This mixture 
was incubated for 10 min at 70°C and subsequently cooled to room temperature to 
achieve primer annealing. 200 U (1 µl) of RevertAidTM M-MuLV Reverse 
Transcriptase (Fermentas GmbH, St. Leon-Rot, Germany), 4 µl of the appropriate 
buffer and 2 µl of dNTPs (10 mM) were added to the mixture and incubated for 1.5 h 
at 37°C. Afterwards the mixture was again incubated for 10 min at 70°C. 1 µl of this 
RT-reaction was used for the subsequent PCR.  
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3.2.2 Cell culture and cell based assays 
3.2.2.1 Cell cultivation 
All cells (Ba/F3-gp130, COS-7 and Pheonix-Eco) were cultured in DMEM + 10% FBS 
+ 1% Pen/Strep (DMEM +/+). The medium for Ba/F3-gp130 cells was supplemented 
with 10 ng/ml Hyper-IL-6. The cells were maintained at 37°C with 5% CO2 in a water 
saturated atmosphere. All cells were cultured in 10 cm dishes. For passaging COS-7 
cells were washed with 10 ml sterile PBS and detached with 2 ml trypsin EDTA (PAA 
Laboratories GmbH, Cölbe, Germany). The cells were passaged in a ratio of 1:10 to 
a new 10 cm dish containing 10 ml fresh medium. Phoenix-Eco cells were directly 
trypzinised with 2 ml of trypsin EDTA and passaged in a ratio of 1:20. Ba/F3-gp130 
cells were passaged in a ratio of 1:100. Stably transduced Ba/F3-gp130 cells which 
exhibited cytokine independent growth were maintained in DMEM +/+ lacking Hyper-
IL-6. 
3.2.2.2 Transfection of eucaryotic cells 
For transfection of Phoenix-Eco cells either Lipofectamine 2000 (Invitrogen GmbH, 
Karlruhe, Germany) or Turbofect (Fermentas GmbH, St. Leon-Rot, Germany) was 
used. For transfection of COS-7 cells only Turbofect was used. In principle the 
manufacturer’s instructions were followed but the amount of DNA and transfection 
reaction were changed. In detail, the day before transfection 8 x 105  Phoenix-Eco 
cells (COS-7: 5 x 105 ) were seeded on a well of a 6-well plate (COS-7: 10 cm dish). 
The day after seeding Phoenix-Eco cells were transfected with 1 µg of DNA (COS-7: 
5 µg) and 3 µl of Lipofectamine 2000 or 2 µl of Turbofect (COS-7: 10 µl). After 6 h of 
incubation the medium was exchanged by fresh DMEM +/+. In case of Phoenix-Eco 
cells IMEM (DMEM) + 30% FBS, 50 µM β-mercaptoethanol + 1% pen/strep was 
used. 24 h later this supernatant was used for retroviral transduction of Ba/F3-gp130 
cells. In the case of COS-7 cells normal DMEM +/+ was used for medium change 
and the cells were lyzed 48 h after transfection. 
3.2.2.3 Starvation of cells  
Ba/F3-gp130 cells (~10 x 106 cells) were collected in a 15 ml tube and pelleted (1000 
x g, 5 min). The medium was removed and the cells were washed three times with 
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PBS. The cells were resuspended in DMEM -/- containing no FBS. The cells were 
starved for 6 h, again collected in a 15 ml tube and pelleted (1000 x g, 5 min). After 
removal of the medium, RNA isolation or cell lysis for protein-biochemical analysis 
was performed. 
Transiently transfected COS-7 cells were also washed three times with PBS and the 
cells were starved in DMEM -/- for at least 20 h prior lysis.  
3.2.2.4 Pervanadat treatment of COS-7 cells 
500 µl of 100 mM sodium orthovanadate solution was incubated with 2.8 µl of 30% 
H2O2 to obtain pervanadate. Immediately after preparation of pervanadate COS-7 
cells were treated with 1 mM pervanadate for 15 min at 37°C prior lysis to block 
tyrosine-dephosphorylation.  
3.2.2.5 Retroviral transduction of Ba/F3-gp130 cells 
Ba/F3-gp130 were retrovirally transduced with supernatants of pMOWS transfected 
Phoenix-Eco cells [169]. In detail, 1 x 105 Ba/F3-gp130 in 50 µl of DMEM +/+ were 
mixed with 250 µl filtrated (pore size 0.45 µM, Carl Roth GmbH, Karlsruhe, Germany) 
Phoenix-Eco supernatants. Additionaly 3 µl of polybrene (f.c. 8 µg/ml) were added. 
The cells were centrifuged for 2 h (300 x g, 25°C). Afterwards the cells were 
cultivated for 48 h in wells of 6-wells plates with 5 ml DMEM +/+ supplemented with 
10 ng/ml Hyper-IL-6. Thereafter, the cells were treated with the appropriate 
antibiotics (puromycin: 1.5 µg/ml and/or hygromycin B: 1 mg/ml or both) for at least 2 
weeks.  
3.2.2.6 Cell viability assay  
Retrovirally transduced Ba/F3-gp130 cells were washed three times with sterile PBS 
and resuspended in DMEM +/+ at 5 x 103 cells per well of a 96-well plate. The cells 
were cultured for three days in a final volume of 100 µl with or without additional 
cytokines as indicated. For inhibition studies with soluble IL-15Rα-sushi domain the 
recombinant protein was added as indicated. The CellTiter-Blue® Cell Viability Assay 
(Promega GmbH, Mannheim, Germany) was used to determine the proliferation 
following the manufacturer’s instructions and measured on a Lambda Fluoro 320 
Fluorimeter (ex-filter 530/25, em-filter 590/35, sensitivity 75, Software KC4). Relative 
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light units (RLU) values were normalized by substraction of negative control values 
(unstimulated Ba/F3-gp130 cells or transduced Ba/F3-gp130 cells which exhibited no 
cytokine independent growth) from all other values. All values were measured in 
quadruplicates. 
3.2.2.7 Co-culture experiments of Ba/F-gp130-GFP cells with Ba/F-gp130 cells 
stably transduced with fusion receptor genes 
Ba/F3-gp130 cells expressing GFP (2 x 105 cells) were co-cultured in a 12-well plate 
with Ba/F3-gp130 cells expressing either IL-15-gp130, IL-15-WSX-1 + sushi-gp130 or 
Fos-gp130 (1 x 104 cells) at a ratio of 20:1. After 24h, 48h, 72h and 96h the green 
fluorescent cells were quantified by flow cytometry.  
3.2.2.8 Co-culture assay of murine dendritic cells with Ba/F3-gp130 cells  
Murine bone marrow derived dendritic cells were prepared as described [171]. 
Murine dendritic cells were plated (2 x 105 cells) into a 12-well plate and stimulated 
with LPS (10 ng/ml) overnight. The cells were washed three times with PBS to wash 
away LPS and Ba/F3-gp130 cells expressing fusion receptors were co-cultured (2 x 
106 cells) at a ratio of 1:10. After 24 h of co-culturing the supernatants were analyzed 
for mIL-6 secretion. Murine IL-6 was measured by ELISA (R&D Systems GmbH, 
Wiesbaden-Nordenstadt, Germany) and normalized to different Ba/F3-gp130 cell 
numbers obtained after 24 h. (this experiment was performed by Elena Bulanova, 
Borstel, Germany) 
 
3.2.2.9 Flow cytometry staining and analysis  
To detect the surface expression of the fusion receptors, 3 x 105 cells were washed 
with 1 ml FACS buffer, centrifuged (300 x g, 5 min, 4°C) and incubated with the 
appropriate antibody in 100 µl FACS buffer for 1 h at 4°C, respectively. After a single 
wash with 1 ml of FACS buffer and centrifugation (300 x g, 5 min, 4°C), cells were 
incubated with the appropriate secondary antibody in 100 µl FACS buffer for 1 h at 
4°C. Cells were washed once with 1 ml FACS buffer, centrifuged (300 x g, 5 min, 
4°C), resuspended in 500 µl FACS buffer and analyzed by flow cytometry (BD – 
FACS-Canto and FACS DIVA software, Heidelberg, Germany). 
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3.2.3 Protein-biochemical methods 
3.2.3.1 Cell lysis 
The medium of COS-7 cells was removed and the cells were once washed with 10 ml 
ice cold PBS. Cells were scraped from the dishes with 1 ml ice cold PBS, the 
suspension was transferred to a 1.5 ml reaction tube and the cells were pelleted 
(16,000 x g, 15 s, 4°C). The cells were lyzed in 250 µl of the appropriate lysis buffer, 
vortexed and incubated for at least 30 min at 4°C under gentle agitation. 
Afterwards the lysates were centrifuged (16,000 x g, 20 min, 4°C) to remove debris. 
The lysate was used directly for protein concentration determination or 
immunoprecipitation and/or subsequent Western blot analysis.  
Starved Ba/F3-gp130 cells were pelleted (16,000 x g, 15 s, 4°C) and lyzed in 300 µl 
of lysis buffer, vortexed and incubated for at least 30 min at 4°C under gentle 
agitation. Afterwards the lysates were transferred to a 1.5 ml reaction tube and 
centrifuged (16,000 x g, 20 min, 4°C) to remove debris. The lysates were directly 
used for protein concentration determination and subsequent western blot analysis. 
All lysates were stored at -20°C.  
3.2.3.2 Determination of protein concentration (BCA protein Assay) 
To analyse the protein concentration of lysates the BCA protein assay (Thermo 
Fisher Scientific, p/a Perbio Science Deutschland, Bonn, Germany) was used 
following the manufacturer’s instructions. The lysates of COS-7 cells were diluted 1:2 
in lysis buffer, Ba/F3-gp130 lysates were diluted 1:5 in lysis buffer. The assay was 
performed in a 96-well plate, incubated for 15 min at 37°C and subsequently 
analyzed at 562 nm in a microtiter plate reader (Tecan Germany GmbH, Crailsheim, 
Germany).  
3.2.3.3 SDS-polyacrylamid gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed with a discontinuous SDS-PAGE using the 
mini Trans-Blot® cell gadgetry (Bio-Rad Laboratories GmbH, Munich, Germany). First 
the running gel was poured (1 mm thickness; 5.5 cm height) and covered with 
isopropanol to avoid air bubbles. After polymerization the isopropanol was removed 
and the stacking gel was poured (1 mm thickness; 1.2 cm height) and a comb with 10 
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wells was added. After polymerization the mini Trans-Blot® cell gadgetry was 
assembled and SDS running buffer was added. Protein lysates were supplemented 
with Laemmli buffer and heated to 95°C for 5 min prior loading to the gel. The gel 
was run at 100 -180 V until the bromphenol blue line reached the end of the gel.   
3.2.3.4 Western blotting 
Proteins were transferred from the SDS-gel on a polyvinylidene difluoride (PVDF) 
membrane (GE Healthcare) using Trans-Blot® SD semi-dry transfer cell (Bio-Rad 
Laboratories GmbH, Munich, Germany). First the PVDF membrane was activated by 
incubation with methanol for 3 min and subsequently incubated with ddH2O for 
additional 3 min. The ddH2O was removed and the membrane and the the Whatman® 
papers were soaked in blotting buffer. 
The blotting sandwich was assembled as described in the manufacturer’s protocol. 
Proteins were transferred electrophoretically semidry at constant voltage (15 V, 60 
min). Afterwards the membrane was blocked in 5% milk powder in TBS-T for 1 h at 
room temperature. The membrane was probed with the primary antibody overnight at 
4°C. The membrane was washed three times with TBS-T for 5 min and the 
appropriate secondary antibody was probed for 1 h at room temperature. After three 
washing steps, the membrane was incubated with ECL PlusTm (GE Healthcare, 
Munich, Germany) following the manufacturer’s protocol. The chemiluminescence 
was meassured with the CCD camera systems LAS-1000 (Fujifilm, Düsseldorf, 
Germany) or FluorChem® Q (Alpha Innotech, Cell Biosciences, Inc., Santa Clara, CA, 
USA). 
3.2.3.5 Stripping of membranes 
After detection, the membranes were stripped in stripping buffer for 30 min at 60°C, 
washed three times in TBS-T, blocked again and probed with a new primary 
antibody. 
3.2.4 Computational biology 
To determine the transmembrane region of WSX-1 the program DAS (Dense 
Alignment Surface) [172] was used. To determine the transmembrane regions of 
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LIFR, OSMR and GPL the program TMHMM (Tied Mixture Hidden Markov Model), 
[173] was used. 
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Ligand independent
Signal
Jun-WSX-1
Fos Jun
CC
Fos-gp130
4 Results 
4.1 Generation of forced heterodimers of gp130 and WSX-1 using a leucine 
zipper based strategy. 
To achieve forced, ligand-independent heterodimerization of gp130 and WSX-1 
based on leucine zipper heterodimerization, the entire extracellular portion of gp130 
except of 15 membrane proximal amino acids was substituted by the 40 amino acid 
Fos leucine zipper sequence of the transcription factor c-Fos [137] and the entire 
extracellular portion of WSX-1 except of 15 amino acids by the 39 amino acid Jun 
leucine zipper sequence of the transcription factor c-Jun [137] as schematically 
illustrated in Figure 4.1. The chimeric proteins were named Fos-gp130 and Jun-
WSX-1. 
 
Figure 4.1 Forced heterodimerization strategy 
scheme of gp130 and WSX-1 based on leucine zipper 
heterodimerization. Gp130 and WSX-1 were truncated 
15 amino acids above the transmembrane domain and 
replaced by the leucine zipper region of the human c-Jun 
or c-Fos gene. The chimeric proteins are stabilized with 
an additional cysteine and a FLAG-tag was introduced to 
ease detection (green rectangle).  
 
 
 
 
 
NH2-terminally of the leucine zipper a linker was introduced, which consists of a 
cysteine residue to stabilize the leucine mediated heterodimerization of gp130 and 
WSX-1. Additionally, we constructed the chimeric protein ∆cys-Fos-gp130, which 
lacks the cysteine residue to prevent unwanted stabilization of a Fos-gp130 
homodimer by a disulfide-bridge. To ease detection of the chimeric proteins, a FLAG 
epitope tag was placed NH2-terminally of the linker. In the following text the cloning 
strategy of Fos-gp130, ∆cys-Fos-gp130 and Jun-WSX-1 will be explained in detail. 
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4.2 Construction of Fos-gp130, ∆cys-Fos-gp130 and Jun-WSX-1 expression 
plasmids  
The Fos-gp130 fusion receptor has the following assembly: gp130 signal peptide 
(MLTLQTWLVQALFIFLTTESTG), FLAG sequence (DYKDDDDK), linker (for Fos-
gp130:ELCGG, for ∆cys-Fos-gp130: ELGGG), 39 amino acid human Fos protein 
fragment (LTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAA) [137] and a N-
terminally truncated gp130-protein (15 aa of the extracellular domain, 
transmembrane domain and cytoplamic domain – amino acids 606-918). In detail, we 
used pQE30-Fos, which encodes a codon optimized Fos protein (Geneart, 
Regensburg, Germany), as a template for PCR to amplify the Fos-coding sequence 
(5’Fos [Fos-gp130] or 5’∆cysFos [∆cys-Fos-gp130] and 3’Fos [for both constructs]). 
The coding sequence of the gp130 signal peptide, FLAG tag and linker was amplified 
by PCR, using the plasmid pBSK-Jun-gp130 as a template (5’SPgp130FLAG and 
3’SPgp130FLAG [Fos-gp130] or 3’SPgp130FLAG∆cys [∆cys-Fos-gp130]). Both PCR 
products were combined in subsequent SOE-PCR, because the coding sequence of 
Fos contains a 5’ overhang, which primes the coding sequence of the linker, using 
the 5’ and 3’ primers of the initial PCRs. The purified PCR products [SP_FLAG_Fos 
or SP_FLAG_∆cys-Fos] were digested with XhoI and EcoRI and subcloned into 
pBSK-gp130 (∆N-term). This vector was obtained by digestion of pBSK-Jun-gp130 
with XhoI and EcoRI. The resulting plasmids were named pBSK-Fos-gp130 or pBSK-
∆cys-Fos-gp130 (Figure 4.1). All constructs were subcloned into pMOWS [169]. In 
detail, the pMOWS plasmid was digested with XagI and blunt ends were generated 
by Klenow fragment reaction. The pBSK plasmids encoding Fos-gp130 and -∆cys-
Fos-gp130 were digested with XhoI and blunt ends were generated by Klenow 
fragment reaction. In a second digestion step, the target plasmid and the insert 
encoding plasmids were digested with BamHI, purified and subcloned. The resulting 
plasmids were named pMOWS-Fos-gp130 and pMOWS-∆cys-Fos-gp130 (Figure 
4.2). The constructs Fos-gp130 and ∆cys-Fos-gp130 were additionally subcloned into 
p409. In brief, the plasmid p409 was digested with SalI and NotI. The pBSK plasmids 
encoding Fos-gp130 and ∆cys-Fos-gp130 were digested with XhoI and NotI, purified 
and subcloned. The resulting plasmids were named p409-Fos-gp130 and p409-∆cys-
Fos-gp130 (Figure 4.1). The cDNA coding for ∆cys-Fos-gp130 was additionally 
subcloned into pEYFP-gp130 [168]. In detail, the plasmid pEYFP-gp130 was 
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digested with XhoI and AccI as well as the plasmid pBSK-∆cys-Fos-gp130. Both 
were purified and subcloned. The resulting plasmid was named pEYFP-∆cys-Fos-
gp130 (Figure 4.2).  
 
 
Figure 4.2 Schematic overview of cloning of Fos-gp130 and ∆cys-Fos-gp130 into different 
plasmids. See text for details. 
 
The Jun-WSX-1 receptor has the following assembly: gp130 signal peptide 
(MLTLQTWLVQALFIFLTTESTG), FLAG sequence (DYKDDDDK), linker (ELCGG), 
39 amino acid human Jun protein fragment 
(RIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMN) [137] and N-terminally 
truncated WSX-1-protein (15 amino acids of the extracellular domain, 
transmembrane domain and cytoplamic domain – amino acids 500-623). In detail, the 
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truncated murine WSX-1 coding sequence was amplified by PCR using cDNA from 
Ba/F3-gp130 cells as a template (5’mWSX-1 and 3’mWSX-1). The purified PCR 
product was digested with EcoRI and BamHI and subcloned in the vector pBSK-Jun, 
which was obtained by digestion of pBSK-Jun-gp130 with EcoRI and BamHI. The 
resulting plasmid was named pBSK-Jun-WSX-1 (Figure 4.3). The cDNA coding for 
Jun-WSX-1 was subcloned to the plasmid pMOWS as described above. The plasmid 
was named pMOWS-Jun-WSX-1 (Figure 4.3). 
 
 
Figure 4.3 Schematic overview of cloning of Jun-WSX-1 into different expression plasmids. See 
text for details. 
  
Ba/F3-gp130 cDNA
PCR
WSX-1 [15 aa ECD + TMD + ICD]
EcoRI + BamHI
+
pBSK-L-gp130
[EcoRI + BamHI]
ligation
pBSK-Jun-WSX-1
XhoI + Klenow + BamHI
+
pMOWS-GFP
[XagI +Klenow + BamHI]
ligation
pMOWS-Jun-WSX-1
RESULTS   
- 44 - 
4.3 Specific Jun/Fos chimeric gp130-type receptor heterodimerization was 
not achieved due to unexpected homodimerization of the Fos-gp130 receptor 
chimera 
First, it was asked whether the chimeric receptors Fos-gp130, ∆cys-Fos-gp130 and 
Jun-WSX-1 induced ligand-independent cell growth in Ba/F3-gp130 cells if expressed 
alone. Ba/F3-gp130 cells are factor-dependent and grow in the presence of Hyper-IL-
6, a fusion protein of IL-6 and the soluble IL-6R connected by a flexible linker [170], 
or IL-3. We selected Ba/F3-gp130 cells as a cellular system to assess the long-term 
activity of the chimeric heterodimeric receptor complexes, because these cells were 
successfully used to show ligand-independent and constitutive activation of the 
homodimeric Jun-gp130 receptor fusion protein (L-gp130) [136]. Ba/F3-gp130 cells 
were retrovirally transduced with the cDNA encoding Fos-gp130, ∆cys-Fos-gp130 or 
Jun-WSX-1. After selection, surface expression of the chimeric receptors was 
measured by flow cytometry (Figure 4.4). 
 
 
Figure 4.4 Cell surface expression of Fos-gp130, ∆cys-Fos-gp130 and Jun-WSX-1 in stably 
transduced Ba/F3-gp130 cell lines analyzed by flow cytometry. The cell lines were labeled as 
described in material & methods. Untransfected Ba/F3-gp130 cells were used as negative control 
(unfilled histograms). 
 
To adress the question whether the stably transfected Ba/F3-gp130 cell lines grow 
cytokine independently, a proliferation assay in medium lacking Hyper-IL-6 was 
performed. Previously it has been shown that cytokine withdrawal led to induction of 
the intrinsic apoptotic pathway in Ba/F3-gp130 cells [103]. In addition we used the 
previously described cell line Ba/F3-gp130-L-gp130 as a positive control for cytokine 
FLAG
∆cys-Fos-gp130 Jun-WSX-1Fos-gp130
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independent growth [136]. Surprisingly, Ba/F3-gp130-Fos-gp130 cells and Ba/F3-
gp130-∆cys-Fos-gp130 cells proliferated in the absence of Hyper-IL-6, indicating that 
the Fos peptide alone was able to mediate homodimerization of gp130. On the other 
hand, Ba/F3-gp130-Jun-WSX-1 cells were not able to grow cytokine independently 
(Figure 4.5).  
 
Figure 4.5 Functionality of Fos-
gp130 chimeric receptor proteins in 
stable transfected Ba/F3-gp130 cell 
lines. Equal numbers of Ba/F3-gp130 
cells stably transfected with Jun-WSX-
1, L-gp130, Fos-gp130 or ∆cys-Fos-
gp130 were cultured for three days in 
the absence of Hyper-IL-6. As a 
control Ba/F3-gp130 were cultured in 
the presence or absence of 10 ng/ml 
Hyper-IL-6. Proliferation was 
measured as indicated in material & 
methods. 
 
To demonstrate that Fos-gp130 homodimers were stabilized by intermolecular 
disulphide bridges, a Western blot analysis of COS-7 cell lysates containing Fos-
gp130 and ∆cys-Fos-gp130 under reducing and non-reducing conditions was 
performed.  
  Figure 4.6 Detection of Fos-gp130 
homodimers under non-reducing 
conditions. COS-7 cells were 
transiently transfected with p409-YFP, 
p409-Fos-gp130 or p409-∆cys-Fos-
gp130. 48 h after transfection, cells 
were lyzed and 50 µg of protein 
lysates were separated by SDS-PAGE 
under reducing or non-reducing 
conditions. Proteins were detected 
with a anti-FLAG-tag antibodies and 
visualized by ECL detection. 
 
Monomeric Fos-gp130 could be detected under reducing conditions and a dimeric 
form of Fos-gp130 under non-reducing conditions, as depicted in Figure 4.6. 
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Importantly, dimeric ∆cys-Fos-gp130 was not detected under non-reducing 
conditions. 
Co-immunoprecipitation analysis was performed to show the physical interaction 
between two ∆cys-Fos-gp130 proteins. Lysates of COS-7 cells containing ∆cys-Fos-
gp130 alone or ∆cys-Fos-gp130 and ∆cys-Fos-gp130-EYFP were incubated with 
anti-GFP antibodies for immunoprecipitation. EYFP is a derivative of GFP and 
therefore can be precipitated by anti-GFP antibodies. As indicated in the left panel of 
Figure 4.7, ∆cys-Fos-gp130 could only be detected in the lysates (input) but not after 
anti-GFP immunoprecipitation in single transfected cells, showing that ∆cys-Fos-
gp130 does not unspecifically interact with anti-GFP antibodies or protein G agarose. 
However, ∆cys-Fos-gp130 could be specifically co-immunoprecipitated with ∆cys-
Fos-gp130-EYFP as indicated in the right panel of Figure 4.7. Consequently, it can 
be concluded that Fos-gp130 homodimers can be formed even in the absence of a 
stabilizing intermolecular disulfide bridge using ∆cys-Fos-gp130. 
 
Figure 4.7 Detection of ∆cys-
Fos-gp130 homodimers by co-
immunoprecipitation. COS-7 
cells were transiently transfected 
with p409-∆cys-Fos-gp130 or 
p409-∆cys-Fos-gp130 and 
pEYFP-∆cys-Fos-gp130. 48 h 
after transfection cells were lyzed 
and ∆cys-Fos-gp130-EYFP was 
immunoprecipitated with anti-
GFP antibodies. As a control, 
lysates were incubated only with protein G agarose. Input, immunoprecipitation supernatant and 
protein G agarose control supernatant were separated by SDS-PAGE. Proteins were detected with 
anti-GFP specific antibodies and an anti-gp130 specific antibody and visualized by ECL detection. 
 
Upon binding of IL-6/IL-6R to gp130, JAK proteins are activated and gp130 is 
subsequently phosporylated at distinct tyrosine residues [54, 174]. To demonstrate 
that ∆cys-Fos-gp130 is also phosphorylated at tyrosine residues after forced 
dimerization via the Fos peptide, an immunoprecipitation assay with COS-7 cell 
lysate containing ∆cys-Fos-gp130 was performed. COS-7 cell lysate containing ∆cys-
Fos-gp130 was incubated with anti-gp130 specific antibodies and ∆cys-Fos-gp130 
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was immunoprecipitated. Western blot analysis with an anti-phospho-tyrosine specific 
antibody revealed that precipitated ∆cys-Fos-gp130 was phosphorylated at tyrosine 
residues (Figure 4.8). 
 
Figure 4.8 Tyrosine-phosphorylation of ∆cys-Fos-
gp130. COS-7 cells were transiently transfected with p409-
∆cys-Fos-gp130 and starved 20 h before lysis. 48 h after 
transfection, COS-7 cells were lyzed and ∆cys-Fos-gp130 
was immunoprecipitated with anti-gp130 antibodies. 
Immunoprecipitation supernatant was separated by SDS-
PAGE. Proteins were transferred onto PVDF membrane 
and were detected with anti-phospho-tyrosine (α-PY) antibodies and visualized by ECL detection. To 
confirm immunoprecipitation of ∆cys-Fos-gp130 the membrane was stripped and probed with anti-
FLAG antibodies. 
 
These results were verified by analysis of the STAT3 phosphorylation status of the 
retrovirally transduced cells. Here, Ba/F3-gp130-Fos-gp130 cells and Ba/F3-gp130-
∆cys-Fos-gp130 cells as well as Ba/F3-gp130-L-gp130 cells but not Ba/F3-gp130-
Jun-WSX-1 cells cells showed a cytokine independent phosphorylation of STAT3 
(Figure 4.9). 
These results indicated that the heterodimerization strategy comprising heterodimers 
of Jun and Fos will not exclusively lead to gp130 heterodimerization with WSX-1 or 
other members of the gp130-like cytokine receptor family. Although it has been 
reported that Fos leucine zippers form unstable homodimers [137], the Fos mediated 
homodimerization of ∆cys-Fos-gp130 was strong enough to induce ligand-
independent growth in Ba/F3-gp130-∆cys-Fos-gp130 cells (Figure 4.5 and 4.10). 
 
Figure 4.9 Ligand-independent phosphorylation 
of STAT3 proteins in Ba/F3-gp130 cells. After 6 h 
of serum starvation Ba/F3-gp130 cells stably 
transfected with Jun-WSX-1, L-gp130, Fos-gp130 
or ∆cys-Fos-gp130 were left untreated, whereas 
untransfected Ba/F3-gp130 were stimulated for 10 
min with 10 ng/ml Hyper-IL-6 or were left untreated. 
Subsequently, cells were lyzed and 50 µg were 
separated by SDS-PAGE. Proteins were transferred onto PVDF membranes and were detected with 
an anti-P-STAT3 specific antibody and visualized by ECL detection. After detection the membrane 
was stripped and probed with an anti-STAT3 specific antibody and proteins were visualized by ECL 
detection. 
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Figure 4.10 Attempt to establish Jun-Fos heterodimeric chimeric receptors failed upon Fos 
homodimerization of ∆cys-Fos-gp130 as schematically illustrated.
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4.4 Generation of forced heterodimers of gp130 and WSX-1, LIFR, OSMR or 
GPL and OSMR using a novel strategy comprising IL-15 and IL-15Rα-
sushi.  
Due to the disappointing results in terms of leucine zipper-based strategy, a complete 
novel strategy to achieve forced receptor heterodimerization was used. Because of 
the high affinity of IL-15 to the sushi domain of IL-15Rα (sushi) [154, 164] it was 
decided to use these proteins or domains to investigate the potency of their ability to 
mediate forced heterodimerization of gp130 with WSX-1, LIFR, OSMR or GPL and 
OSMR.  
The complete extracellular portions of gp130, WSX-1, LIFR, OSMR and GPL except 
of 15 amino acids were exchanged to either the 148-amino acid sequence of IL-15 
(PPL-IL-15) or the 66-amino acid sequence of IL-15Rα-sushi-domain. The transport 
of the IL-15 fused chimeric receptors to the plasma membrane was driven by the 
signal peptide of bovine preprolactin (PPL) and of the IL-15Rα-sushi domain fused 
receptors by the signal peptide of human gp130. To ease detection of IL-15Rα-sushi-
domain fused receptors, a Myc-tag was introduced NH2-terminally of the sushi 
domain. The resulting fusion receptors were named IL-15-gp130, IL-15-WSX-1, IL-
15-LIFR, IL-15-OSMR and IL-15-GPL as well as sushi-gp130, sushi-WSX-1, sushi-
LIFR, sushi-OSMR and sushi-GPL (Figure 4.11). In the following text the cloning 
strategy of the new chimeric receptors will be explained in detail. 
 
Figure 4.11 Forced heterodimerization 
strategy scheme of gp130 and WSX-1, 
LIFR, OSMR or GPL and OSMR based 
on IL-15/IL-15Rα-sushi 
heterodimerization. Gp130, WSX-1, 
LIFR, OSMR and GPL were truncated 15 
amino acids above the transmembrane 
domain and replaced by IL-15 or IL-15Rα-
sushi domain. All IL-15Rα-sushi domain 
chimeras were N-terminally tagged with a 
Myc-tag to ease detection (not shown). 
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4.5 Construction of IL-15-gp130, IL-15-WSX-1, IL-15-LIFR, IL-15-OSMR, IL-15-
GPL, sushi-gp130, sushi-WSX-1, sushi-LIFR, sushi-OSMR and sushi-GPL 
expression plasmids  
The IL-15-fusion receptors pBSK-IL-15-gp130, pBSK-IL-15-WSX-1, pBSK-IL-15-
LIFR, pBSK-IL-15-OSMR and pBSK-IL-15-GPL were assembled as followed: bovine 
preprolactin (PPL) signal peptide 
(MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTR), human IL-15 protein fragment 
[167] and the N-terminally truncated receptor proteins (15 amino acids of the 
extracellular domain, transmembrane domain and cytoplasmic domain). For 
construction of IL-15 fusion receptors, pBSK-PPL-IL-15 was used [167]. The plasmid 
pBSK-PPL-IL-15 encodes human IL-15 which consists of an alternative signal 
peptide from the bovine preprolactin and was used as a template to amplify the 
coding sequence by PCR (5’PPL-IL-15 and 3’PPL-IL-15). The purified PCR product 
was digested with XhoI and EcoRI and subcloned into pBSK-gp130 (∆N-term – 
amino acids 606-918), which was obtained by digestion of pBSK-Jun-gp130 with 
XhoI and EcoRI. The resulting plasmid was named pBSK-IL-15-gp130 (Figure 4.11). 
The IL-15Rα-sushi (sushi) fusion receptors IL-15Rα-sushi-gp130 (sushi-gp130), 
sushi-WSX-1, sushi-LIFR , sushi-OSMR and sushi-GPL were assembled as followed: 
gp130 signal peptide (MLTLQTWLVQALFIFLTTESTG), Myc-tag (EQKLISEEDL), 
human IL-15Rα-sushi protein fragment [143] and the N-terminally truncated receptor 
proteins. pQE30-IL-15Rα-sushi [143] was used as a template for the PCR-
amplification of the cDNA coding for IL-15Rα-sushi (5’mycsushi and 3’sushi). The 
coding sequence of the gp130 signal peptide and Myc-tag was amplified by using the 
plasmid pBSK-Fos-gp130 as a template (5’SPgp130myc and 3’SPgp130myc). Both 
PCR products were used for a SOE-PCR, because the coding sequence for IL-15Rα-
sushi contains a 5’ overhang, which primes the coding sequence of the Myc-tag 
(5’SPgp130myc and 3’sushi). The resulting PCR product was purified, digested with 
XhoI and EcoRI and ligated into pBSK-gp130 (∆N-term – amino acids 606-918) also 
digested with XhoI and EcoRI. The resulting plasmid was named pBSK-IL-15Rα-
sushi-gp130 (Figure 4.12).  
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Figure 4.11 Schematic overview of cloning of IL-15-gp130 into different plasmids. See text for 
details 
 
pBSK-IL-15-gp130 was used to generate the remaining IL-15 fusion receptors by 
digestion of pBSK-IL-15-gp130 with EcoRI and BamHI and subcloning of truncated 
WSX-1 (EcoRI and BamHI digested pBSK-Jun-WSX-1 – amino acids 500-623), or 
PCR produced truncated LIFR (template: p409-hLIFR [165] – 5’hLIFR and 3’hLIFR –
amino acids 820-1097), truncated OSMR (template: p409-hOSMR [166] – 5’hOSMR: 
and 3’hOSMR – amino acids 723-979) or truncated GPL (template: pcDNA3.1-GPL – 
5’hGPL and 3’hGPL – amino acid 500-727), respectively. 
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Figure 4.12 Schematic overview of cloning of IL-15Rα-sushi-gp130 into different plasmids. See 
text for details. 
 
The resulting plasmids were named pBSK-IL-15-WSX-1, pBSK-IL-15-LIFR, pBSK-IL-
15-OSMR or pBSK-IL-15-GPL (Figure 4.13). 
To generate the plasmids pBSK-IL-15Rα-sushi-WSX-1, pBSK-IL-15Rα-sushi-LIFR, 
pBSK-IL-15Rα-sushi-OSMR and pBSK-IL-15Rα-sushi-GPL, the gp130-receptor 
portion was exchanged by digestion of the plasmid pBSK-IL-15Rα-sushi-gp130 with 
EcoRI and BamHI and subcloning of the fragments coding for N-terminally truncated  
WSX-1, LIFR, OSMR or GPL as described above (Figure 4.13). 
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Figure 4.13 Schematic overview of cloning of IL-15-WSX-1, IL-15-LIFR, IL-15-OSMR, IL-15-GPL 
and IL-15Rα-sushi-WSX-1, IL-15Rα-sushi-LIFR, IL-15Rα-sushi-OSMR and IL-15-sushi-GPL into 
different plasmids. See text for details. 
 
The retroviral plasmid pMOWS encodes the puromycin resistance gene [169]. For 
this study we modified the plasmid pMOWS-GFP by replacing the puromycin 
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resistance gene with a hygromycin resistance gene. The hygromycin gene from the 
plasmid pCEP4 was amplified by PCR (5’hygromycinBresistance and 
3’hygromycinBresistance). The purified PCR product was digested with HindIII and 
SalI and subcloned into pMOWS. The resulting plasmid was named pMOWS-GFP-
hygromycin (Figure 4.14).  
The IL-15 fusion receptors and IL-15Rα-sushi fusion receptors were subcloned into 
pMOWS and pMOWS-hygromycin as described above. The resulting plasmids were 
named pMOWS-IL-15-gp130, pMOWS-IL-15-WSX-1, pMOWS-IL-15-LIFR, pMOWS-
IL-15-OSMR, pMOWS-IL-15-GPL as well as pMOWS-hygromycin-IL-15Rα-sushi-
gp130, pMOWS-hygromycin-IL-15Rα-sushi-WSX-1, pMOWS-hygromycin-IL-15Rα-
sushi-LIFR, pMOWS-hygromycin-IL-15Rα-sushi-OSMR and pMOWS-hygromycin-IL-
15Rα-sushi-GPL (Figure 4.13).  
The cDNAs coding for IL-15-gp130, sushi-gp130 and IL-15-WSX-1 were subcloned 
into p409 as described above. The resulting plasmids were named p409-IL-15-
gp130, p409-IL-15Rα-sushi-gp130 and p409-IL-15-WSX-1 (Figures 4.11, 4.12 and 
4.13).The cDNAs coding for IL-15-gp130 and sushi-gp130 were additionally 
subcloned into pEYFP-gp130 as described above. The resulting plasmids were 
named pEYFP-IL-15-gp130 and pEYFP-IL-15Rα-sushi-gp130 (Figures 4.11, 4.12). 
 
 
Figure 4.14 Schematic overview of cloning of hygromycin B resistance into pMOWS-GFP. See 
text for details. 
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4.6 Heterodimerization of gp130 and WSX-1 mediated by IL-15 and IL-15Rα-
sushi was achieved and led to cytokine independent growth of Ba/F3-
gp130 cells 
To address the question whether expression of the new chimeric receptors led to 
constitutively active heterodimers and induction of cytokine independent proliferation, 
Ba/F3-gp130 cells were used. 
 
Figure 4.15 Analysis of gp130 and 
WSX-1 chimeric receptor expression 
in various stably transduced Ba/F3-
gp130 cell lines. (A) The mRNAs of the 
respective cell lines expressing IL-15-
WSX-1, IL-15-gp130, sushi-WSX-1, 
sushi-gp130, IL-15-gp130 + sushi-
gp130, IL-15-gp130 + sushi-WSX-1 and 
IL-15-WSX-1 + sushi-gp130 were 
reversely transcribed into cDNA and 
chimeric receptors were detected with 
specific primers (see material & 
methods) by PCR. (B) Cell surface 
expression of gp130 and WSX-1 
chimeric receptors analyzed by flow 
cytometry. The cell lines were labelled as 
described in material & methods. 
Untransduced Ba/F3-gp130 cells were 
used as negative controls (unfilled 
histograms). 
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These cells lack IL-2Rβ expression [147, 175], which is part of the signaling receptor 
complex of IL-15 [144].  
It has been proposed that IL-15Rα is necessary for IL-15 secretion and that the 
complex of IL-15/IL-15Rα is presented on the cell surface to cells expressing IL-2Rβ 
and IL-2Rγc. This signaling mode has been named trans-presentation [160, 161]. 
Recombinantly expressed IL-15 can also induce the proliferation of cells expressing 
IL-15Rα/IL-2Rβ/IL-2Rγc which is increased by addition of agonistically acting soluble 
IL-15Rα-sushi domain [154]. 
Ba/F3-gp130 cells were retrovirally transduced with IL-15-WSX-1, IL-15-gp130, 
sushi-WSX-1 and sushi-gp130. Additionally double transduced Ba/F3-gp130 cells 
were generated for IL-15-gp130 + sushi-gp130, IL-15-gp130 + sushi-WSX-1 or IL-15-
WSX-1 + sushi-gp130 expression plasmids. The expression of all designated 
receptors and combinations thereof was verified by RT-PCR (Figure 4.15A) and flow 
cytometry (Figure 4.15B) indicating expression of the respective mRNAs and surface 
expression of all chimeric receptors. 
To verify that Ba/F3-gp130 cells do not respond to IL-15 either if presented at the 
cells surface or added to the cell culture medium alone or in combination with soluble 
IL-15Rα-sushi domain the following experiments were performed. On the one hand 
Ba/F3-gp130 cells expressing GFP were cocultured with Ba/F3-gp130 cells 
expressing IL-15-gp130, IL-15-WSX-1 + sushi-gp130, or Fos-gp130 and GFP 
expression was monitored by flow cytometry for a time period of 96h (Figure 4.16A). 
On the other hand Ba/F3-gp130 cells were stimulated with IL-15 alone or in 
combination with soluble IL-15Rα-sushi domain. As a positive control cells were 
stimulated with Hyper-IL-6 (Figure 4.16B). As depicted in Figure 4.16 neither surface 
presented IL-15 alone or in combination with IL-15Rα-sushi domain nor recombinat 
IL-15 alone or in combination with soluble IL-15Rα-sushi domain induced proliferation 
of Ba/F3-gp130 cells. It can be concluded that Ba/F3-gp130 are suitable for further 
experiments. 
Next, to investigate whether IL-15/IL-15Rα-sushi heterodimerization of chimeric 
receptors was sufficient to induce ligand-independent cell growth, the retrovirally 
transduced Ba/F3-gp130 cell lines were cultured in medium lacking Hyper-IL-6. 
Surprisingly, cells transduced with IL-15-gp130 alone proliferated cytokine 
independently, indicating that this chimeric receptor forms active IL-15-gp130 
homodimeric complexes (Figure 4.17). However, expression of neither IL-15-WSX-1 
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nor sushi-WSX-1 nor sushi-gp130 alone led to cytokine independent growth in Ba/F3-
gp130 cells, respectively (Figure 4.17). 
 
 
 
Figure 4.16 Unresponsiveness of Ba/F3-gp130 cells to IL-15. (A) Co-culture experiment of Ba/F3-
gp130 expressing GFP with Ba/F3-gp130 cells expressing IL-15-gp130, IL-15-WSX-1 + sushi-gp130 
or Fos-gp130 at a ratio of 20:1. Decrease/death of GFP expressing cells was measured by flow 
cytometry during a time period of 96 h. (B) Equal numbers of Ba/F3-gp130 cells were cultured for 3 
days in the presence of increasing amounts of recombinant IL-15 or recombinant IL-15 and soluble IL-
15Rα-sushi domain. As a control cells were left untreated or cultured in the presence of Hyper-IL-6 (10 
ng/ml). Proliferation was measured as indicated in material & methods. 
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Figure 4.17 Functionality of IL-15 
and IL-15Rα mediated 
heterodimerization of gp130 and 
WSX-1. Equal numbers of Ba/F3-
gp130 cells stably transduced with 
IL-15-gp130, IL-15-WSX-1, sushi-
gp130, sushi-WSX-1, IL-15-gp130 + 
sushi-gp130, IL-15-gp130 + sushi-
WSX-1 and IL-15-WSX-1 + sushi-
gp130 were cultured for 3 days in 
the absence of Hyper-IL-6. As a 
control Ba/F3-gp130 were cultured 
in the presence or absence of 10 
ng/ml Hyper-IL-6 or IL-27. Ba/F3-gp130 cells can also respond to IL-27 because they endogenously 
express WSX-1. Proliferation was measured as indicated in material & methods. 
 
However, co-transduction of IL-15-WSX-1 with sushi-gp130 led to cytokine 
independent growth in Ba/F3-gp130 cells, indicating that the IL-15/IL-15Rα-sushi 
mediated heterodimerization of these receptors induced a biologically functional 
receptor complex (Figure 4.17). Moreover, Ba/F3-gp130 cells expressing IL-15-
gp130 + sushi-gp130 or IL-15-gp130 + sushi-WSX-1 also displayed cytokine 
independent proliferation (Figure 4.17). Since the IL-15-gp130 receptor chimera 
already induced cytokine independent proliferation in Ba/F3-gp130 cells, it is not 
clear whether the proliferation was induced by IL-15 mediated homodimerization of 
IL-15-gp130 or IL-15/IL-15Rα-sushi mediated homo-/heterodimerization of IL-15-
gp130/sushi-gp130 or IL-15-gp130/sushi-WSX-1 or a mixed type of both. 
Nevertheless it can be concluded that IL-15/IL-15Rα-sushi mediated 
heterodimerization of gp130/WSX-1 led to functional receptor complexes. 
4.7 Interaction analysis of IL-15 mediated homodimerization of gp130/gp130 
and IL-15/IL-15Rα-sushi mediated heterodimerization of gp130/WSX-1  
To demonstrate the physical interaction of two IL-15-gp130 proteins, co-
immunoprecipitation analysis was performed with COS-7 lysates containing IL-15-
gp130 alone or in combination with IL-15-gp130-EYFP. Immunoprecipitation was 
performed with anti-GFP antibodies.  
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Figure 4.18 Detection of IL-15-
gp130 homodimers and IL-15-
WSX-1 / sushi-gp130 
heterodimers by co-
immunoprecipitation. (A) COS-7 
cells were transiently transfected 
with p409-IL-15-gp130 or p409-IL-
15-gp130 and pEYFP-IL-15-
gp130. 48 h after transfection 
cells were lyzed and IL-15-gp130-
EYFP was immunoprecipitated 
with anti-GFP antibodies. As a 
control lysates were incubated 
only with protein G agarose. 
Input, immunoprecipitation 
supernatant and protein G 
agarose control supernatant were 
separated by SDS-PAGE. 
Proteins were detected with anti-
GFP antibodies and visualized by 
ECL detection. The membrane 
was stripped, probed with anti-
gp130 antibodies and proteins were visualized by ECL detection. (B) COS-7 cells were transiently 
transfected with p409-IL-15-WSX-1 or p409-IL-15-WSX-1 and p409-sushi-gp130. 48 h after 
transfection cells were lyzed and sushi-gp130 was immunoprecipitated with anti-gp130 antibodies. As 
a control lysates were incubated only with protein A agarose. Input, immunoprecipitation supernatant 
and protein A agarose control supernatant were separated by SDS-PAGE. Proteins were detected 
with anti-c-myc antibodies and visualized by ECL detection. The membrane was stripped, probed with 
IL-15 antibodies and proteins were visualized by ECL detection. 
 
As depicted in the left panel of Figure 4.18A, IL-15-gp130 alone was not precipitated 
by anti-GFP antibodies, indicating that IL-15-gp130 does not bind unspecifically to 
the anti-GFP antibodies or to protein G agarose. However, IL-15-gp130 was co-
immunoprecipitated if IL-15-gp130-EYFP was immunoprecipitated, as indicated in the 
right panel of Figure 4.18 A. Previously, it has been shown that recombinant IL-15 
protein, produced in the yeast strain Pichia pastoris could not be purified as a 
monomer but always as a dimer or multimer (Inken Lorenzen, personal 
communication). This observation was also reported by Hanick et al. [176]. 
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Furthermore, the physical interaction of sushi-gp130 and IL-15-WSX-1 proteins was 
demonstrated. Again, co-immunoprecipitation analysis was performed with COS-7 
lysates containing either IL-15-WSX-1 alone or in combination with sushi-gp130. 
Immunoprecipitation was performed with anti-gp130 antibodies. As shown in the left 
panel of Figure 4.18B, IL-15-WSX-1 alone was not precipitated, indicating that IL-15-
WSX-1 does not bind unspecifically to anti-gp130 antibodies or to protein A agarose. 
Nonetheless, IL-15-WSX-1 was co-immunoprecipitated if sushi-gp130 was 
immunoprecipitated, as indicated in the right panel of Figure 4.18B. 
 
Figure 4.19 Inhibition of IL-15 
mediated homodimerization of 
IL-15-gp130 by soluble IL-
15Rα-sushi domain. Equal 
numbers of Ba/F3-gp130 cells 
stably transduced with IL-15-
gp130, IL-15-gp130 + sushi-
gp130, IL-15-gp130 + sushi-
WSX-1 and IL-15-WSX-1 + 
sushi-gp130 were cultured for 3 
days in the absence of Hyper-IL-
6 and increasing amounts of 
soluble IL-15Rα-sushi domain. 
Proliferation was measured as indicated in material & methods. 
 
To test whether soluble IL-15Rα-sushi domain was able to inhibit the IL-15 mediated 
homodimerization of gp130 or the IL-15/IL-15Rα-sushi mediated homo-
/heterodimerization of gp30/gp130 or gp130/WSX-1, respectively, a proliferation 
assay with increasing amounts of soluble IL-15Rα-sushi was performed. As shown in 
Figure 4.19 the proliferation of Ba/F3-gp130 cells expressing IL-15-gp130 was 
inhibited by soluble IL-15Rα-sushi domain in a concentration dependent manner. 
These data indicated that the proliferation of these cells is mediated by IL-15 
homodimerization and is competed by soluble IL-15Rα-sushi to abrogate gp130 
signaling. Interestingly, the proliferation of the double transduced Ba/F3-gp130 cells 
expressing IL-15- and IL-15Rα-sushi-receptor chimeras (gp130/gp130, gp130/WSX-
1) was not inhibited by the treatment of soluble IL-15Rα-sushi domain (Figure 4.19).  
Duitman et al. showed that IL-15Rα is essential for the secretion of IL-15 via the 
classical secretion pathway, involving the ER and Golgi apparatus [161]. This might 
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imply that IL-15 and IL-15Rα form a complex before they are presented at the cell 
surface. The high affinity constant of an IL-15/IL-15Rα complex (KD = 114 pM) is 
achieved by a large network of ionic interactions characterized by a low dissociation 
rate (1.56 x 10-5 min-1) [164]. Hence, it can be assumed that the already formed 
complexes between IL-15 and IL-15Rα-sushi chimeric receptors cannot be 
dissociated by high molecular excess of soluble IL-15Rα-sushi domain.  
4.8 Unexpected homodimerization of sushi-gp130 does not lead to a 
functional receptor complex 
Since it was indeed shown that IL-15-gp130 forms a functional homodimer in terms of 
cytokine independent proliferation of stably transduced Ba/F3-gp130 cells, also 
sushi-gp130, which is not functional alone, was analyzed with respect to the ability of 
homodimerization. Co-immunoprecipitation analysis was performed with COS-7 
lysates containing sushi-gp130 alone or in combination with sushi-gp130-EYFP. 
Immunoprecipitation was performed with anti-GFP antibodies. 
Unexpectedly, sushi-gp130 was co-immunoprecipitated with sushi-gp130-EYFP, as 
indicated in the right panel of Figure 4.20. No unspecific binding to the anti-GFP 
antibodies or protein G agarose of sushi-gp130 could be shown as depicted in the 
left panel of Figure 4.20. Additionally, a series of co-immunoprecipitation experiments  
were performed with sushi-gp130 + ∆cys-Fos-gp130 or IL-15-gp130 + ∆cys-Fos-
gp130. In those combinations, the proteins were not expected to interact with each 
other. In each experiment only one of the gp130 chimeric receptors was tagged with 
EYFP. All co-immunprecipitation experiments were also performed vice versa. 
Interestingly, independent of the extracellularly fused domain or protein (Fos leucine 
zipper, IL-15 or IL-15Rα-sushi), each chimeric gp130 receptor could be co-
immunoprecipitated by every other chimeric gp130 receptor in all applied 
combinations (Figure 4.21A-D). To show that this effect was not mediated by 
overexpression or any other experimental cause, the transmembrane protease 
BACE, which does not belong to any cytokine receptor family, was chosen for co-
immunoprecipitation analysis. As depicted in Figure 4.20E, sushi-gp130-EYFP does 
not interact with BACE.  
Taken together all results of the co-immunoprecipitation experiments implicate that 
the interaction of all gp130 chimeric receptors were specific, even if they are not only 
mediated by IL-15 or IL-15 and IL-15Rα-sushi domain. 
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Figure 4.20 Detection of sushi-
gp130 homodimers by co-
immunoprecipitation. COS-7 cells 
were transiently transfected with 
p409-sushi-gp130 or p409-sushi-
gp130 and pEYFP-sushi-gp130. 48 
h after transfection cells were lyzed 
and sushi-gp130-EYFP was 
immunoprecipitated with anti-GFP 
antibodies. As a control lysates 
were incubated with protein G 
agarose alone. Input, immunoprecipitation supernatant and protein G agarose control supernatant 
were separated by SDS-PAGE. Proteins were detected with anti-Myc-tag antibodies and visualized by 
ECL detection.  
 
The possibility that the sushi domain of IL-15Rα is able to mediate homodimerzation 
cannot be excluded completely, but it seems likely that the interaction of those 
chimeric receptors is mediated by the gp130 transmembrane or intracellular domain, 
independent of the N-terminally fused domain. A possible conclusion for those 
experiments is the finding that gp130 forms preformed non-active homodimers as 
well as heterodimers with LIFR in the absence of a ligand [168, 177].  
To analyze the difference between the dimerization of ‘non-active’ sushi-gp130 and 
‘active’ IL-15-gp130, the phosphorylation status of the gp130 receptor chimeras was 
analyzed. An ‘active’ chimeric receptor, in this particular case, is characterized by the 
ability to mediate ligand-independent growth in Ba/F3-gp130 cells. In detail, the 
gp130 chimeric receptors were immunoprecipitated with anti-gp130 antibodies and 
were analyzed for tyrosine-phosphorylation. Interestingly, no tyrosine-
phosphorylation was observed after precipitation of the IL-15-/sushi-gp130 receptor 
chimeras from transiently transfected and starved COS-7 cells. Pervanadate blocks 
tyrosine-phosphatases very efficiently [178, 179]. Precipitated IL-15-gp130 from 
transiently transfected, starved and pervanadate treated COS-7 cells displayed an 
intensive tyrosine-phosphorylation signal if transfected alone or in combination with 
sushi-gp130. In contrast, sushi-gp130 displayed only a faint tyrosine-phosphorylation 
signal when transfected alone, which increased after the co-transfection of IL-15-
gp130 (Figure 4.22). 
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Figure 4.21 Dimerization of sushi-gp130 and IL-15-gp130 with ∆cys-Fos-gp130. (A) Co-
immunoprecipitation of ∆cys-Fos-gp130-EYFP and sushi-gp130. COS-7 cells were transiently 
transfected with p409-sushi-gp130 and pEYFP-∆cys-Fos-gp130. 48 h after transfection cells were 
lyzed and ∆cys-Fos-gp130-EYFP was immunoprecipitated with anti-GFP antibodies. As a control 
lysates were incubated only with protein G agarose. Input, immunoprecipitation supernatant and 
protein G agarose control supernatant were separated by SDS-PAGE. Proteins were detected with 
anti-gp130 antibodies and visualized by ECL detection. (B) Co-immunoprecipitation of ∆cys-Fos-
gp130-EYFP and IL-15-gp130. The experiment was performed as described in (A). (C) Co-
immunoprecipitation of sushi-gp130-EYFP and ∆cys-Fos-gp130. The experiment was performed as 
described in (A). (D) Co-immunoprecipitation of IL-15-gp130-EYFP and ∆cys-Fos-gp130. The 
experiment was performed as described in (A). No co-immunoprecipitation of sushi-gp130-EYFP and 
BACE. The experiment was performed as described in (A) despite the fact that both proteins were 
detected with anti-Myc-tag antibodies.  
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Figure 4.22 Tyrosine-phosphorylation of IL-15-
gp130 and sushi-gp130. COS-7 cells were 
transiently transfected with p409-IL-15-gp130 or p409-
sushi-gp130 or p409-IL-15-gp130 and p409-sushi-
gp130 and starved for the last 20 h before lysis. 48 h 
after transfection, COS-7 cells were treated with 
pervanadate as described in Material & methods and 
lyzed rapidly. The gp130 chimeric proteins were 
immunoprecipitated with anti-gp130 antibodies. 
Immunoprecipitation supernatant was separated by 
SDS-PAGE. Proteins were transferred onto PVDF 
membrane and were detected with anti-
phosphotyrosine (PY) antibodies and visualized by 
ECL detection. To confirm immunoprecipitation of IL-
15-gp130 and sushi-gp130 Western blots against IL-15 or c-myc were performed additionally. 
 
It can be concluded that dimerized sushi-gp130 proteins do not have the capacitiy to 
induce receptor phosphorylation and ligand-independent growth in Ba/F3-gp130 cells 
because sushi-gp130 only appeared to be slightly tyrosine-phosphorylated which 
might be background signal. In contrast to that, IL-15-gp130 dimers were able to 
induce receptor phosphorylation and ligand-independent growth of Ba/F3-gp130 
cells. Co-expression of IL-15-gp130 and sushi-gp130 led to an increase in the 
phosphorylation of sushi-gp130 chain. However, in Ba/F3-gp130 cells expressing IL-
15-gp130 + sushi-gp130 it cannot be dissected which receptor chain contributes to 
ligand-independent growth. This is different to Ba/F3-gp130 cells expressing IL-15-
WSX-1 + sushi-gp130. In those cells expression of both receptor chains is essential 
for ligand-independent growth.  
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4.9 Phosphorylation of STAT1/3 and ERK1/2 proteins in Ba/F3-gp130 cells 
expressing IL-15 or IL-15/IL-15Rα-sushi mediated homo- and heterodimers 
of gp130/gp130 and gp130/WSX-1 
As shown previously, ∆cys-Fos-gp130 induced ligand-independent STAT3 
phosphorylation and growth of Ba/F3-gp130 cells. So it was asked whether the 
chimeric receptors comprising IL-15/IL-15Rα-sushi, which induced cytokine 
independent growth in Ba/F3-gp130 cells, also induced phosphorylation of signaling 
proteins. Therefore lysates of Ba/F3-gp130 cells expressing the different IL-15/IL-
15Rα-sushi based receptor chimeras were analyzed by Western blot for 
phosphorylated STAT1/3 as well as phosphorylated ERK1/2 with specific antibodies. 
As depicted in Figure 4.23A, only those cells expressing IL-15-gp130 alone or in 
combination with sushi-gp130 or sushi-WSX-1 as well as the cells expressing IL-15-
WSX-1 + sushi-gp130 showed phosphorylation of STAT1/3 and ERK1/2. These cell 
lines also induced cytokine independent growth of Ba/F3-gp130 cells. None of the 
cell lines expressing IL-15-WSX-1, sushi-gp130 or sushi-WSX-1 alone, which failed 
to induce cytokine independent growth, showed any phosphorylation of STAT1/3 and 
ERK1/2 molecules.  
The transcription of the genes c-myc and Pim-1 has been shown to be dependent on 
IL-6- and IL-27-induced STAT3 activation [72, 180]. Therefore it was asked whether 
the expression of the functional IL-15 or IL-15/IL-15Rα-sushi homo- or heterodimers, 
which already led to proliferation in a cytokine independent manner and to 
phosphorylation of STAT3 in Ba/F3-gp130 cells, led to an increased expression of 
such STAT3 target genes. As shown in Figure 4.23B, all functional chimeric 
receptors showed an up-regulation of the transcription factor c-myc and the 
serine/threonine kinase Pim-1 with respect to mRNA levels. 
It can be concluded that forced homo- and heterodimeric receptor complexes 
comprising gp130/gp130 and gp130/WSX-1 are fully functional in terms of STAT3 
phosphorylation and triggering the expression of c-myc and Pim-1 thus leading to cell 
growth and proliferation. Cell growth and proliferation can also contribute to ERK1/2 
mediated signaling [181]. ERK1/2 phosphorylation was also mediated by the forced 
homo- and heterodimerized gp130/gp130 and gp130/WSX-1 signaling complexes.  
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Figure 4.23 Activation of STAT and ERK proteins and transcription of the STAT3 target genes 
c-myc and Pim-1 in BaF/3-gp130 cells stably transduced with chimeric receptors comprising IL-
15/IL-15Rα. (A) After 6 h of serum starvation Ba/F3-gp130 cells stably transduced with IL-15-WSX-1, 
IL-15-gp130, sushi-WSX-1, sushi-gp130, sushi-gp130 + IL-15-gp130 , sushi-WSX-1 + IL-15-gp130 +, 
IL-15-WSX-1 + sushi-gp130 were left untreated. Subsequently, cells were lyzed and separated by 
SDS-PAGE. Proteins were transferred onto PVDF membranes and were detected with anti-P-STAT1, 
anti-P-STAT3 or anti-P-ERK1/2 antibodies and visualized by ECL detection. The membranes were 
stripped, probed with anti-STAT1, anti-STAT3 or anti-ERK1/2 antibodies and proteins were visualized 
by ECL detection. (B) Analysis of STAT3 target gene expression of c-myc and Pim-1 in Ba/F3-gp130 
cells stably transduced with the respective chimeric receptor after 6 h of serum starvation by RT-PCR.  
 
4.10 The IL-15/IL-15Rα-sushi mediated heterodimerization of receptors can be 
adapted to other heterodimeric receptor complexes of the gp130-type 
family 
As described previously, the generation of IL-15/IL-15Rα-sushi chimeric receptors 
was applied to all gp130-type receptors comprising gp130, WSX-1, LIFR, OSMR and 
GPL. In this family, also heterodimeric receptor complexes beside gp130/WSX-1 can 
be formed comprising gp130/LIFR, gp130/OSMR and OSMR/GPL [26, 30].  
To prove the applicability of the IL-15/IL-15Rα-sushi mediated heterodimerization 
system, Ba/F3-gp130 cells were stably transduced with IL-15-LIFR, IL-15-LIFR + 
sushi-gp130, IL-15-OSMR, IL-15-OSMR + sushi-gp130, sushi-GPL and IL-15-OSMR 
+ sushi-GPL. Again, the expression of all designated receptors and combinations 
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thereof were verified by RT-PCR (Figure 4.24A) and flow cytometry (Figure 4.24B) 
indicating expression of the respective mRNAs and surface expression of all new 
chimeric receptors. 
 
 
Figure 4.24 Analysis of LIFR, OSMR 
and GPL chimeric receptor 
expression in various stably 
transduced Ba/F3-gp130 cell lines. 
(A) The mRNAs of the respective cell 
lines expressing IL-15-OSMR, IL-15-
LIFR, IL-15-LIFR + sushi-gp130, IL-15-
OSMR + sushi-gp130, sushi-GPL or IL-
15-OSMR + sushi-GPL were reversely 
transcribed into cDNA and chimeric 
receptors were detected with specific 
primers (see material & methods) by 
PCR. (B) Cell surface expression of 
LIFR, OSMR, gp130 and GPL chimeric 
receptors analyzed by flow cytometry. 
The cell lines were labeled as 
described in material & methods. 
Untransduced Ba/F3-gp130 cells were 
used as negative controls (unfilled 
histograms). This figure is adapted from 
the diploma thesis of Anna Tillmann 
[182], who was supervised by the 
author of this work. 
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After expression analysis, it was asked whether the chimeric receptors alone or in 
combination induced ligand-independent growth in Ba/F3-gp130 cells. A proliferation 
assay was performed in medium lacking Hyper-IL-6. Like IL-15-WSX-1, IL-15-LIFR 
and IL-15-OSMR alone did not induce cytokine independent growth of the respective 
cell line. Otherwise, if sushi-gp130 was co-transduced with either IL-15-LIFR or IL-15-
OSMR cytokine independent growth was achieved as depicted in Figure 4.25A. Also 
sushi-GPL alone was not able to induce cytokine independent growth, but co-
transduction of sushi-GPL and IL-15-OSMR lead to proliferation of the respective 
Ba/F3-gp130 cell line (Figure 4.25A). So it was asked again whether the chimeric 
receptors comprising IL-15/IL-15Rα-sushi, which induced cytokine independent 
growth in Ba/F3-gp130 cells, also induce phosphorylation of signaling proteins. 
Therefore lysates of starved Ba/F3-gp130 cells expressing the different IL-15/IL-
15Rα-sushi based receptor chimeras (gp130/LIFR, gp130/OSMR and OSMR/GPL) 
were analyzed by Western blot for phosphorylated STAT1/3 as well as 
phosphorylated ERK1/2 with specific antibodies. As shown in Figure 4.25B the cell 
lines expressing IL-15-LIFR + sushi-gp130 and IL-15-OSMR + sushi-gp130 but not 
IL-15-LIFR, IL-15-OSMR or sushi-GPL alone exhibited phosphorylation of STAT1/3 
as well as ERK1/2. The cell line expressing IL-15-OSMR + sushi-GPL exhibited 
phosphorylation of STAT3 and ERK1/2 but not STAT1. It has been shown previously 
that IL-31 only show low level phosphorylation of STAT1 [183].  
To investigate whether the phosphorylation of STAT3 lead to an up-regulation of c-
myc and Pim-1 in the respective Ba/F3-gp30 cell lines, a RT-PCR study was 
performed. As shown in Figure 4.26C the Ba/F3-gp130 cell lines expressing IL-15-
LIFR + sushi-gp130, IL-15-OSMR + sushi-gp130 and IL-15-OSMR + sushi-GPL 
exhibited an up-regulation of c-myc and Pim-1 expression at mRNA levels. No up-
regulation of the respective STAT3 target genes was observed in cells expressing IL-
15-LIFR, IL-15-OSMR and sushi-GPL. 
Taken together, it can be concluded that the IL-15/IL-15Rα-sushi heterodimerization 
system can be adapted to all gp130-type receptor complexes comprising 
gp130/gp130, gp130/WSX-1, gp130/LIFR, gp130/OSMR and OSMR/GPL. 
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4.26 Functionality of IL-15/IL-15Rα-sushi mediated heterodimerization of gp130/LIFR, 
gp130/OSMR and OSMR/GPL. (A) Equal numbers of Ba/F3-gp130 cells stably transduced with IL-15-
LIFR, IL-15-LIFR + sushi-gp130, IL-15-OSMR, IL-15-OSMR + sushi-gp130, sushi-GPL or IL-15-OSMR 
+ sushi-GPL were cultured for 3 days in the absence of Hyper-IL-6. Proliferation was measured as 
indicated in Material & methods. (B) After 6 h of serum starvation Ba/F3-gp130 cells expressing the 
respective chimeric receptors were left untreated. Subsequently, cells were lyzed and separated by 
SDS-PAGE. Proteins were transferred onto PVDF membranes and were detected with anti-P-STAT1, 
anti-P-STAT3 or anti-P-ERK1/2 antibodies and visualized by ECL detection. The membranes were 
stripped, probed with anti-STAT1, anti-STAT3 or anti-ERK1/2 antibodies and proteins were visualized 
by ECL detection. (B) Analysis of STAT3 target gene expression of c-myc and Pim-1 in Ba/F3-gp130 
cells stably transduced with the respective chimeric receptors after 6 h of serum starvation by RT-
PCR. This figure is adapted from the diploma thesis of Anna Tillmann [182], who was supervised by 
the author of this work. 
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4.11 Analysis of all possible combinations between all gp130-type receptors 
using the IL-15/IL-15Rα-sushi based system.  
As shown before, the IL-15/IL-15Rα-sushi based system was used to generate 
ligand-independent, constitutively active heterodimeric receptor complexes of all 
known gp130-type receptors. The question was raised whether new combinations of 
receptors of the gp130-type family such as LIFR/OSMR or GPL/WSX-1 are functional 
in terms of cytokine independent growth induction of Ba/F3-gp130 cells. To analyze 
this, all cloned IL-15 and IL-15Rα-sushi chimeras comprising WSX-1, LIFR, OSMR, 
GPL and gp130 (only sushi-gp130) were stably transduced into Ba/F3-gp130 cells. 
To ensure that every cell line expressed their respective receptors a RT-PCR 
analysis was performed as depicted in Figure 4.27.  
Furthermore, all cell lines were screened for cytokine independent growth as 
depicted in Figure 4.28. This assay revealed that combinations beside the known 
naturally occurring heterodimers gp130/LIFR, gp130/OSMR, gp130/WSX-1 and 
OSMR/GPL are also functional in terms of cytokine independent growth of Ba/F3-
gp130 cells. These constitutively active combinations, mediated by IL-15/IL-15Rα-
sushi, comprised of LIFR/OSMR (Figure 4.28B+C), LIFR/GPL (Figure 4.28B+D) and 
GPL/gp130 (Figure 4.28D), which have already been described using artificial ligand 
induced dimerization methods [58, 64]. In those works the extracellular domains of 
gp130, LIFR, OSMR, and GPL were exchanged to the extracellular domains of either 
IL-5Rα or IL-3βc . Heterodimerization, which led to phosphorylation of STAT proteins, 
of LIFR/OSMR, LIFR/GPL and GPL/gp130 could be achieved by triggering these 
chimeric receptors with IL-5.  
The observation of ligand-independent heterodimerization of LIFR/OSMR and 
LIFR/GPL was not dependent on the choice of the fusion protein, meaning that e.g. 
either expression of IL-15-LIFR + sushi-OSMR or IL-15-OSMR + sushi-LIFR led to 
cytokine independent growth of the respective Ba/F3-gp130 cell line (Figure 
4.28B+C). For the heterodimer of GPL/gp130 only IL-15-GPL + sushi-gp130 was 
used (Figure 4.28D) because IL-15-gp130 is active on its own as shown before. 
Remarkably, as shown before IL-15-LIFR alone did not induce cytokine independent 
growth but co-transduction of sushi-LIFR led to proliferation in a ligand-independent 
manner (Figure 4.28B). The same effect was observed monitoring ligand-
independent proliferation of IL-15-GPL + sushi-GPL, whereas expression of IL-15-
GPL alone did not induced cytokine independent proliferation of Ba/F3-gp130 cells  
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Figure 4.27 Analysis of WSX-1, LIFR, OSMR, GPL and gp130 chimeric receptor expression in 
various stably transduced Ba/F3-gp130 cell lines. mRNAs of the respective cell lines expressing  
(A) IL-15-WSX-1 + sushi-WSX-1, IL-15-WSX-1 + sushi-LIFR, IL-15-WSX-1 + sushi-OSMR, IL-15-
WSX-1 + sushi-GPL or (B) IL-15-LIFR + sushi-WSX-, IL-15-LIFR + sushi-LIFR, IL-15-LIFR + sushi-
OSMR, IL-15-LIFR + sushi-GPL or (C) IL-15-OSMR + sushi-WSX-1, IL-15-OSMR + sushi-LIFR, IL-15-
OSMR + sushi-OSMR or (D) IL-15-GPL, IL-15-GPL + sushi-WSX-1, IL-15-GPL + sushi-LIFR, IL-15-
GPL + sushi-GPL and IL-15-GPL + sushi-gp130 were reversely transcribed into cDNA and chimeric 
receptors were detected with specific primers (see material & methods) by PCR. As a negative control 
ddH2O was used.  
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(Figure 4.28D). Homodimers of LIFR and GPL has been analyzed previously with the 
same artificial ligand induced system as mentioned above [58, 64]. 
This is an interesting finding with respect to the ability of IL-15 to dimerize or 
multimerize. As shown before, IL-15-gp130 was the only chimeric receptor which 
induced cytokine independent growth on its own. So, dimerization of IL-15-WSX-1, 
IL-15-LIFR, IL-15-OSMR or IL-15-GPL by IL-15 had no impact on the onset of 
signaling of those receptors. But co-expression of IL-15-LIFR + sushi-LIFR or IL-15-
GPL + sushi-GPL induced signaling, leading to the assumption that the conformation 
of the transmembrane and cytoplasmic domains achieved by chimeric IL-15-LIFR/IL-
15-LIFR or IL-15-GPL/IL-15-GPL homodimers are different to IL-15-LIFR/sushi-LIFR 
or IL-15-GPL/sushi-GPL homodimers.  
The co-expression of IL-15-OSMR + sushi-OSMR instead did not lead to cytokine 
independent growth of the respective Ba/F3-gp130 cell line (Figure 4.28 C). 
However, OSMR homodimers using artificial ligand induced dimerization have been 
described previously [64] but the authors of this work announced that the signaling 
ability of OSMR homodimers seems to depend on the cellular context. It could also 
be true, that the IL-15/IL-15Rα-sushi based system is not suitable to induce OSMR 
homodimerization.  
Interestingly, WSX-1 only led to a functional heterodimer with gp130 (Figure 4.17) but 
not with LIFR, OSMR, GPL or a homodimer with itself (Figure 4.28A-D). There were 
also no detectable amounts of phosphorylated STAT1 measured for all combinations 
applied here with IL-15-WSX-1 by Western blot analysis (data not shown). To date 
there is no report in literature which showed the ability of WSX-1 to homodimerize or 
heterodimerize with any other member of the gp130-type or IL-12R-type family 
except gp130.  
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Figure 4.28 Functionality of IL-15/IL-15Rα-sushi mediated homo-/heterodimerization of 
LIFR/LIFR, LIFR/OSMR and LIFR/GPL and GPL/GPL. Equal numbers of Ba/F3-gp130 cells stably 
transduced with (A) IL-15-WSX-1, IL-15-WSX-1 + sushi-WSX-1, IL-15-WSX-1 + sushi-LIFR, IL-15-
WSX-1 + sushi-OSMR, IL-15-WSX-1 + sushi-GPL or (B) IL-15-LIFR,  IL-15-LIFR + sushi-WSX-, IL-15-
LIFR + sushi-LIFR, IL-15-LIFR + sushi-OSMR, IL-15-LIFR + sushi-GPL or (C) IL-15-OSMR, IL-15-
OSMR + sushi-WSX-1, IL-15-OSMR + sushi-LIFR, IL-15-OSMR + sushi-OSMR or (D) IL-15-GPL, IL-
15-GPL + sushi-WSX-1, IL-15-GPL + sushi-LIFR, IL-15-GPL + sushi-GPL and IL-15-GPL + sushi-
gp130 were cultured for 3 days in the absence of Hyper-IL-6. Proliferation was measured as indicated 
in material & methods.  
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4.12 Second generation of IL-15/IL-15Rα-sushi based heterodimerization 
system – avoiding signaling capacity of IL-15 and expression of two open 
reading frames from one cDNA: FUSIO 
In order to improve the IL-15/IL-15Rα-sushi based heterodimerization system a new 
cDNA coding for human IL-15/murine WSX-1 and human IL-15Rα-sushi/murine 
gp130 was generated. The cDNA sequence of human IL-15 was mutated at two 
distinct sites, which lead to two amino acid changes at D8S and Q108S resulting in a 
IL-2Rβ and IL-2Rγc binding deficiency, respectively [184]. Moreover, both cDNAs 
coding for mutated IL-15-WSX-1 and sushi-gp130 were combined in one transcript, 
separated by a furin cleavage site and a 2A peptide. The 2A peptide from the foot-
and-mouth disease virus and other members of the piconavirus family is a self 
processing sequence (D(V/I)EXNPGP) to achieve expression of at least two separate 
proteins from one single open reading frame [185, 186]. It is believed that the 
reaction driven by 2A is a translational recoding event in which a peptide bond is 
‘skipped’ during elongation [187]. The 2A peptide reaction occurs in the 
peptidyltransferase center of the ribosome. Ribosomes pause at the end of the 2A 
coding sequence, at the glycine and proline codons, and the nascent chain up to and 
including this glycine is released. Thereafter the translation continues leading to 
generation of the separate downstream product [188].The 2A peptide technology has 
been used for expression of two proteins from one open reading frame [189-193].  
 
 
Figure 4.29 Schematic overview of FUSIO cDNA (A) and cloning into pMOWS plasmid (B). See 
text for details. 
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The resulting cDNA was named FUSIO. As depicted in Figure 4.29A FUSIO cDNA 
consist of the signal peptide from bovine preprolactin, a FLAG-tagged human IL-15 
mutant, N-terminally truncated murine WSX-1, furin cleavage site, 2A peptid, signal 
peptide of human gp130 Myc-tagged human IL-15Rα-sushi and N-terminally 
truncated murine gp130. The cDNA was synthesized by Geneart (Regensburg, 
Germany) and delivered in a pMk plasmid. The pMk-FUSIO plasmid was digested 
with EcoRV. The target plasmid pMOWS was digested with XagI and BamHI and 
blunt ends were generated by Klenow fragment reaction. Plasmid and FUSIO were 
purified and subcloned. The resulting plasmid was named pMOWS-FUSIO (Figure 
4.29 B). 
 
 
 
Figure 4.30 Functionality of FUSIO. (A) Cell surface expression of gp130 and WSX-1 chimeric 
receptor encoded by FUSIO in stably transduced Ba/F3-gp130 cells analyzed by flow cytometry. The 
cell lines were labeled as described in material & methods. Untransduced Ba/F3-gp130 cells were 
used as negative controls (unfilled histograms). (B) Equal numbers of Ba/F3-gp130 cells stably 
transduced with GFP or FUSIO were cultured for 3 days in the absence of Hyper-IL-6. Proliferation 
was measured as indicated in material & methods. (D) Activation of STAT-3 proteins in Ba/F3-gp130 
cells stably transduced with GFP or FUSIO .After 6 h of serum starvation Ba/F3-gp130 cells stably 
transduced with GFP or FUSIO were left untreated. Subsequently, cells were lyzed and 50 µg were 
separated by SDS/PAGE. Proteins were transferred onto a PVDF membrane and were detected with 
anti-P-STAT3 antibodies and visualized by ECL detection. The membrane was stripped and probed 
with anti-STAT3 antibodies and proteins were visualized by ECL detection. 
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Ba/F3-gp130 cell were stably transduced with the cDNA encoding FUSIO or GFP as 
a control. As shown in Figure 4.30A both chimeric receptor chains were expressed at 
the cell surface of stably transduced Ba/F3-gp130 cells. Furthermore, Ba/F3-gp130 
cells expressing FUSIO also exhibited cytokine independent growth and 
phosphorylation of STAT3, whereas control cells expressing GFP were not able to 
proliferate in a cytokine independent manner and showed no phosphorylation of 
STAT3 (Figure 4.30B and C), demonstrating that the 2A peptide technology is 
applicable for our approach. 
Since it was not known whether the presentation of IL-15 chimeric receptors at the 
cell surface led to an induction of IL-15-mediated signaling in neighbouring cells , a 
co-culture experiment with Ba/F3-gp130 cells expressing IL-15-gp130, IL-15-WSX-1 
+ sushi-gp130, FUSIO or Fos-gp130 and primary murine dendritic cells was 
performed. Primary murine dendritic cells were described to produce IL-6 after 
stimulation with IL-15 [194]. This approach was used to prove if the two point 
mutations of IL-15 used for the FUSIO construct lead to an abrogation of IL-15 
mediated signaling. The co-culture experiment revealed that Ba/F3-gp130 cells 
expressing IL-15-gp130 or IL-15-WSX-1 + sushi-gp130 but not FUSIO or Fos-gp130 
induced a strong induction of IL-6 expression, indicating that the membrane located 
wildtype IL-15 protein was biologically active and induced IL-15 trans-presentation 
mediated signaling. Remarkably, Ba/F3-gp130-FUSIO cells, which expressed the IL-
15 mutant, which cannot bind to the β- and γc-receptor subunits of IL-15 signaling 
receptor complex, failed to induce IL-6 protein expression by trans-presentation of IL-
15 (Figure 4.31).  
This further development of the IL-15/IL-15Rα-sushi based heterodimerization 
system is the first step towards a potential analysis of in vivo consequences of 
cytokine independent, constitutively active heterodimeric receptor complexes of the 
gp130-type receptor family.  
It can be concluded from all experiments that the application of the IL-15/IL-15Rα-
sushi based system is useful for the generation of ligand-independent, constitutively 
active heterodimers of all known gp130-type receptor complexes leading to long-term 
activation of associated intracellular gp130-type receptor signaling pathways and 
target gene activation.  
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4.31 Co-culture experiment of primary murine dendritic cells with Ba/F3-gp130 cell lines 
expressing different chimeric receptors and quantification of IL-15 mediated murine IL-6 
secretion. Primary murine dendritic cells were stimulated with LPS (10 ng/ml) overnight. The day after 
murine DCs were washed and co-cultured with Ba/F-gp130 cells expressing either IL-15-gp130, IL-15-
WSX-1 + sushi-gp130, FUSIO or Fos-gp130 in a ratio of 1:10 for 24 h. As a control murine dendritic 
cells were stimulated with 1, 10 and 100 ng/ml recombinant IL-15 or left untreated. After 24 h 
supernatants were analyzed for mIL-6 secretion. This experiment was performed by Elena Bulanova 
(Borstel, Germany). 
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5 Discussion  
5.1 Establishment of a novel system to generate ligand-independent, 
constitutively active, heterodimeric receptor complexes.  
In this work, a novel strategy to generate ligand-independent, constitutively active 
heterodimeric receptor complexes was described. First, replacing the extracellular 
domains of gp130, LIFR, OSMR, WSX-1, and GPL by either IL-15 or IL-15Rα-sushi 
domain is sufficient to heterodimerize gp130 with LIFR, OSMR, and WSX-1 as well 
as OSMR with GPL. As a consequence of forced dimerization leading to sustained 
STAT1 and/or STAT3 and ERK1/2 phosphorylation and transcriptional activation of 
the STAT3 target genes c-myc and Pim-1. Those functional combinations of the 
chimeric receptors reflected ligand-independent activation of the full-length receptor 
complexes. gp130/LIFR is engaged by LIF, OSM, CNTF, CT-1, CLC, and NP, 
gp130/OSMR is engaged by OSM, gp130/WSX-1 is engaged by IL-27, OSMR/GPL is 
engaged by IL-31. Furthermore, additional combinations of gp130-type receptor 
chimeras were obtained. These included LIFR/OSMR, gp130/GPL, LIFR/GPL 
heterodimers as well as LIFR/LIFR and GPL/GPL homodimers which have not been 
described so far to occur naturally. Introduction of functional combinations of the 
chimeric receptor proteins into Hyper-IL-6-dependent Ba/F3-gp130 pre B-cells 
confers sustained and long-term ligand-independent growth of these cells suggesting 
permanent activation of the heterodimeric receptor complexes.  
Exploiting the higher stability of an IL-15/IL-15Rα-sushi domain heterodimer when 
compared to IL-15 homodimers alone, we demonstrate that soluble IL-15Rα-sushi 
domain cannot be used to destabilize heterodimeric IL-15/IL-15Rα-sushi domain 
complexes. This was not the case for homodimeric IL-15-gp130 complexes. Soluble 
IL-15Rα-sushi domain interfered with the constitutive signaling activity of IL-15-gp130 
but not with IL-15/IL-15Rα-sushi domain complexes, again demonstrating the 
exceptionally high affinity between the IL-15 receptor chimera and the IL-15Rα-sushi 
receptor chimera. These findings indicate that once formed IL-15/IL-15Rα-sushi 
chimeric receptor complexes could not be dissociated by soluble IL-15Rα-sushi 
domain. Interestingly, IL-15 was recently described as a cytokine that can only leave 
the cell in complex with its α-receptor [161]. 
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Figure 5.1 Scheme of all functional combinations of ligand-independent gp130-type receptor 
complexes in Ba/F3-gp130 cells achieved by the IL-15/IL-15Rα-sushi based system. These 
combinations comprise gp130/gp130, gp130/LIFR, gp130/OSMR, gp130/WSX-1, OSMR/GPL, 
LIFR/OSMR, LIFR/GPL, gp130/GPL, LIFR/LIFR, and GPL/GPL. The combinations of IL-15-gp130 + 
sushi-gp130 and IL-15-gp130 + sushi-WSX-1 are also displayed here because it could be shown that 
high molecular access of soluble IL-15Rα-sushi did not interfered with the complex of those receptors 
and the proliferation of Ba/F3-gp130 cells expressing those combinations did not change (Figure 
4.19). 
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IL-15-gp130 IL-15-LIFR IL-15-OSMR IL-15-WSX-1 IL-15-GPL 
none active inactive inactive inactive inactive 
sushi-gp130 active active active active active 
sushi-LIFR n.d.* active active inactive active 
sushi-OSMR n.d.* active inactive inactive n.d.+  
sushi-WSX-1 active inactive inactive inactive no 
sushi-GPL n.d.* active active no active 
 
Table 1.2 List of all functional combinations of ligand-independent gp130-type receptor 
complexes in Ba/F3-gp130 cells achieved by the IL-15/IL-15Rα-sushi based system. These 
combinations comprises gp130/gp130, gp130/LIFR, gp130/OSMR, gp130/WSX-1, OSMR/GPL, 
LIFR/OSMR, LIFR/GPL, gp130/GPL, LIFR/LIFR, and GPL/GPL. abbreviations: n.d.: not determined; *: 
all combinations with IL-15-gp130 are supposed to grow ligand-independent because IL-15-gp130 is 
active on its own and all active combinations were tested with the sushi-gp130 variant; +: the 
combination of IL-15-GPL + sushi-OSMR was not achieved because IL-15-OSMR + sushi-GPL has 
been shown to be functionally active. 
 
Here, surface expression of IL-15 was detected in the absence of IL-15Rα (e.g. IL-
15-gp130), demonstrating that IL-15 fused to a truncated gp130 can also be 
transported to the cell surface, and that the driving force in our experimental setting 
of IL-15 secretion is not its specific association with IL-15Rα but its fusion or 
association with a membrane receptor. 
5.2 Dimerization and activation vs. dimerization and non-activation 
The approach to heterodimerize gp130-type receptor complexes with the help of the 
IL-15/IL-15Rα-sushi domain is the first successful strategy to confer constitutive 
heterodimeric gp130-type receptor activation in the complete absence of any 
extracellular stimulation. Our findings add support to the current view that all IL-6-
type cytokines induce conformational changes within the extracellular domains of 
heterodimeric gp130 receptor complexes that are necessary for optimal alignment 
and binding of the amino acids in the heterodimerization domain. Finally, this 
rearrangement stabilizes the heterodimerized receptor in a conformation that holds 
gp130-type receptor associated JAK kinases in close proximity thereby facilitating 
signaling.  
In this work it was shown that the fusion of IL-15 to N-terminally truncated gp130 was 
sufficient to induce ligand-independent signaling. Importantly, fusion of IL-15Rα-sushi 
domain to gp130 did not induced ligand-independent signaling even when either IL-
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15-gp130 or sushi-gp130 could be detected as homodimers by co-
immunoprecipitation. Furthermore, either IL-15-gp130 or sushi-gp130 showed 
dimerization with ∆cys-Fos-gp130, which was unexpected. There is increasing 
evidence that many cytokine receptors appear to exist as inactive, preassembled 
complexes on the cellular surface. This has been demonstrated for erythropoietin 
receptor [195-198], growth hormone receptor [199] interferon γ receptor [200], IL-
3Rβc [201], IL-17R [202], IL-6R [203], and also for gp130 as well as the gp130/LIFR 
heterodimer [168, 177]. These data implied that ligand binding induces a local 
reorganization within the receptor complex, thereby triggering intracellular signaling. 
In the light of these data it seems likely that sushi-gp130 dimerizes without activation 
in contrast to IL-15-gp130 because IL-15 has a tendency to dimerize or oligomerize 
([176] and Inken Lorenzen, personal communication). However, the current model of 
preformed dimerization of gp130 is that the extracellular domain D1 of one gp130 
molecule interacts with the D2 and D3 domain of the other gp130 molecule. This 
model has been evolved using data obtained by purification of soluble gp130 D1-D6 
which only could be purified as a dimer. Interestingly, deletion of the D1 domain 
resulted in the purification of monomeric gp130 D2-D6 (Stefan Rose-John, personal 
communication). It is known that the D1 domain (Ig-like domain) plays an important 
role in ligand recognititon. IL-6 binds initially the CHD of its α-receptor via site I, the 
CHD (D2 and D3) of gp130 via its site II and the D1 (Ig-like domain) of the second 
gp130 to form a hexameric signaling complex consisting of two IL-6, two IL-6Rα, and 
two gp130 molecules [21]. Interestingly, another report from our laboratory regarding 
the naturally occuring, ligand-independent, and constitutively active gp130 variants 
identified by Rebouissou et al. [135] showed also an important role for the D1 domain 
of gp130. Deletion of the D1 domain resulted in an abrogation of ligand-independent 
gp130-mediated signaling, suggesting that this domain is envolveld in dimerization, 
even if no physical interaction analysis has proved this so far (Timo Effenberger and 
Jan Sommer, personal communication). However, there were no extracellular 
domains of gp130 which could be invovled in this preformed dimerization of sushi-
gp130 in our experimental setting which formally did not exclude that preformed 
dimer formation is mediated by the extracellular domains in vivo. Here, one might 
suggest that preformed dimerization occurs via the transmembrane domain or 
intracellular domain. This has been assumed by studying the physical interaction 
between sushi-gp130 and ∆cys-Fos-gp130 as well as IL-15-gp130 and ∆cys-Fos-
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gp130. It was not expected that these chimeric proteins interacted with each other. In 
this study, the interaction between gp130 molecules lacking the complete 
extracellular portion could not be addressed directly, since a completely extracellular 
truncated gp130 molecule was not transported to the cell surface [136]. It is a 
preferred option that gp130 forms preformed dimerization via its transmembrane 
domain. This has been assumed because of two studies showing preformed 
dimerization of the erythropoietin receptor which was mediated by the 
transmembrane domain [195, 198]. This view is supported by the work of Sternberg 
and Gullick which shows that a sequence motif in the transmembrane domain of 
certain growth factor receptors with tyrosine activity mediated dimerization [204]. This 
sequence motif encompasses a five residue segment in which position 0 (P0) 
requires a small side chain (Gly, Ala, Ser, Thr or Pro), P3 an aliphatic side chain (Ala, 
Val, Leu, Ile) and P4 only the smallest side chains (Gly or Ala) [204]. Interestingly, 
gp130 matches those criteria, even though gp130 does not belong to the group of 
receptor tyrosine kinases. The results regarding sushi-gp130 imply that a functional 
active gp130-type receptor dimer needs to be positioned not only in close proximity to 
allow for full activation of the receptor, but also to be aligned in a specific manner 
[53]. 
 
NH3-AIVVPVCLAFLLTTLLGVLFCF-COOH 
 
Figure 5.2 Assumed dimerization motif of the transmembrane domain of gp130 using the 
sequence motif found in many growth factor receptors with tyrosine activity by Sternberg and 
Gullick [204]. The sequence motif encompasses a five residue segment (italic) which starts with 
position P0 (red - small side chain), P3 (green - aliphatic side chain) and P3 (blue - smallest side 
chain). 
 
Another interesting finding of this study is that gp130 was the only molecule which 
could be activated by IL-15 alone with respect to the onset of signaling. IL-15-WSX-1, 
IL-15-LIFR, IL-15-OSMR, and IL-15-GPL did not show any activation, although 
homodimerization of LIFR or GPL could be achieved by co-expression of e.g. IL-15-
LIFR + sushi-LIFR. Because of this, functional dimerization of gp130 achieved by IL-
15 must be considered as special. If a receptor has the capability to form 
homodimers, even if they can only be achieved by artificial dimerization, it is not clear 
why functional homodimerization of e.g. LIFR cannot be achieved by IL-15. A 
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possible explanation for this is the principle that gp130 is the only member of the 
gp130-type receptors which exhibits homodimers in vivo. This might explain why IL-
15-gp130 does show activation of the receptor chains and the other IL-15 chimeric 
receptors do not. Contrary to this, another study from our laboratory revealed that IL-
23R which is one component of the IL-23 signaling complex and belongs to the group 
two of class I cytokine receptor like gp130 also showed ligand-independent and 
constitutive activation if fused to IL-15 (Doreen Floss, personal communication). It is 
not known if IL-23R homodimerizes in vivo. Also, IL-23R does not belong to the 
cytokine receptors which are shared by many cytokines like IL-2Rγc, IL-3Rβc or 
gp130 [46]. IL-23R and the IL-12Rβ1 form the receptor complex for IL-23 (Table 1.1). 
Furthermore the IL-12Rβ1 is also utilized by IL-12 to form the receptor complex of IL-
12 with the IL-12Rβ2 (Table 1.1). Interestingly, fusion of IL-15 to IL-12Rβ1 did not 
lead to functional activation of this chimeric receptor (Doreen Floss, personal 
communication). It remains an open question which receptors are capable to induce 
ligand-independent and constitutive activation after fusion to IL-15 and how functional 
dimerization is achieved by IL-15 in contrast to IL-15 and IL-15Rα-sushi. 
5.3 Applications of the IL-15/IL-15Rα-sushi based system 
5.3.1 In vitro applications 
It was successfully shown that the IL-15/IL-15Rα-sushi based system was applicable 
to all gp130-type receptor complexes. It would be interesting to investigate the 
application of this system to other heterodimeric receptor complexes of the class I 
cytokine receptor family comprising all complexes listed in Table 1.1 to see if ligand-
independent and constitutive activation is also achieved. Furthermore, heterodimeric 
receptor complexes from other superfamilies such as class II cytokine receptors [8], 
interleukin-1 (IL-1) receptors [10], tyrosine kinase receptors [11], and IL-17 receptors 
[14] might be targets for the application of the IL-15/IL-15Rα-sushi based system.  
The IL-15/IL-15Rα-sushi based system can be used to study differences of ligand-
dependent and ligand-independent signaling over a long period of time. Prolonged 
ligand-dependent signaling by IL-6-like cytokine is highly regulated and leads to 
attenuation of the phosphorylation of e.g. STAT3. This is achieved for instance by a 
negative-feedback loop inhibitors like SOCS3 [73]. One mechanism is the 
internalization of gp130-type receptor complexes after ligand binding [205]. In gp130 
and LIFR dileucine-like motifs in the intracellular region have been identified to be 
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required for receptor mediated internalization [206, 207]. It would be interesting to 
investigate if the ligand-independent and constitutively active heterodimeric receptor 
complexes are also internalized and how this is regulated. Furthermore, another 
question to solve is if the constitutively active heterodimeric receptor complexes 
display also a constant STAT activation over time. Upregulation of SOCS3 as a direct 
target of STAT3 would also be an approach to analyze. A useful tool to study this is 
the usage of inducible expression system like the tetracycline-based systems [208]. 
5.3.2 Optimization of the IL-15/IL-15Rα-sushi based system for future in vivo 
applications 
Naturally occurring and constitutively active gp130-variants were described to play a 
role in inflammatory hepatocellular adenomas, which was directly caused by gain-of-
function somatic mutations within the gp130 receptor chain [135]. The gain-of-
function gp130 variants were active in a ligand-independent manner and led to 
marked activation of the IL-6 signaling pathway [135], which is highly comparable to 
our homo- and heterodimeric receptor complexes. Therefore, it would be of high 
interest to study constitutive activation of heterodimeric gp130-type receptors in vivo.  
Constitutive activation of STAT3 has been implicated in many human neoplastic 
malignancies including multiple myeloma [209, 210], prostate cancer, melanoma, 
ovarian cancer, pancreatic cancer, renal carcinoma [211], colon cancer [212, 213], 
breast cancer [214, 215] and gastric cancer [216-221]. Artificially dimerized,  
constitutively active STAT3 was shown to possess oncogenic potential and STAT3 
was therefore designated as an oncogene [222]. In some of these malignancies, 
involvement of IL-6 or IL-11 has been shown [212, 213, 216-221]. ERK1/2 activities 
also contribute to different cancer diseases, in which Ras mutations have been found 
or not [223-228]. It is not unlikely that in such malignancies, constitutive activation of 
homodimeric gp130 receptor complex or a heterodimeric gp130/WSX-1, gp130/LIFR, 
gp130/OSMR or GPL/OSMR receptor complex lead to the activation of STAT3 and 
ERK1/2. This study might be the starting point to study the oncogenic potential of 
permanently activated heterodimeric gp130 receptor complexes resulting in 
constitutively activated STATs and ERK1/2 in vivo. Moreover, constitutively active 
heterodimeric gp130-type receptor complexes would provide novel molecular tools to 
establish animal models of diseases in which activated STATs and/or ERK1/2 are 
believed to play a role. There are two potential advantages of using models based on 
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ligand-independent, constitutive heterodimeric gp130-type receptor complexes rather 
than to rely on a constitutively active STAT3 mutant or to transgenic mice over-
expressing the respective cytokines. First, activation of STAT3 does not reflect the 
activation pattern after heterodimeric gp130-type recepor activation since the 
Ras/Raf/MAPK pathway and the PI3K pathway is not activated. Secondly, systemic 
cytokine supply does not reflect situations in which chronic activation of the receptors 
is achieved only in certain tissues or areas of the body. Our receptor chimeras could 
now be used to induce gp130-type receptor signaling in a cell autonomous manner 
and if combined with tissue specific promoters in tissue specific transgenic mouse 
models. The use of the receptor chimeras therefore will provide novel insights into 
the consequences of uncontrolled activation of heterodimeric gp130-type receptor 
complexes and the resulting signaling cascades in vivo. 
To avoid IL-15 mediated-responses of our receptor chimeras in vivo, we have used 
an IL-15 mutant, which can not bind to the IL-2Rβ- and IL-2Rγc-receptor chains of the 
IL-15 receptor signaling complex, but was still able to bind the IL-15Rα-sushi domain 
to induce cytokine independent dimerization of the chimeric receptor proteins [184]. 
Therefore, our constitutively active heterodimeric receptor molecules in combination 
with the 2A peptide technology [189-193] may be used to generate animal models to 
assess the consequences of constitutive pathophysiologic activation of gp130-type 
heterodimeric receptor complexes at a cell autonomous level. 
To achieve this, the IL-15/IL-15Rα-sushi based system needs to be further improved. 
IL-15 and the IL-15Rα are expressed by many cell types like monocytes [229], 
macrophages [230], dendritic cells [160, 231], mast cells [232] other undefined 
hematopoietic cells, T-cells [233], parenchymal cells [158, 234], fibroblasts [235, 
236], renal tubular epithelial cells [237, 238], endothelial cells [239], hepatocytes 
[240], and adipocytes [241]. Furthermore IL-15 and IL-15Rα are widely expressed in 
the central nervous system of mice and human, including the frontal and parietal 
cortex, hippocampus, medulla oblongata, thalamus and cerebellum [242, 243].  
It has been shown that human IL-15 can interact with murine IL-15Rα and murine IL-
15 with human IL-15Rα with similar binding kinetics [244]. Expression of the chimeric 
receptors in cells, expressing endogenous IL-15 and IL-15Rα, could interfere with 
normal signaling of IL-15 and complex formation of the chimeric heterodimeric 
receptors when meeting in the ER or Golgi apparatus. Since the binding affinities of 
IL-15 to its receptor is approximately 40-times higher than to the sushi domain of the 
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IL-15Rα (Table 1.2), binding of e.g. IL-15-WSX-1 to murine IL-15Rα would be 
preferred. Otherwise, as tested with increasing amounts of soluble IL-15Rα-sushi 
domain, once formed complexes of e.g. IL-15-WSX-1 + sushi-gp130 could not be 
destroyed. This effect could be explained by the assumption that receptor fused IL-15 
displays a higher affinity to its receptor fused IL-15Rα-sushi domain and vice versa. It 
remains as an open question to what extent the affinity of IL-15 to its receptor is 
increased by fusion of IL-15 to a receptor (e.g. IL-15-WSX-1) and if binding of IL-15-
WSX-1 to sushi-gp130 or endogenous IL-15Rα is preferred. Besides, endogenous IL-
15Rα and sushi-gp130 would compete, in turn, for the binding of endogenous IL-15. 
Therefore, there are four major problems of in vivo usage of chimeric receptors in 
cells expressing endogenous IL-15 and IL-15Rα.  
First, endogenous murine IL-15 might bind to sushi-gp130. This endogenous murine 
IL-15 would have the capacity to mediate signaling because it would be presented at 
the cell surface, the negative regulation of IL-15 mediated signaling could be 
impaired. One regulatory mechanism to circumvent increased signaling by the 
endogenous IL-15/IL-15Rα complex is shedding of the IL-15Rα by the protease 
ADAM17 [162, 163]. The complex of IL-15/sIL-15Rα is generated by cleavage 
exhibits antagonistic properties [162, 163].   
Second, IL-15-WSX-1 might bind to the murine IL-15Rα and as a consequence lead 
to a decreased endogenous IL-15 signaling because endogenous IL-15 cannot bind 
to its receptor and it is not presented the cell surface. As written above, IL-15 might 
bind to sushi-gp130 but in this context, it needs to be clarified whether expression 
levels of IL-15-WSX-1 and sushi-gp130, encoded by the FUSIO construct, are 
comparable. If IL-15-WSX-1 is expressed e.g. 1.1-fold higher than sushi-gp130 would 
lead to free IL-15-WSX-1 proteins which in turn would interact with the endogenous 
IL-15Rα. Therefore, endogenous IL-15 and IL-15-WSX-1 would compete for the 
binding to sushi-gp130 and endogenous IL-15 biology would be impaired.  
Third, the endogenous IL-15 and IL-15Rα can interfere with the complex formation of 
chimeric heterodimers. Especially, this effect would take place in a situation of 
increased IL-15/IL-15Rα expression leading to an abrogation of signaling by e.g. IL-
15-WSX-1 + sushi-gp130.  
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Figure 5.3 Problems of in vivo usage of chimeric receptors in cells expressing endogenous IL-
15 and IL-15Rα. (1.) No negative regulation of IL-15 signaling by shedding. (2.) Impairment of IL-15 
signaling. (3.) Interference with chimeric heterodimer complex formation. (4.) Unwanted signaling 
mediated by IL-15Rα in cis or trans. See text for further details. 
 
Fourth, a study of Bulanova and coworkers suggested that the IL-15Rα chain alone is 
capable of mediating a signal upon activation by IL-15 through selective association 
with Syk kinase in human B cells [149]. This could also be true for murine B cells. 
Furthermore, other data demonstrated that IL-15 is capable of rescuing murine L929 
fibroblasts from TNFα-induced apoptosis through recruitment of TNFR-associated 
factor 2 (TRAF2) to the IL-15Rα chain, and NF-κB activation [245]. Expression of 
chimeric receptors (e.g. IL-15-WSX-1) in those or neighboring cells would lead to 
unwanted signaling events mediated by IL-15Rα.  
These suboptimal requirements for an in vivo model of constitutively active 
heterodimeric gp130-type receptor complexes can be avoided by rational redesign of 
the IL-15/IL-15Rα-sushi complex. The binding interface of IL-15 could be transferred 
to IL-15Rα-sushi and vice versa. The transfer of functional sites has been shown in 
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our group previously [165]. Transfer of the LIFR binding site from CNTF to IL-6 
resulted in an IL-6/CNTF chimera which can signal via a complex of IL-
6Rα/gp130/LIFR [165]. Using molecular modeling techniques it was also possible to 
identify the residues of vIL-6 which are essential for direct binding to gp130. This has 
been shown using IL-6/vIL-6 chimeras [246]. Furthermore, transfer of the CNTFRα 
binding site of CLC to CNTF, which exhibits also binding to the IL-6Rα at high 
concentrations, improved the specificity of CNTF with respect to CNTFRα binding 
[247].  
A minor problem could be the aggregation potential of IL-15. Since nobody knows 
which residues are essential for this effect and if this effect is caused by over-
expression or has a physiological role, only random mutagenesis of IL-15 could lead 
to a non-aggregating IL-15 molecule. However, in our system aggregation of IL-15 
led to functional dimerization of the respective gp130 chimera. This effect could be 
diminished by addition of soluble IL-15Rα-sushi domain. In vivo this could mean that 
even aggregated IL-15 is recruited to IL-15Rα as a monomer. Solving the crystal 
structure of the IL-15/IL-15Rα complex revealed that IL-15 binds to its α-receptor in a 
1:1 stoichoimetry resulting in a quaternary complex of IL-15/IL-15Rβ/IL-2Rβ/IL-2Rγc 
[248].  
To transfer these in vitro data into an in vivo situation, a useful tool to generate 
mouse models is the generation of conditional knock-in mice. This can be achieved 
by homological recombination of the transgene into the ROSA26 locus of mice. 
Knockout of the ROSA26 locus has been shown to have no impact on development 
or physiology of the mice and lead to ubiquitous expression of an introduced β-
galactosidase [249]. Combining the integration into the ROSA26 locus with tissue-
specific Cre recombinase/loxP inducible systems has been used for the analysis of 
skeletal-specific expression of vascular endothelial growth factor (VEGF) [250] or 
dendritic cell-specific expression of the diphtheria toxin [251].  
Several reports suggested that LIF signaling promotes proliferation in different 
cancers such as prostate [252, 253] or skin [254]. Furthermore, the expression of 
LIFR, OSMR, and gp130 was highly increased in infiltrative breast carcinomas 
suggesting a highly active autocrine effect for LIF and OSM in the epithelial 
compartment of infiltrative breast carcinoma [255]. A Genome-wide gene copy 
number and expression analysis of primary gastric tumors and gastric cancer cell 
lines revealed that OSMR expression can be used as a prognostic marker [256]. 
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Further studies are however required to decipher its biological significance in gastric 
cancer initiation and progression. Interestingly, IL-27 possesses a potent anti-tumor 
activity which has been shown by analysis of a murine tumor models comprising 
colon carcinoma [257], neuroblastoma [258] or melanoma [259]. The anti-tumor 
activity of IL-27 was mediated through CD8 T-cells, NK cells, or its own anti-
angiogenic activity [257-259]. Especially in this context it would be interesting to 
analyze a constitutively active gp130/WSX-1 complex expressed in healthy tissues to 
clarify whether gp130/WSX-1 mediated signaling would never be involved in the 
onset of cancer.   
In summary, the usage of tissue-specific expression of ligand-independent, 
constitutively active gp130/LIFR, gp130/OSMR, or gp130/WSX-1 complexes would 
give insight into the role of their signaling in initiation and progression of 
cancerogenesis or other hyperplasic disorders. 
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6 Summary 
The IL-6 family of cytokines consists of IL-6, vIL-6, IL-11, IL-27, CNTF, CT-1, LIF, 
CLC, NP, OSM, and IL-31. IL-6, vIL-6, IL-11 induce the formation of a gp130-
homodimer, whereas signaling by CNTF, CT-1, LIF, CLC, and NP results in the 
formation of a gp130/LIFR heterodimer. OSM can induce the formation of a dimer of 
gp130 with LIFR or the related protein OSMR. IL-27 exclusively signals via a 
heterodimer comprising gp130 and WSX-1, whereas IL-31 induces the formation of 
an OSMR/GPL heterodimer. Interestingly, naturally occurring, ligand-independent, 
and constitutively active gp130 variants were described to play a role in the onset of 
inflammatory hepatocellular adenomas. In the past, constitutively active gp130 
variants based on homodimerization of Jun leucine zippers were generated in this 
laboratory. However, using a Fos leucine zipper-gp130 (Fos-gp130) chimera and a 
Jun leucine zipper-WSX-1 chimera (Jun-WSX-1), Fos and Jun form the AP-1 
transcription factor complex, revealed that also Fos-gp130 alone was able to induce 
ligand-independent STAT3 phosphorylation and ligand-independent growth of 
cytokine-dependent cells indicating that this approach was not suitable for the 
generation of ligand-independent, constitutive activation of heterodimeric receptors. 
Therefore a novel IL-15/IL-15Rα based system to generate ligand-independent, 
constitutively active heterodimeric complexes for all known gp130-receptor members 
was developed. In this system, IL-15 was genetically fused to one receptor 
component whereas IL-15Rα was fused to the second receptor component. Ligand-
independent heterodimerization of gp130 with WSX-1, LIFR and OSMR and of 
OSMR with GPL led to constitutive, ligand-independent STAT1 and/or STAT3 and 
ERK1/2 phosphorylation. Moreover, these receptor combinations induced 
transcription of the STAT3 target genes c-myc and Pim-1 upon stable transfection 
and conferred to independent growth of cytokine-dependent cells. The IL-15/IL-15Rα 
system is established as a novel system to mimic constitutive and ligand-independent 
activation of homo- and heterodimeric receptor complexes, which could also be 
applicable to other heterodimeric cytokine receptor and growth factor receptor 
families. Additionally, in an improved approach a mutated IL-15 protein was used, 
which was still able to bind the IL-15Rα-sushi domain, but not to IL-2Rβ and IL-2Rγc 
receptor chains. In combination with the 2A peptide technology, this is the first step 
towards to translation of the in vitro data to analyse the tumorigenic potential of 
gp130-heterodimeric receptor complexes in vivo. 
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7 Zusammenfassung 
Die IL-6 Zytokinfamilie besteht aus IL-6, vIL-6, IL-11, IL-27, CNTF, CT-1, LIF, CLC, 
NP, OSM und IL-31. IL-6, vIL-6 und IL-11 induzieren die Bildung eines gp130 
Homodimers, wohingegen die Signalwirkung von CNTF, CT-1, LIF, CLC und NP zur 
Bildung eines gp130/LIFR Heterodimers führen. OSM induziert die Bildung eines 
Dimers aus gp130 und LIFR oder dem verwandten Protein OSMR. IL-27 betreibt 
ausschließlich Signalwirkung durch ein Heterodimer bestehend aus gp130 und WSX-
1, wohingegen IL-31 die Bildung eines OSMR/GPL Heterodimers induziert. 
Interessanterweise wurden natürlich vorkommende, Liganden-unabhängige und 
konstitutiv aktive gp130 Varianten beschrieben, welche eine Rolle bei der Entstehung 
von entzündlichen hepatozellulären Adenomen spielen. In der Vergangenheit wurde 
in dieser Arbeitsgruppe eine Liganden-unabhängige und konstitutiv aktive gp130 
Variante, auf der Homodimerisierung von Jun „Leucinzippern“ basierend, hergestellt. 
Allerdings, unter Verwendung einer Fos „Leucinzipper“ gp130 Chimäre (Fos-gp130) 
und einer Jun „Leucinzipper“ WSX-1 Chimäre (Jun-WSX-1), Fos und Jun bilden den 
AP-1 Transkriptionsfaktorkomplex, stellte sich heraus, dass Fos-gp130 bereits alleine 
in der Lage ist eine Liganden-unabhängige STAT3-Phosphorylierung und 
unabhängiges Wachstum von Zytokin-abhängigen Zellen zu induzieren. Dieser 
Ansatz konnte daher nicht für die Herstellung von Liganden-unabhängigen, 
konstitutiv aktiven heterodimeren Rezeptorkomplexen verwendet werden. Daher 
wurde ein neues auf IL-15/IL-15Rα-sushi basierendes System zur Herstellung von 
Liganden-unabhängigen und konstitutiv aktiven Heterodimeren aller gp130 ähnlichen 
Rezeptoren entwickelt. In diesem System wurde eine Rezeptorkomponente mit IL-15, 
die andere mit der sushi Domäne des IL-15Rα, fusioniert. Liganden-unabhängige 
Heterodimerisierung von gp130 mit WSX-1, LIFR und OSMR bzw. OSMR mit GPL 
führte zur konstitutiven, liganden-unabhängigen STAT1- und/oder STAT3- und 
ERK1/2-Phosphorylierung. Darüber hinaus führten diese Rezeptorkombinationen zur 
Induktion der Transkription der STAT3 Zielgene c-myc und Pim-1 und zu 
unabhängigem Wachstum von Zytokin-abhängigen Zellen. Die Etablierung des 
neuartigen IL-15/IL-15Rα-sushi basierenden Systems, zur Nachahmung von 
konstitutiver, Liganden-unabhängiger Aktiverung homo- oder heterodimerer 
Rezeptorkomplexe, kann wohlmöglich auch auf andere heterodimere 
Zytokinrezeptor- oder Wachstumsfaktorrezeptor-Familien anwendbar sein. Zusätzlich 
wurde in einem verbesserten Ansatz ein mutiertes IL-15 Protein verwendet, welches 
zwar noch an die IL-15Rα-sushi Domäne, allerdings nicht mehr an die IL-2Rβ und IL-
2Rγc Rezeptoren, binden kann. Kombiniert mit der 2A Peptid Technology, ist dies der 
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erste Schritt die in vitro Daten anzuwenden, um das tumorigene Potential von gp130 
heterodimeren Rezeptorkomplexen in vivo zu analysieren. 
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9 Appendix 
9.1 Abbreviations 
A   adenine 
aa    amino acid  
ADAM  a disintegrin and metalloproteinase 
Amp   ampicillin 
APC   allophycocyanine 
C   celsius or cytosine 
cDNA   complementary DNA 
CD   cluster of differentiation 
CLC   cardiotrophin-like cytokine 
CLF-1   cytokine-like factor 1 
CPD   cytoplasmic domain 
CNTF    ciliary neurotrophic factor 
CNTFR  ciliary neurotrophic factor receptor 
DC   dendritic cells 
DNA   desoxyribonucleic acid 
dNTP   desoxynucleotide triphosphate 
E.coli       Escherichia coli 
ECD   extracellular domain 
ER   endoplamic reticulum 
ERK    extracellular signal-regulated kinase 
EYFP   enhanced yellow fluorescent protein 
FBS   fetal bovine serum 
FC   flow cytometry 
g   gram or gravity 
G   guanine 
GFP   green fluorescent protein 
gp130   glycoprotein 130 
GPL   gp130-like receptor 
Gab-1   Grb2-associating binder 1 
GRB-2  growth factor receptor bound protein 2 
h   human 
HIL-6   Hyper-IL-6 
IL   interleukin 
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IL-xR   interleukin-x receptor 
IP   immunoprecipitation 
JAK   Janus kinase 
Kan   kanamycin 
kb   kilobase  
kDa   kilo Dalton 
l   liter 
LB   Luria Bertani 
LIF   leukemia inhibitory factor 
LIFR   leukemia inhibitory factor receptor 
M   molar 
m   murine, milli or meter 
min   minute 
µ   micro 
MAPK   mitogen activated protein kinase  
MEK-1  MAPK/ERK kinase 1 
mRNA  messenger RNA 
n   nano 
n.d.    not determined 
NP     neuropoeitin 
P-x   phosphorylated x 
PBS   phophate buffered saline 
PCR   polymerase chain reaction 
PtdIns(3,4,5)P3 phosphatidylinositol-(3,4,5)-phosphate 
Puro   puromycin 
OSM     oncostatin M 
OSMR  oncostatin M receptor 
rpm   rounds per minute 
RT    room temperature 
RT-PCR  reverse transcribtion followed by a polymerase chain reaction 
PIAS   protein inhibitor of STATs 
s   second 
sIL-6R  soluble interleukin-6 receptor 
SOCS   suppressor of cytokine signaling 
SP   signal peptide 
STAT    signal transducer and activator of transcription 
T   thymidine 
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Taq   thermophilus aquaticus    
Th   T helper cell 
TBS   Tris buffered saline 
TMD   transmembrane domain 
TNF   tumor necrosis factor 
TNFR   tumor necrosis factor receptor 
TRAF   TNFR-associated factor  
U   unit(s) 
V   volt 
WB   Western Blot 
WSX-1  interleukin-27 receptor alpha  
 
9.2 Amino acids 
A (Ala)   alanine    
C (Cys)   cysteine  
D (Asp)  aspartic acid  
E (Glu)  glutamic acid 
F (Phe)  phenylalanine  
G (Gly)  glycine  
H (His)  histidine  
I (Ile)   isoleucine  
K (Lys9  lysine  
L (Leu)  leucine  
M (Met)  methionine  
N (Asn)  asparagine  
P (Pro)  proline  
Q (Gln)  glutamine  
R (Arg)  arginine  
S (Ser)  serine  
T (Thr)  threonine  
V (Val)  valine 
W (Trp)  tryptophan 
Y (Tyr)  tyrosine  
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9.3 Sequences and plasmid maps 
1. pBSK(+)-Fos-gp130 
 
Nucleotide sequence of Fos-gp130 including relevant restriction sites: 
 GGTACCGG GCCCCCCCTC GAGTCTAGAC CCCGCAAGAT GTTGACGTTG 
 701 CAGACTTGGC TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC 
 751 AGGTGACTAC AAAGATGACG ATGATAAAGA ATTGTGCGGC GGCTTAACCG 
 801 ACACCCTGCA GGCTGAAACC GACCAGCTGG AAGACGAGAA AAGCGCGCTC 
 851 CAGACCGAAA TCGCTAACCT GCTTAAGGAA AAGGAGAAAC TGGAATTCAC 
 901 TTTTACTACC CCAAAGTTTG CTCAAGGAGA AATTGAAGCC ATAGTCGTGC 
 951 CTGTTTGCTT AGCATTCCTA TTGACAACTC TTCTGGGAGT GCTGTTCTGC 
1001 TTTAATAAGC GAGACCTAAT TAAAAAACAC ATCTGGCCTA ATGTTCCAGA 
1051 TCCTTCAAAG AGTCATATTG CCCAGTGGTC ACCTCACACT CCTCCAAGGC 
1101 ACAATTTTAA TTCAAAAGAT CAAATGTATT CAGATGGCAA TTTCACTGAT 
1151 GTAAGTGTTG TGGAAATAGA AGCAAATGAC AAAAAGCCTT TTCCAGAAGA 
1201 TCTGAAATTA TTGGACCTGT TCAAAAAGGA AAAAATTAAT ACTGAAGGAC 
1251 ACAGCAGTGG TATTGGGGGG TCTTCATGCA TGTCATCTTC TAGGCCAAGC 
1301 ATTTCTAGCA GTGATGAAAA TGAATCTTCA CAAAACACTT CGAGCACTGT 
1351 CCAGTATTCT ACCGTGGTAC ACAGTGGCTA CAGACACCAA GTTCCGTCAG 
1401 TCCAAGTCTT CTCAAGATCC GAGTCTACCC AGCCCTTGTT AGATTCAGAG 
1451 GAGCGGCCAG AAGATCTACA ATTAGTAGAT CATGTAGATG GCGGTGATGG 
1501 TATTTTGCCC AGGCAACAGT ACTTCAAACA GAACTGCAGT CAGCATGAAT 
1551 CCAGTCCAGA TATTTCACAT TTTGAAAGGT CAAAGCAAGT TTCATCAGTC 
1601 AATGAGGAAG ATTTTGTTAG ACTTAAACAG CAGATTTCAG ATCATATTTC 
1651 ACAATCCTGT GGATCTGGGC AAATGAAAAT GTTTCAGGAA GTTTCTGCAG 
1701 CAGATGCTTT TGGTCCAGGT ACTGAGGGAC AAGTAGAAAG ATTTGAAACA 
1751 GTTGGCATGG AGGCTGCGAC TGATGAAGGC ATGCCTAAAA GTTACTTACC 
1801 ACAGACTGTA CGGCAAGGCG GCTACATGCC TCAGTGAAGG ACTAGGGGGA 
1851 TCCACTAGTT CTAGAGCGGC CGCCACCGCG GTGGAGCTC 
Bold: start and stop codons 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGDYKDDDDKELCGGLTDTLQAETDQLEDE 50 
KSALQTEIANLLKEKEKLEFTFTTPKFAQGEIEAIVVPVCLAFLLTTLLG 100 
VLFCFNKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQMYSDG 150 
NFTDVSVVEIEANDKKPFPEDLKLLDLFKKEKINTEGHSSGIGGSSCMSS 200 
SRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQVPSVQVFSRSESTQPL 250 
LDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISHFERSKQ 300 
VSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFGPGTEGQVE 350 
RFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ* 
Black: human gp130 (SP and 15aa ECD+TMD+CPD); green: FLAG tag; italic: linker 
(with cysteine); blue: Fos leucine zipper; brown: EcoRI site 
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2. pBSK(+)-∆cys-Fos-gp130 
 
 
Nucleotide sequence of ∆cys-Fos-gp130 including relevant restriction sites : 
 GGTACCGG GCCCCCCCTC GAGTCTAGAC CCCGCAAGAT GTTGACGTTG 
 701 CAGACTTGGC TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC 
 751 AGGTGACTAC AAAGATGACG ATGATAAAGA ATTGGGCGGC GGCTTAACCG 
 801 ACACCCTGCA GGCTGAAACC GACCAGCTGG AAGACGAGAA AAGCGCGCTC 
 851 CAGACCGAAA TCGCTAACCT GCTTAAGGAA AAGGAGAAAC TGGAATTCAC 
 901 TTTTACTACC CCAAAGTTTG CTCAAGGAGA AATTGAAGCC ATAGTCGTGC 
 951 CTGTTTGCTT AGCATTCCTA TTGACAACTC TTCTGGGAGT GCTGTTCTGC 
1001 TTTAATAAGC GAGACCTAAT TAAAAAACAC ATCTGGCCTA ATGTTCCAGA 
1051 TCCTTCAAAG AGTCATATTG CCCAGTGGTC ACCTCACACT CCTCCAAGGC 
1101 ACAATTTTAA TTCAAAAGAT CAAATGTATT CAGATGGCAA TTTCACTGAT 
1151 GTAAGTGTTG TGGAAATAGA AGCAAATGAC AAAAAGCCTT TTCCAGAAGA 
1201 TCTGAAATTA TTGGACCTGT TCAAAAAGGA AAAAATTAAT ACTGAAGGAC 
1251 ACAGCAGTGG TATTGGGGGG TCTTCATGCA TGTCATCTTC TAGGCCAAGC 
1301 ATTTCTAGCA GTGATGAAAA TGAATCTTCA CAAAACACTT CGAGCACTGT 
1351 CCAGTATTCT ACCGTGGTAC ACAGTGGCTA CAGACACCAA GTTCCGTCAG 
1401 TCCAAGTCTT CTCAAGATCC GAGTCTACCC AGCCCTTGTT AGATTCAGAG 
1451 GAGCGGCCAG AAGATCTACA ATTAGTAGAT CATGTAGATG GCGGTGATGG 
1501 TATTTTGCCC AGGCAACAGT ACTTCAAACA GAACTGCAGT CAGCATGAAT 
1551 CCAGTCCAGA TATTTCACAT TTTGAAAGGT CAAAGCAAGT TTCATCAGTC 
1601 AATGAGGAAG ATTTTGTTAG ACTTAAACAG CAGATTTCAG ATCATATTTC 
1651 ACAATCCTGT GGATCTGGGC AAATGAAAAT GTTTCAGGAA GTTTCTGCAG 
1701 CAGATGCTTT TGGTCCAGGT ACTGAGGGAC AAGTAGAAAG ATTTGAAACA 
1751 GTTGGCATGG AGGCTGCGAC TGATGAAGGC ATGCCTAAAA GTTACTTACC 
1801 ACAGACTGTA CGGCAAGGCG GCTACATGCC TCAGTGAAGG ACTAGGGGGA 
1851 TCCACTAGTT CTAGAGCGGC CGCCACCGCG GTGGAGCTC 
Bold: start and stop codons 
Amino acid sequence : 
MLTLQTWLVQALFIFLTTESTGDYKDDDDKELGGGLTDTLQAETDQLEDE 50 
KSALQTEIANLLKEKEKLEFTFTTPKFAQGEIEAIVVPVCLAFLLTTLLG 100 
VLFCFNKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQMYSDG 150 
NFTDVSVVEIEANDKKPFPEDLKLLDLFKKEKINTEGHSSGIGGSSCMSS 200 
SRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQVPSVQVFSRSESTQPL 250 
LDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISHFERSKQ 300 
VSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFGPGTEGQVE 350 
RFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ* 
Black: human gp130(SP and 15aa ECD+TMD+CPD); green: FLAG tag; italic: linker 
(w/o cysteine); blue: Fos leucine zipper; brown: EcoRI site 
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3. pBSK(+)-Jun-WSX-1 
 
 
 
Nucleotide sequence of Jun-WSX-1 including relevant restriction sites: 
 GGTACCGG GCCCCCCCTC GAGTCTAGAC CCCGCAAGAT GTTGACGTTG 
 701 CAGACTTGGC TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC 
 751 AGGTGACTAC AAAGATGACG ATGATAAAGA ATTGTGCGGC GGCAGAATCG 
 801 CCCGGCTGGA GGAAAAAGTG AAAACCTTGA AAGCTCAGAA CTCGGAGCTG 
 851 GCGTCCACGG CCAACATGCT CAGGGAACAG GTGGCACAGC TTAAACAGAA 
 901 AGTCATGAAC GAATTCTCAC TTCACCTACC AGATAATAGG ATCAGGTGGA 
 951 AAGCTCTGCC CTGGTTTCTG TCCCTGTGGG GTTTGCTTCT GATGGGCTGT 
1001 GGCCTGAGCC TGGCCAGTAC CAGGTGCCTA CAGGCCAGGT GCTTACACTG 
1051 GCGACACAAG TTGCTTCCCC AGTGGATCTG GGAGAGGGTT CCTGATCCTG 
1101 CCAACAGCAA TTCTGGGCAA CCTTACATCA AGGAGGTGAG CCTGCCCCAA 
1151 CCGCCCAAGG ACGGACCCAT CCTGGAGGTG GAGGAAGTGG AGCTACAGCC 
1201 TGTTGTGGAG TCCCCTAAAG CCTCTGCCCC GATTTACTCT GGGTATGAGA 
1251 AACACTTCCT GCCCACACCA GAGGAGCTGG GCCTTCTAGT CTGAGGATCC 
1301 ACTAGTTCTA GAGCGGCCGC CACCGCGGTG GAGCT 
 
Bold: start and stop codons 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGDYKDDDDKELCGGRIARLEEKVKTLKAQ 50 
NSELASTANMLREQVAQLKQKVMNEFSLHLPDNRIRWKALPWFLSLWGLL 100 
LMGCGLSLASTRCLQARCLHWRHKLLPQWIWERVPDPANSNSGQPYIKEV 150 
SLPQPPKDGPILEVEEVELQPVVESPKASAPIYSGYEKHFLPTPEELGLL 200 
V* 
 
Black: human gp130 SP; green: FLAG tag; italic: linker (w/o cysteine); red: Jun 
leucine zipper; brown: EcoRI site; purple: murine WSX-1 (15aa ECD+TMD+CPD) 
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4. pBSK(+)-IL-15-gp130 
 
 
Nucleotide sequence of IL-15-gp130 including relevant restriction sites: 
 GGTACCGG GCCCCCCCTC GAGCCACCAT GGACAGCAAA GGTTCGTCGC 
 701 AGAAAGCAGG GTCCCGCCTG CTCCTGCTGC TGGTGGTGTC AAATCTACTC 
 751 TTGTGCCAGG GTGTGGTCTC CACCACGCGT AACTGGGTGA ATGTAATAAG 
 801 TGATTTGAAA AAAATTGAAG ATCTTATTCA ATCTATGCAT ATTGATGCTA 
 851 CTTTATATAC GGAAAGTGAT GTTCACCCCA GTTGCAAAGT AACAGCAATG 
 901 AAGTGCTTTC TCTTGGAGTT ACAAGTTATT TCACTTGAGT CCGGAGATGC 
 951 AAGTATTCAT GATACAGTAG AAAATCTGAT CATCCTAGCA AACAACAGTT 
1001 TGTCTTCTAA TGGGAATGTA ACAGAATCTG GATGCAAAGA ATGTGAGGAA 
1051 CTGGAGGAAA AAAATATTAA AGAATTTTTG CAGAGTTTTG TACATATTGT 
1101 CCAAATGTTC ATCAACACTT CTGAATTCAC TTTTACTACC CCAAAGTTTG 
1151 CTCAAGGAGA AATTGAAGCC ATAGTCGTGC CTGTTTGCTT AGCATTCCTA 
1201 TTGACAACTC TTCTGGGAGT GCTGTTCTGC TTTAATAAGC GAGACCTAAT 
1251 TAAAAAACAC ATCTGGCCTA ATGTTCCAGA TCCTTCAAAG AGTCATATTG 
1301 CCCAGTGGTC ACCTCACACT CCTCCAAGGC ACAATTTTAA TTCAAAAGAT 
1351 CAAATGTATT CAGATGGCAA TTTCACTGAT GTAAGTGTTG TGGAAATAGA 
1401 AGCAAATGAC AAAAAGCCTT TTCCAGAAGA TCTGAAATTA TTGGACCTGT 
1451 TCAAAAAGGA AAAAATTAAT ACTGAAGGAC ACAGCAGTGG TATTGGGGGG 
1501 TCTTCATGCA TGTCATCTTC TAGGCCAAGC ATTTCTAGCA GTGATGAAAA 
1551 TGAATCTTCA CAAAACACTT CGAGCACTGT CCAGTATTCT ACCGTGGTAC 
1601 ACAGTGGCTA CAGACACCAA GTTCCGTCAG TCCAAGTCTT CTCAAGATCC 
1651 GAGTCTACCC AGCCCTTGTT AGATTCAGAG GAGCGGCCAG AAGATCTACA 
1701 ATTAGTAGAT CATGTAGATG GCGGTGATGG TATTTTGCCC AGGCAACAGT 
1751 ACTTCAAACA GAACTGCAGT CAGCATGAAT CCAGTCCAGA TATTTCACAT 
1801 TTTGAAAGGT CAAAGCAAGT TTCATCAGTC AATGAGGAAG ATTTTGTTAG 
1851 ACTTAAACAG CAGATTTCAG ATCATATTTC ACAATCCTGT GGATCTGGGC 
1901 AAATGAAAAT GTTTCAGGAA GTTTCTGCAG CAGATGCTTT TGGTCCAGGT 
1951 ACTGAGGGAC AAGTAGAAAG ATTTGAAACA GTTGGCATGG AGGCTGCGAC 
2001 TGATGAAGGC ATGCCTAAAA GTTACTTACC ACAGACTGTA CGGCAAGGCG 
2051 GCTACATGCC TCAGTGAAGG ACTAGGGGGA TCCACTAGTT CTAGAGCGGC 
2101 CGCCACCGCG GTGGAGCTC 
 
Bold: start and stop codons 
Amino acid sequence: 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
TFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVP 200 
DPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPE 250 
DLKLLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSST 300 
VQYSTVVHSGYRHQVPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGD 350 
GILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHI 400 
SQSCGSGQMKMFQEVSAADAFGPGTEGQVERFETVGMEAATDEGMPKSYL 450 
PQTVRQGGYMPQ* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  orange: 
human IL-15; brown: EcoRI site; black: human gp130 (15aa ECD+TMD+CPD)  
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5. pBSK(+)-IL-15-WSX-1 
 
 
 
Nucleotide sequence of IL-15-WSX-1 including relevant restriction sites 
        GTACCGG GCCCCCCCTC GAGCCACCAT GGACAGCAAA GGTTCGTCGC 
 701 AGAAAGCAGG GTCCCGCCTG CTCCTGCTGC TGGTGGTGTC AAATCTACTC 
 751 TTGTGCCAGG GTGTGGTCTC CACCACGCGT AACTGGGTGA ATGTAATAAG 
 801 TGATTTGAAA AAAATTGAAG ATCTTATTCA ATCTATGCAT ATTGATGCTA 
 851 CTTTATATAC GGAAAGTGAT GTTCACCCCA GTTGCAAAGT AACAGCAATG 
 901 AAGTGCTTTC TCTTGGAGTT ACAAGTTATT TCACTTGAGT CCGGAGATGC 
 951 AAGTATTCAT GATACAGTAG AAAATCTGAT CATCCTAGCA AACAACAGTT 
1001 TGTCTTCTAA TGGGAATGTA ACAGAATCTG GATGCAAAGA ATGTGAGGAA 
1051 CTGGAGGAAA AAAATATTAA AGAATTTTTG CAGAGTTTTG TACATATTGT 
1101 CCAAATGTTC ATCAACACTT CTGAATTCTC ACTTCACCTA CCAGATAATA 
1151 GGATCAGGTG GAAAGCTCTG CCCTGGTTTC TGTCCCTGTG GGGTTTGCTT 
1201 CTGATGGGCT GTGGCCTGAG CCTGGCCAGT ACCAGGTGCC TACAGGCCAG 
1251 GTGCTTACAC TGGCGACACA AGTTGCTTCC CCAGTGGATC TGGGAGAGGG 
1301 TTCCTGATCC TGCCAACAGC AATTCTGGGC AACCTTACAT CAAGGAGGTG 
1351 AGCCTGCCCC AACCGCCCAA GGACGGACCC ATCCTGGAGG TGGAGGAAGT 
1401 GGAGCTACAG CCTGTTGTGG AGTCCCCTAA AGCCTCTGCC CCGATTTACT 
1451 CTGGGTATGA GAAACACTTC CTGCCCACAC CAGAGGAGCT GGGCCTTCTA 
1501 GTCTGAGGAT CCACTAGTTC TAGAGCGGCC GCCACCGCGG TGGAGCTC 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
SLHLPDNRIRWKALPWFLSLWGLLLMGCGLSLASTRCLQARCLHWRHKLL 200 
PQWIWERVPDPANSNSGQPYIKEVSLPQPPKDGPILEVEEVELQPVVESP 250 
KASAPIYSGYEKHFLPTPEELGLLV* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  
orange: human IL-15; brown: EcoRI site; purple: murine WSX-1 (15aa ECD+TMD+CPD) 
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6. pBSK(+)-IL-15-LIFR 
 
 
 
Nucleotide sequence of IL-15-GPL including relevant restriction sites 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GGACAGCAAA GGTTCGTCGC 
 701 AGAAAGCAGG GTCCCGCCTG CTCCTGCTGC TGGTGGTGTC AAATCTACTC 
 751 TTGTGCCAGG GTGTGGTCTC CACCACGCGT AACTGGGTGA ATGTAATAAG 
 801 TGATTTGAAA AAAATTGAAG ATCTTATTCA ATCTATGCAT ATTGATGCTA 
 851 CTTTATATAC GGAAAGTGAT GTTCACCCCA GTTGCAAAGT AACAGCAATG 
 901 AAGTGCTTTC TCTTGGAGTT ACAAGTTATT TCACTTGAGT CCGGAGATGC 
 951 AAGTATTCAT GATACAGTAG AAAATCTGAT CATCCTAGCA AACAACAGTT 
1001 TGTCTTCTAA TGGGAATGTA ACAGAATCTG GATGCAAAGA ATGTGAGGAA 
1051 CTGGAGGAAA AAAATATTAA AGAATTTTTG CAGAGTTTTG TACATATTGT 
1101 CCAAATGTTC ATCAACACTT CTGAATTCCC GGAGAAGAGT ATGTATGTGG 
1151 TGACAAAGGA AAATTCTGTG GGATTAATTA TTGCCATTCT CATCCCAGTG 
1201 GCAGTGGCTG TCATTGTTGG AGTGGTGACA AGTATCCTTT GCTATCGGAA 
1251 ACGAGAATGG ATTAAAGAAA CCTTCTACCC TGATATTCCA AATCCAGAAA 
1301 ACTGTAAAGC ATTACAGTTT CAAAAGAGTG TCTGTGAGGG AAGCAGTGCT 
1351 CTTAAAACAT TGGAAATGAA TCCTTGTACC CCAAATAATG TTGAGGTTCT 
1401 GGAAACTCGA TCAGCATTTC CTAAAATAGA AGATACAGAA ATAATTTCCC 
1451 CAGTAGCTGA GCGTCCTGAA GATCGCTCTG ATGCAGAGCC TGAAAACCAT 
1501 GTGGTTGTGT CCTATTGTCC ACCCATCATT GAGGAAGAAA TACCAAACCC 
1551 AGCCGCAGAT GAAGCTGGAG GGACTGCACA GGTTATTTAC ATTGATGTTC 
1601 AGTCGATGTA TCAGCCTCAA GCAAAACCAG AAGAAGAACA AGAAAATGAC 
1651 CCTGTAGGAG GGGCAGGCTA TAAGCCACAG ATGCACCTCC CCATTAATTC 
1701 TACTGTGGAA GATATAGCTG CAGAAGAGGA CTTAGATAAA ACTGCGGGTT 
1751 ACAGACCTCA GGCCAATGTA AATACATGGA ATTTAGTGTC TCCAGACTCT 
1801 CCTAGATCCA TAGACAGCAA CAGTGAGATT GTCTCATTTG GAAGTCCATG 
1851 CTCCATTAAT TCCCGACAAT TTTTGATTCC TCCTAAAGAT GAAGACTCTC 
1901 CTAAATCTAA TGGAGGAGGG TGGTCCTTTA CAAACTTTTT TCAGAACAAA 
1951 CCAAACGATT AAGGATCCAC TAGTTCTAGA GCGGCCGCCA CCGCGGTGGA 
2001 GCTC 
 
Bold: start and stop codons 
 
Amino acid sequence: 
 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
PEKSMYVVTKENSVGLIIAILIPVAVAVIVGVVTSILCYRKREWIKETFY 200 
PDIPNPENCKALQFQKSVCEGSSALKTLEMNPCTPNNVEVLETRSAFPKI 250 
EDTEIISPVAERPEDRSDAEPENHVVVSYCPPIIEEEIPNPAADEAGGTA 300 
QVIYIDVQSMYQPQAKPEEEQENDPVGGAGYKPQMHLPINSTVEDIAAEE 350 
DLDKTAGYRPQANVNTWNLVSPDSPRSIDSNSEIVSFGSPCSINSRQFLI 400 
PPKDEDSPKSNGGGWSFTNFFQNKPND* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  orange: 
human IL-15; brown: EcoRI site; red: human LIFR (15aa ECD+TMD+CPD) 
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7. pBSK(+)-IL-15-OSMR 
 
 
 
Nucleotide sequence of IL-15-OSMR including relevant restriction sites 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GGACAGCAAA GGTTCGTCGC 
 701 AGAAAGCAGG GTCCCGCCTG CTCCTGCTGC TGGTGGTGTC AAATCTACTC 
 751 TTGTGCCAGG GTGTGGTCTC CACCACGCGT AACTGGGTGA ATGTAATAAG 
 801 TGATTTGAAA AAAATTGAAG ATCTTATTCA ATCTATGCAT ATTGATGCTA 
 851 CTTTATATAC GGAAAGTGAT GTTCACCCCA GTTGCAAAGT AACAGCAATG 
 901 AAGTGCTTTC TCTTGGAGTT ACAAGTTATT TCACTTGAGT CCGGAGATGC 
 951 AAGTATTCAT GATACAGTAG AAAATCTGAT CATCCTAGCA AACAACAGTT 
1001 TGTCTTCTAA TGGGAATGTA ACAGAATCTG GATGCAAAGA ATGTGAGGAA 
1051 CTGGAGGAAA AAAATATTAA AGAATTTTTG CAGAGTTTTG TACATATTGT 
1101 CCAAATGTTC ATCAACACTT CTGAATTCCC CAGTGCTACG TTCACGAAGG 
1151 TCACGACTCC GGATGAACAC TCCTCGATGC TGATTCATAT CCTACTGCCC 
1201 ATGGTTTTCT GCGTCTTGCT CATCATGGTC ATGTGCTACT TGAAAAGTCA 
1251 GTGGATCAAG GAGACCTGTT ATCCTGACAT CCCTGACCCT TACAAGAGCA 
1301 GCATCCTGTC ATTAATAAAA TTCAAGGAGA ACCCTCACCT AATAATAATG 
1351 AATGTCAGTG ACTGTATCCC AGATGCTATT GAAGTTGTAA GCAAGCCAGA 
1401 AGGGACAAAG ATACAGTTCC TAGGCACTAG GAAGTCACTC ACAGAAACCG 
1451 AGTTGACTAA GCCTAACTAC CTTTATCTCC TTCCAACAGA AAAGAATCAC 
1501 TCTGGCCCTG GCCCCTGCAT CTGTTTTGAG AACTTGACCT ATAACCAGGC 
1551 AGCTTCTGAC TCTGGCTCTT GTGGCCATGT TCCAGTATCC CCAAAAGCCC 
1601 CAAGTATGCT GGGACTAATG ACCTCACCTG AAAATGTACT AAAGGCACTA 
1651 GAAAAAAACT ACATGAACTC CCTGGGAGAA ATCCCAGCTG GAGAAACAAG 
1701 TTTGAATTAT GTGTCCCAGT TGGCTTCACC CATGTTTGGA GACAAGGACA 
1751 GTCTCCCAAC AAACCCAGTA GAGGCACCAC ACTGTTCAGA GTATAAAATG 
1801 CAAATGGCAG TCTCCCTGCG TCTTGCCTTG CCTCCCCCGA CCGAGAATAG 
1851 CAGCCTCTCC TCAATTACCC TTTTAGATCC AGGTGAACAC TACTGCTAAG 
1901 GATCCACTAG TTCTAGAGCG GCCGCCACCG CGGTGGAGCT C 
 
Amino acid sequence: 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
PSATFTKVTTPDEHSSMLIHILLPMVFCVLLIMVMCYLKSQWIKETCYPD 200 
IPDPYKSSILSLIKFKENPHLIIMNVSDCIPDAIEVVSKPEGTKIQFLGT 250 
RKSLTETELTKPNYLYLLPTEKNHSGPGPCICFENLTYNQAASDSGSCGH 300 
VPVSPKAPSMLGLMTSPENVLKALEKNYMNSLGEIPAGETSLNYVSQLAS 350 
PMFGDKDSLPTNPVEAPHCSEYKMQMAVSLRLALPPPTENSSLSSITLLD 400 
PGEHYC* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  
orange: human IL-15; brown: EcoRI site; green: human OSMR (15aa ECD+TMD+CPD) 
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8. pBSK(+)-IL-15-GPL 
 
 
 
Nucleotide sequence of IL-15-GPL including relevant restriction sites 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GGACAGCAAA GGTTCGTCGC 
 701 AGAAAGCAGG GTCCCGCCTG CTCCTGCTGC TGGTGGTGTC AAATCTACTC 
 751 TTGTGCCAGG GTGTGGTCTC CACCACGCGT AACTGGGTGA ATGTAATAAG 
 801 TGATTTGAAA AAAATTGAAG ATCTTATTCA ATCTATGCAT ATTGATGCTA 
 851 CTTTATATAC GGAAAGTGAT GTTCACCCCA GTTGCAAAGT AACAGCAATG 
 901 AAGTGCTTTC TCTTGGAGTT ACAAGTTATT TCACTTGAGT CCGGAGATGC 
 951 AAGTATTCAT GATACAGTAG AAAATCTGAT CATCCTAGCA AACAACAGTT 
1001 TGTCTTCTAA TGGGAATGTA ACAGAATCTG GATGCAAAGA ATGTGAGGAA 
1051 CTGGAGGAAA AAAATATTAA AGAATTTTTG CAGAGTTTTG TACATATTGT 
1101 CCAAATGTTC ATCAACACTT CTGAATTCAC CAGCATAAAT TTCAAGACAT 
1151 TGTCATTCAG TGTCTTTGAG ATTATCCTCA TAACTTCTCT GATTGGTGGA 
1201 GGCCTTCTTA TTCTCATTAT CCTGACAGTG GCATATGGTC TCAAAAAACC 
1251 CAACAAATTG ACTCATCTGT GTTGGCCCAC CGTTCCCAAC CCTGCTGAAA 
1301 GTAGTATAGC CACATGGCAT GGAGATGATT TCAAGGATAA GCTAAACCTG 
1351 AAGGAGTCTG ATGACTCTGT GAACACAGAA GACAGGATCT TAAAACCATG 
1401 TTCCACCCCC AGTGACAAGT TGGTGATTGA CAAGTTGGTG GTGAACTTTG 
1451 GGAATGTTCT GCAAGAAATT TTCACAGATG AAGCCAGAAC GGGTCAGGAA 
1501 AACAATTTAG GAGGGGAAAA GAATGGGTAT GTGACCTGCC CCTTCAGGCC 
1551 TGATTGTCCC CTGGGGAAAA GTTTTGAGGA GCTCCCAGTT TCACCTGAGA 
1601 TTCCGCCCAG AAAATCCCAA TACCTACGTT CGAGGATGCC AGAGGGGACC 
1651 CGCCCAGAAG CCAAAGAGCA GCTTCTCTTT TCTGGTCAAA GTTTAGTACC 
1701 AGATCATCTG TGTGAGGAAG GAGCCCCAAA TCCATATTTG AAAAATTCAG 
1751 TGACAGCCAG GGAATTTCTT GTGTCTGAAA AACTTCCAGA GCACACCAAG 
1801 GGAGAAGTCT AAGGATCCAC TAGTTCTAGA GCGGCCGCCA CCGCGG 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
TSINFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWP 200 
TVPNPAESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVI 250 
DKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGYVTCPFRPDCPLGKSFE 300 
ELPVSPEIPPRKSQYLRSRMPEGTRPEAKEQLLFSGQSLVPDHLCEEGAP 350 
NPYLKNSVTAREFLVSEKLPEHTKGEV* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  
orange: human IL-15; brown: EcoRI site; blue: human GPL (15aa ECD+TMD+CPD) 
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9.  pBSK(+)-IL-15Rα-sushi-gp130 
 
 
 
Nucleotide sequence of sushi-gp130 including relevant restriction sites: 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GTTGACGTTG CAGACTTGGC 
 701 TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC AGGTGAGCAG 
 751 AAGCTGATCA GCGAGGAGGA CCTGATCACA TGCCCTCCCC CCATGTCCGT 
 801 GGAACACGCA GACATCTGGG TCAAGAGCTA CAGCTTGTAC TCCAGGGAGC 
 851 GGTACATTTG TAACTCTGGT TTCAAGCGTA AAGCCGGCAC GTCCAGCCTG 
 901 ACGGAGTGCG TGTTGAACAA GGCCACGAAT GTCGCCCACT GGACAACCCC 
 951 CAGTCTCAAA TGCATTAGAG ACGAATTCAC TTTTACTACC CCAAAGTTTG 
1001 CTCAAGGAGA AATTGAAGCC ATAGTCGTGC CTGTTTGCTT AGCATTCCTA 
1051 TTGACAACTC TTCTGGGAGT GCTGTTCTGC TTTAATAAGC GAGACCTAAT 
1101 TAAAAAACAC ATCTGGCCTA ATGTTCCAGA TCCTTCAAAG AGTCATATTG 
1151 CCCAGTGGTC ACCTCACACT CCTCCAAGGC ACAATTTTAA TTCAAAAGAT 
1201 CAAATGTATT CAGATGGCAA TTTCACTGAT GTAAGTGTTG TGGAAATAGA 
1251 AGCAAATGAC AAAAAGCCTT TTCCAGAAGA TCTGAAATTA TTGGACCTGT 
1301 TCAAAAAGGA AAAAATTAAT ACTGAAGGAC ACAGCAGTGG TATTGGGGGG 
1351 TCTTCATGCA TGTCATCTTC TAGGCCAAGC ATTTCTAGCA GTGATGAAAA 
1401 TGAATCTTCA CAAAACACTT CGAGCACTGT CCAGTATTCT ACCGTGGTAC 
1451 ACAGTGGCTA CAGACACCAA GTTCCGTCAG TCCAAGTCTT CTCAAGATCC 
1501 GAGTCTACCC AGCCCTTGTT AGATTCAGAG GAGCGGCCAG AAGATCTACA 
1551 ATTAGTAGAT CATGTAGATG GCGGTGATGG TATTTTGCCC AGGCAACAGT 
1601 ACTTCAAACA GAACTGCAGT CAGCATGAAT CCAGTCCAGA TATTTCACAT 
1651 TTTGAAAGGT CAAAGCAAGT TTCATCAGTC AATGAGGAAG ATTTTGTTAG 
1701 ACTTAAACAG CAGATTTCAG ATCATATTTC ACAATCCTGT GGATCTGGGC 
1751 AAATGAAAAT GTTTCAGGAA GTTTCTGCAG CAGATGCTTT TGGTCCAGGT 
1801 ACTGAGGGAC AAGTAGAAAG ATTTGAAACA GTTGGCATGG AGGCTGCGAC 
1851 TGATGAAGGC ATGCCTAAAA GTTACTTACC ACAGACTGTA CGGCAAGGCG 
1901 GCTACATGCC TCAGTGAAGG ACTAGGGGGA TCCACTAGTT CTAGAGCGGC 
1951 CGCCACCGCG GTGGAGCTC 
 
Bold: start and stop codons 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
TFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVP 150 
DPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPE 200 
DLKLLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSST 250 
VQYSTVVHSGYRHQVPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGD 300 
GILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHI 350 
SQSCGSGQMKMFQEVSAADAFGPGTEGQVERFETVGMEAATDEGMPKSYL 400 
PQTVRQGGYMPQ* 
 
Black: human gp130 (SP and 15aa ECD+TMD+CPD); pink: Myc-tag; light blue: human IL-15Rα-
sushi domain; brown: EcoRI site 
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10. pBSK(+)-IL-15Rα-sushi-WSX-1 
 
 
 
Nucleotide sequence of sushi-WSX-1 including relevant restriction sites 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GTTGACGTTG CAGACTTGGC 
 701 TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC AGGTGAGCAG 
 751 AAGCTGATCA GCGAGGAGGA CCTGATCACA TGCCCTCCCC CCATGTCCGT 
 801 GGAACACGCA GACATCTGGG TCAAGAGCTA CAGCTTGTAC TCCAGGGAGC 
 851 GGTACATTTG TAACTCTGGT TTCAAGCGTA AAGCCGGCAC GTCCAGCCTG 
 901 ACGGAGTGCG TGTTGAACAA GGCCACGAAT GTCGCCCACT GGACAACCCC 
 951 CAGTCTCAAA TGCATTAGAG ACGAATTCTC ACTTCACCTA CCAGATAATA 
1001 GGATCAGGTG GAAAGCTCTG CCCTGGTTTC TGTCCCTGTG GGGTTTGCTT 
1051 CTGATGGGCT GTGGCCTGAG CCTGGCCAGT ACCAGGTGCC TACAGGCCAG 
1101 GTGCTTACAC TGGCGACACA AGTTGCTTCC CCAGTGGATC TGGGAGAGGG 
1151 TTCCTGATCC TGCCAACAGC AATTCTGGGC AACCTTACAT CAAGGAGGTG 
1201 AGCCTGCCCC AACCGCCCAA GGACGGACCC ATCCTGGAGG TGGAGGAAGT 
1251 GGAGCTACAG CCTGTTGTGG AGTCCCCTAA AGCCTCTGCC CCGATTTACT 
1301 CTGGGTATGA GAAACACTTC CTGCCCACAC CAGAGGAGCT GGGCCTTCTA 
1351 GTCTGAGGAT CCACTAGTTC TAGAGCGGCC GCCACCGCGG TGGAGCTC 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
SLHLPDNRIRWKALPWFLSLWGLLLMGCGLSLASTRCLQARCLHWRHKLL 200 
PQWIWERVPDPANSNSGQPYIKEVSLPQPPKDGPILEVEEVELQPVVESP 250 
KASAPIYSGYEKHFLPTPEELGLLV* 
 
Black: human gp130 SP; pink: Myc-tag light blue: human IL-15Rα-sushi domain; 
brown: EcoRI site; purple: murine WSX-1 (15aa ECD+TMD+CPD) 
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11. pBSK(+)-IL-15Rα-sushi-LIFR 
 
 
 
Nucleotide sequence of sushi-LIFR including relevant restriction sites 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GTTGACGTTG CAGACTTGGC 
 701 TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC AGGTGAGCAG 
 751 AAGCTGATCA GCGAGGAGGA CCTGATCACA TGCCCTCCCC CCATGTCCGT 
 801 GGAACACGCA GACATCTGGG TCAAGAGCTA CAGCTTGTAC TCCAGGGAGC 
 851 GGTACATTTG TAACTCTGGT TTCAAGCGTA AAGCCGGCAC GTCCAGCCTG 
 901 ACGGAGTGCG TGTTGAACAA GGCCACGAAT GTCGCCCACT GGACAACCCC 
 951 CAGTCTCAAA TGCATTAGAG ACGAATTCCC GGAGAAGAGT ATGTATGTGG 
1001 TGACAAAGGA AAATTCTGTG GGATTAATTA TTGCCATTCT CATCCCAGTG 
1051 GCAGTGGCTG TCATTGTTGG AGTGGTGACA AGTATCCTTT GCTATCGGAA 
1101 ACGAGAATGG ATTAAAGAAA CCTTCTACCC TGATATTCCA AATCCAGAAA 
1151 ACTGTAAAGC ATTACAGTTT CAAAAGAGTG TCTGTGAGGG AAGCAGTGCT 
1201 CTTAAAACAT TGGAAATGAA TCCTTGTACC CCAAATAATG TTGAGGTTCT 
1251 GGAAACTCGA TCAGCATTTC CTAAAATAGA AGATACAGAA ATAATTTCCC 
1301 CAGTAGCTGA GCGTCCTGAA GATCGCTCTG ATGCAGAGCC TGAAAACCAT 
1351 GTGGTTGTGT CCTATTGTCC ACCCATCATT GAGGAAGAAA TACCAAACCC 
1401 AGCCGCAGAT GAAGCTGGAG GGACTGCACA GGTTATTTAC ATTGATGTTC 
1451 AGTCGATGTA TCAGCCTCAA GCAAAACCAG AAGAAGAACA AGAAAATGAC 
1501 CCTGTAGGAG GGGCAGGCTA TAAGCCACAG ATGCACCTCC CCATTAATTC 
1551 TACTGTGGAA GATATAGCTG CAGAAGAGGA CTTAGATAAA ACTGCGGGTT 
1601 ACAGACCTCA GGCCAATGTA AATACATGGA ATTTAGTGTC TCCAGACTCT 
1651 CCTAGATCCA TAGACAGCAA CAGTGAGATT GTCTCATTTG GAAGTCCATG 
1701 CTCCATTAAT TCCCGACAAT TTTTGATTCC TCCTAAAGAT GAAGACTCTC 
1751 CTAAATCTAA TGGAGGAGGG TGGTCCTTTA CAAACTTTTT TCAGAACAAA 
1801 CCAAACGATT AAGGATCCAC TAGTTCTAGA GCGGCCGCCA CCGCGGTGGA 
1851 GCTC 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
PEKSMYVVTKENSVGLIIAILIPVAVAVIVGVVTSILCYRKREWIKETFY 200 
PDIPNPENCKALQFQKSVCEGSSALKTLEMNPCTPNNVEVLETRSAFPKI 250 
EDTEIISPVAERPEDRSDAEPENHVVVSYCPPIIEEEIPNPAADEAGGTA 300 
QVIYIDVQSMYQPQAKPEEEQENDPVGGAGYKPQMHLPINSTVEDIAAEE 350 
DLDKTAGYRPQANVNTWNLVSPDSPRSIDSNSEIVSFGSPCSINSRQFLI 400 
PPKDEDSPKSNGGGWSFTNFFQNKPND* 
 
Black: human gp130 SP; pink: Myc-tag light blue: human IL-15Rα-sushi domain; 
brown: EcoRI site; red: human LIFR (15aa ECD+TMD+CPD) 
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12. pBSK(+)-IL-15Rα-sushi-OSMR 
 
 
 
Nucleotide sequence of sushi-OSMR including relevant restriction sites: 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GTTGACGTTG CAGACTTGGC 
 701 TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC AGGTGAGCAG 
 751 AAGCTGATCA GCGAGGAGGA CCTGATCACA TGCCCTCCCC CCATGTCCGT 
 801 GGAACACGCA GACATCTGGG TCAAGAGCTA CAGCTTGTAC TCCAGGGAGC 
 851 GGTACATTTG TAACTCTGGT TTCAAGCGTA AAGCCGGCAC GTCCAGCCTG 
 901 ACGGAGTGCG TGTTGAACAA GGCCACGAAT GTCGCCCACT GGACAACCCC 
 951 CAGTCTCAAA TGCATTAGAG ACGAATTCCC CAGTGCTACG TTCACGAAGG 
1001 TCACGACTCC GGATGAACAC TCCTCGATGC TGATTCATAT CCTACTGCCC 
1051 ATGGTTTTCT GCGTCTTGCT CATCATGGTC ATGTGCTACT TGAAAAGTCA 
1101 GTGGATCAAG GAGACCTGTT ATCCTGACAT CCCTGACCCT TACAAGAGCA 
1151 GCATCCTGTC ATTAATAAAA TTCAAGGAGA ACCCTCACCT AATAATAATG 
1201 AATGTCAGTG ACTGTATCCC AGATGCTATT GAAGTTGTAA GCAAGCCAGA 
1251 AGGGACAAAG ATACAGTTCC TAGGCACTAG GAAGTCACTC ACAGAAACCG 
1301 AGTTGACTAA GCCTAACTAC CTTTATCTCC TTCCAACAGA AAAGAATCAC 
1351 TCTGGCCCTG GCCCCTGCAT CTGTTTTGAG AACTTGACCT ATAACCAGGC 
1401 AGCTTCTGAC TCTGGCTCTT GTGGCCATGT TCCAGTATCC CCAAAAGCCC 
1451 CAAGTATGCT GGGACTAATG ACCTCACCTG AAAATGTACT AAAGGCACTA 
1501 GAAAAAAACT ACATGAACTC CCTGGGAGAA ATCCCAGCTG GAGAAACAAG 
1551 TTTGAATTAT GTGTCCCAGT TGGCTTCACC CATGTTTGGA GACAAGGACA 
1601 GTCTCCCAAC AAACCCAGTA GAGGCACCAC ACTGTTCAGA GTATAAAATG 
1651 CAAATGGCAG TCTCCCTGCG TCTTGCCTTG CCTCCCCCGA CCGAGAATAG 
1701 CAGCCTCTCC TCAATTACCC TTTTAGATCC AGGTGAACAC TACTGCTAAG 
1751 GATCCACTAG TTCTAGAGCG GCCGCCACCG CGGTGGAGCT C 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
PSATFTKVTTPDEHSSMLIHILLPMVFCVLLIMVMCYLKSQWIKETCYPD 200 
IPDPYKSSILSLIKFKENPHLIIMNVSDCIPDAIEVVSKPEGTKIQFLGT 250 
RKSLTETELTKPNYLYLLPTEKNHSGPGPCICFENLTYNQAASDSGSCGH 300 
VPVSPKAPSMLGLMTSPENVLKALEKNYMNSLGEIPAGETSLNYVSQLAS 350 
PMFGDKDSLPTNPVEAPHCSEYKMQMAVSLRLALPPPTENSSLSSITLLD 400 
PGEHYC* 
 
Black: human gp130 SP; pink: Myc-tag light blue: human IL-15Rα-sushi domain; 
brown: EcoRI site; green: human OSMR (15aa ECD+TMD+CPD) 
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13. pBSK(+)-IL-15Rα-sushi-GPL 
 
 
 
Nucleotide sequence of sushi-OSMR including relevant restriction sites: 
       GGTACCGG GCCCCCCCTC GAGCCACCAT GTTGACGTTG CAGACTTGGC 
 701 TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC AGGTGAGCAG 
 751 AAGCTGATCA GCGAGGAGGA CCTGATCACA TGCCCTCCCC CCATGTCCGT 
 801 GGAACACGCA GACATCTGGG TCAAGAGCTA CAGCTTGTAC TCCAGGGAGC 
 851 GGTACATTTG TAACTCTGGT TTCAAGCGTA AAGCCGGCAC GTCCAGCCTG 
 901 ACGGAGTGCG TGTTGAACAA GGCCACGAAT GTCGCCCACT GGACAACCCC 
 951 CAGTCTCAAA TGCATTAGAG ACGAATTCAC CAGCATAAAT TTCAAGACAT 
1001 TGTCATTCAG TGTCTTTGAG ATTATCCTCA TAACTTCTCT GATTGGTGGA 
1051 GGCCTTCTTA TTCTCATTAT CCTGACAGTG GCATATGGTC TCAAAAAACC 
1101 CAACAAATTG ACTCATCTGT GTTGGCCCAC CGTTCCCAAC CCTGCTGAAA 
1151 GTAGTATAGC CACATGGCAT GGAGATGATT TCAAGGATAA GCTAAACCTG 
1201 AAGGAGTCTG ATGACTCTGT GAACACAGAA GACAGGATCT TAAAACCATG 
1251 TTCCACCCCC AGTGACAAGT TGGTGATTGA CAAGTTGGTG GTGAACTTTG 
1301 GGAATGTTCT GCAAGAAATT TTCACAGATG AAGCCAGAAC GGGTCAGGAA 
1351 AACAATTTAG GAGGGGAAAA GAATGGGTAT GTGACCTGCC CCTTCAGGCC 
1401 TGATTGTCCC CTGGGGAAAA GTTTTGAGGA GCTCCCAGTT TCACCTGAGA 
1451 TTCCGCCCAG AAAATCCCAA TACCTACGTT CGAGGATGCC AGAGGGGACC 
1501 CGCCCAGAAG CCAAAGAGCA GCTTCTCTTT TCTGGTCAAA GTTTAGTACC 
1551 AGATCATCTG TGTGAGGAAG GAGCCCCAAA TCCATATTTG AAAAATTCAG 
1601 TGACAGCCAG GGAATTTCTT GTGTCTGAAA AACTTCCAGA GCACACCAAG 
1651 GGAGAAGTCT AAGGATCCAC TAGTTCTAGA GCGGCCGCCA CCGCGG 
 
Bold: start and stop codons 
 
Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
TSINFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWP 200 
TVPNPAESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVI 250 
DKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGYVTCPFRPDCPLGKSFE 300 
ELPVSPEIPPRKSQYLRSRMPEGTRPEAKEQLLFSGQSLVPDHLCEEGAP 350 
NPYLKNSVTAREFLVSEKLPEHTKGEV* 
 
Black: human gp130 SP; pink: Myc-tag light blue: human IL-15Rα-sushi domain; 
brown: EcoRI site; blue: human GPL (15aa ECD+TMD+CPD) 
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14. pEYFP-∆cys-Fos-gp130 
 
 
Nucleotide sequence of ∆cys-Fos-gp130-EYFP including relevant restriction sites: 
 
                                                       GCTA 
 601 CCGGACTCAG ATCTCGAGTC TAGACCCCGC AAGATGTTGA CGTTGCAGAC 
 651 TTGGCTAGTG CAAGCCTTGT TTATTTTCCT CACCACTGAA TCTACAGGTG 
 701 ACTACAAAGA TGACGATGAT AAAGAATTGG GCGGCGGCTT AACTGATACA 
 751 CTCCAAGCGG AGACAGACCA ACTAGAAGAT GAGAAGTCTG CTTTGCAGAC 
 801 CGAGATTGCC AACCTGCTGA AGGAGAAGGA AAAACTAGAG TTCATCCTGG 
 851 CAGCTGAATT CACTTTTACT ACCCCAAAGT TTGCTCAAGG AGAAATTGAA 
 901 GCCATAGTCG TGCCTGTTTG CTTAGCATTC CTATTGACAA CTCTTCTGGG 
 951 AGTGCTGTTC TGCTTTAATA AGCGAGACCT AATTAAAAAA CACATCTGGC 
1001 CTAATGTTCC AGATCCTTCA AAGAGTCATA TTGCCCAGTG GTCACCTCAC 
1051 ACTCCTCCAA GGCACAATTT TAATTCAAAA GATCAAATGT ATTCAGATGG 
1101 CAATTTCACT GATGTAAGTG TTGTGGAAAT AGAAGCAAAT GACAAAAAGC 
1151 CTTTTCCAGA AGATCTGAAA TTATTGGACC TGTTCAAAAA GGAAAAAATT 
1201 AATACTGAAG GACACAGCAG TGGTATTGGG GGGTCTTCAT GCATGTCATC 
1251 TTCTAGGCCA AGCATTTCTA GCAGTGATGA AAATGAATCT TCACAAAACA 
1301 CTTCGAGCAC TGTCCAGTAT TCTACCGTGG TACACAGTGG CTACAGACAC 
1351 CAAGTTCCGT CAGTCCAAGT CTTCTCAAGA TCCGAGTCTA CCCAGCCCTT 
1401 GTTAGATTCA GAGGAGCGGC CAGAAGATCT ACAATTAGTA GATCATGTAG 
1451 ATGGCGGTGA TGGTATTTTG CCCAGGCAAC AGTACTTCAA ACAGAACTGC 
1501 AGTCAGCATG AATCCAGTCC AGATATTTCA CATTTTGAAA GGTCAAAGCA 
1551 AGTTTCATCA GTCAATGAGG AAGATTTTGT TAGACTTAAA CAGCAGATTT 
1601 CAGATCATAT TTCACAATCC TGTGGATCTG GGCAAATGAA AATGTTTCAG 
1651 GAAGTTTCTG CAGCAGATGC TTTTGGTCCA GGTACTGAGG GACAAGTAGA 
1701 AAGATTTGAA ACAGTTGGCA TGGAGGCTGC GACTGATGAA GGCATGCCTA 
1751 AAAGTTACTT ACCACAGACT GTACGGCAAG GCGGCTACAT GCCTCAGGAT 
1801 CCACCGGTCG CCACCATGGT GAGCAAGGGC GAGGAGCTGT TCACCGGGGT 
1851 GGTGCCCATC CTGGTCGAGC TGGACGGCGA CGTAAACGGC CACAAGTTCA 
1901 GCGTGTCCGG CGAGGGCGAG GGCGATGCCA CCTACGGCAA GCTGACCCTG 
1951 AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT 
2001 GACCACCTTC GGCTACGGCC TGCAGTGCTT CGCCCGCTAC CCCGACCACA 
2051 TGAAGCAGCA CGACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG 
2101 GAGCGCACCA TCTTCTTCAA GGACGACGGC AACTACAAGA CCCGCGCCGA 
2151 GGTGAAGTTC GAGGGCGACA CCCTGGTGAA CCGCATCGAG CTGAAGGGCA 
2201 TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT GGAGTACAAC 
2251 TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT 
2301 CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC 
2351 TCGCCGACCA CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG 
2401 CTGCCCGACA ACCACTACCT GAGCTACCAG TCCGCCCTGA GCAAAGACCC 
2451 CAACGAGAAG CGCGATCACA TGGTCCTGCT GGAGTTCGTG ACCGCCGCCG 
2501 GGATCACTCT CGGCATGGAC GAGCTGTACA AGTAAAGCGG CCGC 
 
Bold: start and stop codons 
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Amino acid sequence: 
MLTLQTWLVQALFIFLTTESTGDYKDDDDKELGGGLTDTLQAETDQLEDE 50 
KSALQTEIANLLKEKEKLEFILAAEFTFTTPKFAQGEIEAIVVPVCLAFL 100 
LTTLLGVLFCFNKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKD 150 
QMYSDGNFTDVSVVEIEANDKKPFPEDLKLLDLFKKEKINTEGHSSGIGG 200 
SSCMSSSRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQVPSVQVFSRS 250 
ESTQPLLDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISH 300 
FERSKQVSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFGPG 350 
TEGQVERFETVGMEAATDEGMPKSYLPQTVRQGGYMPQDPPVATMVSKGE 400 
ELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPV 450 
PWPTLVTTFGYGLQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGN 500 
YKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMAD 550 
KQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSYQS 600 
ALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK* 
 
Black: human gp130(SP and 15aa ECD+TMD+CPD); green: FLAG tag; italic: linker 
(w/o cysteine); blue: Fos leucine zipper; brown: EcoRI site, bold: linker; bold 
and yellow framed: EYFP 
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15. pEYFP-IL-15-gp130 
 
 
 
Nucleotide sequence of IL-15-gp130 including relevant restriction sites: 
      GCTA 
 601 CCGGACTCAG ATCTCGAGCC ACCATGGACA GCAAAGGTTC GTCGCAGAAA 
 651 GCAGGGTCCC GCCTGCTCCT GCTGCTGGTG GTGTCAAATC TACTCTTGTG 
 701 CCAGGGTGTG GTCTCCACCA CGCGTAACTG GGTGAATGTA ATAAGTGATT 
 751 TGAAAAAAAT TGAAGATCTT ATTCAATCTA TGCATATTGA TGCTACTTTA 
 801 TATACGGAAA GTGATGTTCA CCCCAGTTGC AAAGTAACAG CAATGAAGTG 
 851 CTTTCTCTTG GAGTTACAAG TTATTTCACT TGAGTCCGGA GATGCAAGTA 
 901 TTCATGATAC AGTAGAAAAT CTGATCATCC TAGCAAACAA CAGTTTGTCT 
 951 TCTAATGGGA ATGTAACAGA ATCTGGATGC AAAGAATGTG AGGAACTGGA 
1001 GGAAAAAAAT ATTAAAGAAT TTTTGCAGAG TTTTGTACAT ATTGTCCAAA 
1051 TGTTCATCAA CACTTCTGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 
1101 GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC 
1151 AACTCTTCTG GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA 
1201 AACACATCTG GCCTAATGTT CCAGATCCTT CAAAGAGTCA TATTGCCCAG 
1251 TGGTCACCTC ACACTCCTCC AAGGCACAAT TTTAATTCAA AAGATCAAAT 
1301 GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA ATAGAAGCAA 
1351 ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATTATTGGA CCTGTTCAAA 
1401 AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC 
1451 ATGCATGTCA TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT 
1501 CTTCACAAAA CACTTCGAGC ACTGTCCAGT ATTCTACCGT GGTACACAGT 
1551 GGCTACAGAC ACCAAGTTCC GTCAGTCCAA GTCTTCTCAA GATCCGAGTC 
1601 TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT CTACAATTAG 
1651 TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 
1701 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA 
1751 AAGGTCAAAG CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA 
1801 AACAGCAGAT TTCAGATCAT ATTTCACAAT CCTGTGGATC TGGGCAAATG 
1851 AAAATGTTTC AGGAAGTTTC TGCAGCAGAT GCTTTTGGTC CAGGTACTGA 
1901 GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT GCGACTGATG 
1951 AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 
2001 ATGCCTCAGG ATCCACCGGT CGCCACCATG GTGAGCAAGG GCGAGGAGCT 
2051 GTTCACCGGG GTGGTGCCCA TCCTGGTCGA GCTGGACGGC GACGTAAACG 
2101 GCCACAAGTT CAGCGTGTCC GGCGAGGGCG AGGGCGATGC CACCTACGGC 
2151 AAGCTGACCC TGAAGTTCAT CTGCACCACC GGCAAGCTGC CCGTGCCCTG 
2201 GCCCACCCTC GTGACCACCT TCGGCTACGG CCTGCAGTGC TTCGCCCGCT 
2251 ACCCCGACCA CATGAAGCAG CACGACTTCT TCAAGTCCGC CATGCCCGAA 
2301 GGCTACGTCC AGGAGCGCAC CATCTTCTTC AAGGACGACG GCAACTACAA 
2351 GACCCGCGCC GAGGTGAAGT TCGAGGGCGA CACCCTGGTG AACCGCATCG 
2401 AGCTGAAGGG CATCGACTTC AAGGAGGACG GCAACATCCT GGGGCACAAG 
2451 CTGGAGTACA ACTACAACAG CCACAACGTC TATATCATGG CCGACAAGCA 
2501 GAAGAACGGC ATCAAGGTGA ACTTCAAGAT CCGCCACAAC ATCGAGGACG 
2551 GCAGCGTGCA GCTCGCCGAC CACTACCAGC AGAACACCCC CATCGGCGAC 
2601 GGCCCCGTGC TGCTGCCCGA CAACCACTAC CTGAGCTACC AGTCCGCCCT 
2651 GAGCAAAGAC CCCAACGAGA AGCGCGATCA CATGGTCCTG CTGGAGTTCG 
2701 TGACCGCCGC CGGGATCACT CTCGGCATGG ACGAGCTGTA CAAGTAAAGC 
2751 GGCCGC 
 
Bold: start and stop codons 
 
APPENDIX   
- 128 - 
Amino acid sequence: 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRNWVNVISDLKKIEDLI 50 
QSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL 100 
IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSEF 150 
TFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVP 200 
DPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPE 250 
DLKLLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSST 300 
VQYSTVVHSGYRHQVPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGD 350 
GILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHI 400 
SQSCGSGQMKMFQEVSAADAFGPGTEGQVERFETVGMEAATDEGMPKSYL 450 
PQTVRQGGYMPQDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSG 500 
EGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGLQCFARYPDHMKQH 550 
DFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFK 600 
EDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADH 650 
YQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGITL 700 
GMDELYK* 
 
Grey: bovine preprolactin SP; italic: one additional amino acid and MluI site  orange: 
human IL-15; brown: EcoRI site; black: human gp130 (15aa ECD+TMD+CPD); bold: linker; 
bold and yellow framed: EYFP 
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16. pEYFP-IL-15Rα-sushi-gp130 
 
 
 
Nucleotide sequence of IL-15-gp130 including relevant restriction sites: 
  GCTA 
 601 CCGGACTCAG ATCTCGAGCC ACCATGTTGA CGTTGCAGAC TTGGCTAGTG 
 651 CAAGCCTTGT TTATTTTCCT CACCACTGAA TCTACAGGTG AGCAGAAGCT 
 701 GATCAGCGAG GAGGACCTGA TCACATGCCC TCCCCCCATG TCCGTGGAAC 
 751 ACGCAGACAT CTGGGTCAAG AGCTACAGCT TGTACTCCAG GGAGCGGTAC 
 801 ATTTGTAACT CTGGTTTCAA GCGTAAAGCC GGCACGTCCA GCCTGACGGA 
 851 GTGCGTGTTG AACAAGGCCA CGAATGTCGC CCACTGGACA ACCCCCAGTC 
 901 TCAAATGCAT TAGAGACGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 
 951 GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC 
1001 AACTCTTCTG GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA 
1051 AACACATCTG GCCTAATGTT CCAGATCCTT CAAAGAGTCA TATTGCCCAG 
1101 TGGTCACCTC ACACTCCTCC AAGGCACAAT TTTAATTCAA AAGATCAAAT 
1151 GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA ATAGAAGCAA 
1201 ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATTATTGGA CCTGTTCAAA 
1251 AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC 
1301 ATGCATGTCA TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT 
1351 CTTCACAAAA CACTTCGAGC ACTGTCCAGT ATTCTACCGT GGTACACAGT 
1401 GGCTACAGAC ACCAAGTTCC GTCAGTCCAA GTCTTCTCAA GATCCGAGTC 
1451 TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT CTACAATTAG 
1501 TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 
1551 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA 
1601 AAGGTCAAAG CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA 
1651 AACAGCAGAT TTCAGATCAT ATTTCACAAT CCTGTGGATC TGGGCAAATG 
1701 AAAATGTTTC AGGAAGTTTC TGCAGCAGAT GCTTTTGGTC CAGGTACTGA 
1751 GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT GCGACTGATG 
1801 AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 
1851 ATGCCTCAGG ATCCACCGGT CGCCACCATG GTGAGCAAGG GCGAGGAGCT 
1901 GTTCACCGGG GTGGTGCCCA TCCTGGTCGA GCTGGACGGC GACGTAAACG 
1951 GCCACAAGTT CAGCGTGTCC GGCGAGGGCG AGGGCGATGC CACCTACGGC 
2001 AAGCTGACCC TGAAGTTCAT CTGCACCACC GGCAAGCTGC CCGTGCCCTG 
2051 GCCCACCCTC GTGACCACCT TCGGCTACGG CCTGCAGTGC TTCGCCCGCT 
2101 ACCCCGACCA CATGAAGCAG CACGACTTCT TCAAGTCCGC CATGCCCGAA 
2151 GGCTACGTCC AGGAGCGCAC CATCTTCTTC AAGGACGACG GCAACTACAA 
2201 GACCCGCGCC GAGGTGAAGT TCGAGGGCGA CACCCTGGTG AACCGCATCG 
2251 AGCTGAAGGG CATCGACTTC AAGGAGGACG GCAACATCCT GGGGCACAAG 
2301 CTGGAGTACA ACTACAACAG CCACAACGTC TATATCATGG CCGACAAGCA 
2351 GAAGAACGGC ATCAAGGTGA ACTTCAAGAT CCGCCACAAC ATCGAGGACG 
2401 GCAGCGTGCA GCTCGCCGAC CACTACCAGC AGAACACCCC CATCGGCGAC 
2451 GGCCCCGTGC TGCTGCCCGA CAACCACTAC CTGAGCTACC AGTCCGCCCT 
2501 GAGCAAAGAC CCCAACGAGA AGCGCGATCA CATGGTCCTG CTGGAGTTCG 
2551 TGACCGCCGC CGGGATCACT CTCGGCATGG ACGAGCTGTA CAAGTAAAGC 
2601 GGCCGC 
 
Bold: start and stop codons 
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Amino acid sequence: 
 
MLTLQTWLVQALFIFLTTESTGEQKLISEEDLITCPPPMSVEHADIWVKS 50 
YSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDEF 100 
TFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVP 150 
DPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPE 200 
DLKLLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSST 250 
VQYSTVVHSGYRHQVPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGD 300 
GILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHI 350 
SQSCGSGQMKMFQEVSAADAFGPGTEGQVERFETVGMEAATDEGMPKSYL 400 
PQTVRQGGYMPQDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSG 450 
EGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGLQCFARYPDHMKQH 500 
DFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFK 550 
EDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADH 600 
YQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGITL 650 
GMDELYK* 
 
Black: human gp130 (SP and 15aa ECD+TMD+CPD); pink: Myc-tag; light blue: human 
IL-15Rα-sushi domain; brown: EcoRI site; bold: linker; bold and yellow framed: 
EYFP 
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17.  pMK-FUSIO 
 
 
 
Nucleotide sequence of IL-15-gp130 including relevant restriction sites: 
    GATAT CTCTAGAGCC ACCATGGACA 
 401 GCAAGGGCTC TAGCCAGAAG GCCGGCAGCA GACTGCTCCT GCTCCTGGTC 
 451 GTGTCCAACC TGCTGCTGTG CCAGGGCGTG GTGTCCACCA CCAGAGACTA 
 501 CAAGGACGAC GACGACAAGG CGGCCGCCGG CCTGCCCAAG ACCGAGGCCA 
 551 ACTGGGTGAA CGTGATCAGC AGCCTGAAGA AGATCGAGGA CCTGATCCAG 
 601 AGCATGCACA TCGACGCCAC CCTGTACACA GAGAGCGACG TCCACCCCAG 
 651 CTGCAAGGTG ACCGCCATGA AGTGCTTTCT GCTGGAGCTG CAGGTCATCA 
 701 GCCTGGAGAG CGGCGACGCC AGCATCCACG ACACCGTGGA GAACCTGATC 
 751 ATCCTGGCCA ACAACAGCCT GAGCAGCAAC GGCAACGTGA CCGAGAGCGG 
 801 CTGCAAGGAG TGCGAGGAGC TGGAGGAGAA GAACATCAAG GAGTTTCTGC 
 851 AGAGCTTCGT GCACATCGTG TCCATGTTCA TCAACACAAG CACTAGTAGC 
 901 CTGCATCTGC CCGACAACAG AATCAGATGG AAGGCCCTGC CCTGGTTCCT 
 951 GAGCCTGTGG GGCCTGCTGC TGATGGGCTG TGGCCTGAGC CTGGCCAGCA 
1001 CCCGGTGTCT GCAGGCCAGA TGCCTGCATT GGCGGCACAA GCTGCTGCCC 
1051 CAGTGGATCT GGGAGAGAGT GCCCGACCCC GCCAACAGCA ACAGCGGCCA 
1101 GCCCTACATC AAGGAGGTGT CCCTGCCCCA GCCCCCCAAG GACGGCCCCA 
1151 TCCTGGAGGT GGAAGAGGTG GAGCTGCAGC CCGTGGTGGA GAGCCCTAAG 
1201 GCCAGCGCCC CCATCTACAG CGGCTACGAG AAGCACTTCC TGCCCACCCC 
1251 TGAGGAGCTG GGACTGCTGG TGAAGCTTAG AGCCAAGAGG GCCCCTGTGA 
1301 AGCAGACCCT GAACTTCGAC CTGCTGAAGC TGGCCGGCGA CGTGGAGAGC 
1351 AACCCTGGCC CTGCTAGCAT GCTGACCCTG CAGACCTGGC TGGTGCAGGC 
1401 CCTGTTCATC TTCCTGACCA CCGAGAGCAC CGGCGAGCAG AAGCTGATCA 
1451 GCGAGGAGGA TCTGATCACC TGCCCCCCTC CCATGAGCGT GGAGCACGCC 
1501 GACATCTGGG TGAAGTCCTA CTCTCTGTAT TCCAGAGAGC GGTACATCTG 
1551 CAACTCCGGC TTCAAGAGAA AGGCCGGCAC CAGCTCCCTG ACCGAGTGCG 
1601 TGCTGAACAA GGCCACCAAC GTGGCCCACT GGACCACCCC CAGCCTGAAG 
1651 TGCATCAGGG ACGAATTCAC CTTCACCACC CCCAAGTTCG CTCAGGGCGA 
1701 GATTGAGGCC ATCGTGGTGC CCGTGTGCCT GGCCTTCCTG CTGACAACCC 
1751 TGCTGGGCGT GCTGTTCTGC TTCAACAAGC GGGACCTGAT CAAGAAGCAC 
1801 ATCTGGCCCA ACGTGCCTGA CCCCAGCAAG AGCCACATCG CCCAGTGGAG 
1851 CCCCCACACC CCCCCCAGAC ACAACTTCAA CAGCAAGGAC CAGATGTACA 
1901 GCGACGGCAA CTTCACCGAC GTGTCTGTGG TGGAGATCGA GGCTAACAAC 
1951 AAGAAGCCCT GCCCCGACGA CCTGAAGTCC GTGGACCTGT TTAAGAAGGA 
2001 GAAGGTCTCC ACCGAGGGCC ACAGCAGCGG CATCGGCGGC AGCAGCTGCA 
2051 TGAGCAGCAG CAGACCCAGC ATCAGCAGCA ACGAGGAGAA CGAGAGCGCC 
2101 CAGAGCACCG CCAGCACCGT GCAGTACAGC ACCGTGGTGC ACTCCGGCTA 
2151 CAGACACCAG GTGCCCAGCG TGCAGGTGTT CAGCAGAAGC GAGAGCACCC 
2201 AGCCCCTGCT GGACAGCGAG GAGAGGCCCG AGGACCTGCA GCTGGTCGAC 
2251 AGCGTGGACG GCGGCGACGA GATCCTGCCC AGACAGAGCT ACTTCAAGCA 
2301 GAACTGCAGC CAGCCCGAGG CCTGCCCCGA GATCAGCCAC TTCGAGAGAA 
2351 GCAACCAGGT GCTGTCCGGC AATGAGGAGG ACTTCGTCAG ACTGAAGCAG 
2401 CAGCAGGTGT CCGACCACAT CAGCCAGCCT TACGGCAGCG AGCAGAGAAG 
2451 GCTGTTCCAG GAGGGCAGCA CCGCCGACGC TCTCGGAACA GGCGCCGACG 
2501 GCCAGATGGA GAGATTCGAG AGCGTGGGCA TGGAGACAAC CATCGACGAG 
2551 GAGATCCCCA AGAGCTACCT GCCCCAGACC GTGCGGCAGG GCGGCTACAT 
2601 GCCCCAGTGA TGACTCGAGG ATATC 
 
Bold: start and stop codons 
 
APPENDIX   
- 132 - 
Amino acid sequence (both proteins are separated by 2A peptide): 
 
MDSKGSSQKAGSRLLLLLVVSNLLLCQGVVSTTRDYKDDDDKAAAGLPKT 50 
EANWVNVISSLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQ 100 
VISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKE 150 
FLQSFVHIVSMFINTSTSSLHLPDNRIRWKALPWFLSLWGLLLMGCGLSL 200 
ASTRCLQARCLHWRHKLLPQWIWERVPDPANSNSGQPYIKEVSLPQPPKD 250 
GPILEVEEVELQPVVESPKASAPIYSGYEKHFLPTPEELGLLVKLRAKRA 300 
PVKQTLNFDLLKLAGDVESNPGPASMLTLQTWLVQALFIFLTTESTGEQK 350 
LISEEDLITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLT 400 
ECVLNKATNVAHWTTPSLKCIRDEFTFTTPKFAQGEIEAIVVPVCLAFLL 450 
TTLLGVLFCFNKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQ 500 
MYSDGNFTDVSVVEIEANNKKPCPDDLKSVDLFKKEKVSTEGHSSGIGGS 550 
SCMSSSRPSISSNEENESAQSTASTVQYSTVVHSGYRHQVPSVQVFSRSE 600 
STQPLLDSEERPEDLQLVDSVDGGDEILPRQSYFKQNCSQPEACPEISHF 650 
ERSNQVLSGNEEDFVRLKQQQVSDHISQPYGSEQRRLFQEGSTADALGTG 700 
ADGQMERFESVGMETTIDEEIPKSYLPQTVRQGGYMPQ* 
 
 
Grey: bovine preprolactin SP; italic and yellow framed: one additional amino 
acid and MluI site; green: FLAG-tag; brown: different restriction sites in 
chronological order NotI, SpeI, HindIII, NheI EcoRI; italic: linker; orange: 
human IL-15 mutated D8S + Q108S; purple: murine WSX-1 (15aa ECD+TMD+CPD); bold 
and green framed: furin cleavage site; bold and red framed: 2A peptide; pink: 
Myc-tag; light blue: human IL-15Rα-sushi domain; black: human gp130 SP; black 
framed: murine gp130(15aa ECD+TMD+CPD) 
 
 
Please contact the author of this work (Jan.Suthaus@web.de) if complete plasmid 
sequences and additional plasmid sequences (pMOWS and p409) containing the 
chimeric receptors ORFs are needed. 
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